NEW PIPERIDINYL DERIVATIVES SUBSTITUTED BY (HETERO)ARYL, THEIR PREPARATION PROCESS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Abstract

The invention relates to compounds of formula (i), in which r1, r2, j, k, l, n and w are as defined in the description. The invention also relates to medicinal products.

Description

[0001] The present invention relates to new (hetero)aryl-substituted-piperidinyl derivatives, to a process for their preparation and to pharmaceutical compositions containing them.

[0002] The compounds of the present invention are new and have very valuable pharmacological characteristics in the field of apoptosis and oncology.

[0003] Ubiquitination is a process controlling essential cellular functions such as protein turnover and homeostasis, protein activation and localisation. Ubiquitin is a 76 amino acids polypeptide which is covalently attached to postranslationnaly modified protein substrates via an isopeptide bond. Deubiquinating enzymes (DUBs) are in majority cysteine proteases that cleave the ubiquitin-ubiquitin bond or ubiquitin-protein bond at the Cter glycine of Ubiquitin. Approximately 100 DUBs regulate the thousands ubiquitinated proteins and then some redundancy of deubiquitinase substrates regulation are observed. Dysregulation of DUBs have been associated with several diseases such as neurodegenerative and infectious diseases (Edelman et al., Expert Rev. Mol. Med. 2011, 13, 1-17) and human malignancies (Pal et al., Cancer Res. 2014, 74, 4955-4966). Accordingly, overexpression of DUBs or increase of their activity have been associated to numerous types of cancers (Luise et al., Plos One 2011, 6, e15891; Rolen et al., Mol. Carcinog. 2006, 45, 260-269) and poor prognosis. Ubiquitin Specific Protease 7 (USP7), also known as Herpes-virus-Associated Ubiquitin-Specific Protease (HAUSP), belongs to the deubiquitinating family. USP7 has been reported to stabilize numerous oncogenes involved in survival and proliferations via cell cycle progression, apoptosis, DNA repair, DNA replication and epigenetic factors regulation (Nicholson et al., Cell Biochem. Biophys. 2011, 60, 61-68). In addition, USP7 has been shown to regulate immune response via inflammation and Treg modulation (Van Loosdregt et al., Immunity 2013, 39, 259-27; Colleran et al., Proc. Natl. Acad. Sci. USA 2013, 110, 618-623). USP7 has also been implicated in other pathologic states such as neurodevelopmental disorder (Hao et al., Mol. Cell 2015, 59, 956-969) and viral infection (Holowaty et al., Biochem. Soc. Trans. 2004, 32, 731-732).

[0004] USP7 overexpression has been associated with late stages of cancers and poor prognosis in lung, neuroblastoma, myeloma, prostate, colon and breast cancers. Although some inhibitors have been published in the literature, most of them were not selective and, to date, no USP7 inhibitors have entered the clinic (Kemp et al., Progress in Medicinal Chemistry 2016, 55, 149-192). WO 2013 / 030218 also discloses USP7 inhibitors useful for the treatment of cancer and immunological disorders. There is, therefore, a therapeutic need for compounds that inhibit the activity of the protein USP7.

[0005] In addition to being new, the compounds of the present invention have pro-apoptotic and / or anti-proliferative properties making it possible to use them in pathologies involving a defect in apoptosis, such as, for example, in the treatment of cancer and of immune and auto-immune diseases.

[0006] The present invention relates more especially to compounds of formula (I): wherein: ◆ R 1 represents an aryl group or a heteroaryl group, ◆ R 2 represents a hydrogen atom or a halogen atom, ◆ n is an integer equal to 0, 1 or 2, ◆ J represents a -C(O)- group, a -CH(R 3 )- group, or a -SO 2 - group, ◆ R 3 represents a hydrogen atom or a linear or branched (C 1 -C 6 )alkyl group, ◆ K represents a bond or a -Cy 1 - group, ◆ L represents a -Cy 2 group or a -CH 2 -Cy 2 group, ◆ W represents the group wherein: ▪ A represents a heteroaryl ring, ▪ X represents a carbon atom or a nitrogen atom, ▪ R 4 represents a hydrogen atom, a halogen atom, a linear or branched (C 1 -C 6 )alkyl group, a linear or branched (C 2 -C 6 )alkenyl group, a linear or branched (C 2 -C 6 )alkynyl group, a -Y 1 -NR 6 R 7 group, a -Y 1 -OR 6 group, a linear or branched halo(C 1 -C 6 )alkyl group, an oxo group, a -Y 1 -Cy 3 group, a -Cy 3 -R 7 group, a -Cy 3 -OR 7 group, or a -Y 1 -NR 6 -C(O)-R 7 group, ▪ R 5 represents a hydrogen atom, a halogen atom, or a linear or branched (C 1 -C 6 )alkyl group, ▪ R 6 represents a hydrogen atom or a linear or branched (C 1 -C 6 )alkyl group, ▪ R 7 represents a hydrogen atom, a linear or branched (C 1 -C 6 )alkyl group, or a -Y 2 -Cy 4 group, ▪ Y 1 and Y 2 independently of one another represent a bond or a linear or branched (C 1 -C 4 )alkylene group, ◆ Cy 1 represents a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group, which is linked to the group J and to the group L, ◆ Cy 2 , Cy 3 and Cy 4 independently of one another, represent a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group,

[0007] it being understood that: "aryl" means a phenyl, naphthyl, or indanyl group, "heteroaryl" means any mono- or fused bi-cyclic group composed of from 5 to 10 ring members, having at least one aromatic moiety and containing from 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen, "cycloalkyl" means any mono- or fused bi-cyclic non-aromatic carbocyclic group containing from 3 to 7 ring members, "heterocycloalkyl" means any non-aromatic mono- or fused bi-cyclic group containing from 3 to 10 ring members, and containing from 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen, it being possible for the aryl, heteroaryl, cycloalkyl and heterocycloalkyl groups so defined to be substituted by from 1 to 4 groups selected from linear or branched (C1-C6)alkyl, linear or branched (C2-C6)alkenyl, linear or branched (C2-C6)alkynyl, linear or branched halo(C1-C6)alkyl, -Y1-OR', -Y1-NR'R", -Y1-S(O)m-R', oxo (or N-oxide where appropriate), nitro, cyano, -C(O)-R', -C(O)-OR', -O-C(O)-R', -C(O)-NR'R", -Y1-NR'-C(O)-R", -Y1-NR'-C(O)-OR", halogen, cyclopropyl, and pyridinyl which can be substituted by a linear or branched (C1-C6)alkyl group, it being understood that R' and R" independently of one another, represent a hydrogen atom, a linear or branched (C1-C6)alkyl group, a linear or branched (C2-C6)alkenyl group, a linear or branched (C1-C6)alkoxy group, a linear or branched halo(C1-C6)alkyl, a linear or branched hydroxy(C1-C6)alkyl group, a linear or branched (C1-C6)alkoxy(C1-C6)alkyl group, a phenyl group, a cyclopropylmethyl group, a tetrahydropyranyl group, or the substituents of the pair (R', R") form together with the nitrogen atom carrying them a non-aromatic ring composed of from 5 to 7 ring members, which may contain in addition to the nitrogen a second heteroatom selected from oxygen and nitrogen, it being understood that the second nitrogen in question may be substituted by from 1 to 2 groups representing a hydrogen atom, or a linear or branched (C1-C6)alkyl group, and it being understood that m is an integer equal to 0, 1 or 2, their enantiomers, diastereoisomers and addition salts thereof with a pharmaceutically acceptable acid or base.

[0008] Among the pharmaceutically acceptable acids there may be mentioned, without implying any limitation, hydrochloric acid, hydrobromic acid, sulphuric acid, phosphonic acid, acetic acid, trifluoroacetic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, tartaric acid, maleic acid, citric acid, ascorbic acid, oxalic acid, methanesulphonic acid, camphoric acid etc.

[0009] Among the pharmaceutically acceptable bases there may be mentioned, without implying any limitation, sodium hydroxide, potassium hydroxide, triethylamine, tert-butylamine etc.

[0010] Among the heteroaryl groups there may be mentioned, without implying any limitation, pyrrolyl, furyl, thienyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrazolyl, imidazolyl, pyridinyl (also known as pyridyl), pyrazinyl, pyridazinyl, pyrimidinyl, pyridinonyl, indolyl, dihydroindolyl, dihydroisoindolyl, indazolyl, dihydrocyclopentathienyl, benzothienyl, tetrahydrobenzothienyl, benzofuranyl, imidazopyridinyl, benzotriazolyl, benzodioxolyl, dihydrobenzodioxinyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, quinoxalinyl, dihydroquinoxalinyl, dihydrothienodioxinyl, quinazolinonyl, pyrrolopyridazinyl, dihydropyrrolizinyl, tetrahydroindolizinyl, etc.

[0011] Among the cycloalkyl groups there may be mentioned, without implying any limitation, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc.

[0012] Among the heterocycloalkyl groups there may be mentioned, without implying any limitation, pyrrolidinyl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, etc.

[0013] In another embodiment of the invention, W advantageously represents the group wherein R 4 , R 5 and A are as defined for formula (I).

[0014] More especially, represents or

[0015] More particularly, represents

[0016] Advantageously, represents

[0017] Preferably, represents

[0018] In another embodiment of the invention, W advantageously represents the group wherein R 4 , R 5 and A are as defined for formula (I).

[0019] More especially, represents

[0020] R 1 advantageously represents a phenyl group or a thienyl group. More preferably, R 1 represents a phenyl group.

[0021] Advantageously, the compounds of formula (I) display a trans configuration as follows: or

[0022] More preferably, the compounds of formula (I) display a trans configuration as follows:

[0023] Preferably, R 2 represents a hydrogen atom or a fluorine atom. More preferably, R 2 represents a hydrogen atom. Advantageously, the -(R 2 ) n group represents a gem-difluoro group.

[0024] In some preferred embodiment of the invention, R 3 represents a hydrogen atom or a methyl group. More preferably, R 3 represents a hydrogen atom.

[0025] In the preferred compounds of the invention, J represents a -C(O)- group or a -CH 2 - group. Preferably, J represents a -C(O)- group. Advantageously, J represents a -CH 2 - group.

[0026] K preferably represents a bond or a -Cy 1 - group selected from a phenyl group, a pyrrolyl group, a thienyl group, a thiazolyl group, a pyridinyl group, a tetrahydrobenzothienyl group, a dihydrothienodioxinyl group, a cyclopropyl group, a cyclobutyl group, or a pyrrolidinyl group. More preferably, K preferably represents a bond or a -Cy 1 - group selected from a thienyl group, a thiazolyl group or a pyridinyl group.

[0027] Advantageously, L represents a -Cy 2 group. More preferably, Cy 2 represents a phenyl group, an indanyl group, a pyrrolyl group, a furyl group, a thienyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyrazolyl group, a pyridinyl group, a pyrazinyl group, a pyridazinyl group, a pyrimidinyl group, a pyridinonyl group, an indolyl group, a dihydroindolyl group, a dihydroisoindolyl group, an indazolyl group, a dihydrocyclopentathienyl group, a tetrahydrobenzothienyl group, a benzofuranyl group, an imidazopyridinyl group, a benzotriazolyl group, a benzodioxolyl group, a dihydrobenzodioxinyl group, a quinolinyl group, a tetrahydroquinolinyl group, a tetrahydroisoquinolinyl group, a quinoxalinyl group, a dihydroquinoxalinyl group, a quinazolinonyl group, or a pyrrolidinyl group. Even more preferably, Cy 2 represents a phenyl group, a pyrrolyl group, a furyl group, a thienyl group, a thiazolyl group, an oxazolyl group, an isoxazolyl group, a pyrazolyl group, a pyridinyl group, a pyrazinyl group, a pyridazinyl group, a pyrimidinyl group, or an imidazopyridinyl group. Preferably, Cy 2 represents a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group which are substituted by 1 or 2 groups selected from linear or branched (C 1 -C 6 )alkyl, linear or branched halo(C 1 -C 6 )alkyl, -Y 1 -OR', -Y 1 -NR'R", N-oxide, cyano, -C(O)-OR', -C(O)-NR'R", halogen, in which R' and R" independently of one another represent a hydrogen atom, a linear or branched (C 1 -C 6 )alkyl group, a linear or branched (C 1 -C 6 )alkoxy group, a tetrahydropyranyl group, or the substituents of the pair (R', R") form together with the nitrogen atom carrying them a non-aromatic ring composed of from 5 to 7 ring members, which may contain in addition to the nitrogen a second heteroatom selected from oxygen and nitrogen, it being understood that the second nitrogen in question may be substituted by a linear or branched (C 1 -C 6 )alkyl group.

[0028] In some preferred embodiment of the invention, K represents a thienyl group, a thiazolyl group or a pyridinyl group and L represents a pyrrolyl group, a furyl group, a thienyl group, a pyrazolyl group, a pyridinyl group, a pyrimidinyl group, or an imidazopyridinyl group, each said heteroaryl group may be substituted by 1 or 2 groups selected from linear or branched (C 1 -C 6 )alkyl, linear or branched halo(C 1 -C 6 )alkyl, -Y 1 -OR', -Y 1 -NR'R", N-oxide, cyano, -C(O)-NR'R", halogen, in which R' and R" independently of one another represent a hydrogen atom, a linear or branched (C 1 -C 6 )alkyl group, a linear or branched (C 1 -C 6 )alkoxy group, a linear or branched (C 1 -C 6 )alkoxy(C 1 -C 6 )alkyl group, a tetrahydropyranyl group, or the substituents of the pair (R', R") form together with the nitrogen atom carrying them a non-aromatic ring composed of from 5 to 7 ring members, which may contain in addition to the nitrogen a second heteroatom selected from oxygen and nitrogen. More preferably, K represents a thiazolyl group and L represents a pyridinyl group.

[0029] Other compounds of the invention to which preference is given are those wherein K represents a bond and L represents a phenyl group, a thiazolyl group, an oxazolyl group, an isoxazolyl group, a pyrazolyl group, a pyridinyl group, a pyrazinyl group, a pyridazinyl group or a pyrimidinyl group, each said group may be substituted by 1 or 2 groups selected from linear or branched (C 1 -C 6 )alkyl, -Y 1 -OR', -Y 1 -NR'R", cyano, -C(O)-OR', halogen, it being understood that R' and R" independently of one another represent a hydrogen atom, a linear or branched (C 1 -C 6 )alkyl group, or the substituents of the pair (R', R") form together with the nitrogen atom carrying them a non-aromatic ring composed of from 5 to 7 ring members, which may contain in addition to the nitrogen a second heteroatom selected from oxygen and nitrogen, it being understood that the second nitrogen in question may be substituted by from 1 to 2 groups representing a hydrogen atom, or a linear or branched (C 1 -C 6 )alkyl group.

[0030] In a preferred embodiment, the -J-K-L group linked to the piperidinyl ring is defined such as J represents a -C(O)- group, K represents a -Cy 1 - group and L represents a -Cy 2 group. In another preferred embodiment, the -J-K-L group is defined such as J represents a -CH 2 - group, K represents a bond and L represents a -Cy 2 group.

[0031] In another preferred embodiment, the -J-K-L group is defined such as J represents a -C(O)- group, K represents a bond and L represents a -Cy 2 group.

[0032] In another preferred embodiment, the -J-K-L group is defined such as J represents a -CH 2 - group, K represents a -Cy 1 - group and L represents a -Cy 2 group

[0033] In the preferred compounds of the invention, R 4 represents a halogen atom, a linear or branched (C 1 -C 6 )alkyl group, or a -Y 1 -Cy 3 group. Preferably, R 4 represents a bromine atom, a methyl group, or a -Cy 3 group.

[0034] Advantageously, Cy 3 represents a phenyl group, a naphthyl group, a pyrrolyl group, a furyl group, a thienyl group, a thiazolyl group, a pyrazolyl group, an imidazolyl group, a pyridinyl group, a pyrimidinyl group, a pyridinonyl group, an indolyl group, a benzodioxolyl group, a dihydrobenzodioxinyl group, a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a pyrrolidinyl group, a tetrahydropyranyl group, or a piperidinyl group.

[0035] Cy 3 preferably represents a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group which are substituted by from 1 to 3 groups selected from linear or branched (C 1 -C 6 )alkyl, linear or branched halo(C 1 -C 6 )alkyl, -Y 1 -OR', -Y 1 -NR'R", cyano, halogen, in which R' and R" independently of one another represent a hydrogen atom or a linear or branched (C 1 -C 6 )alkyl group, or the substituents of the pair (R', R") form together with the nitrogen atom carrying them a non-aromatic ring composed of from 5 to 7 ring members which may contain in addition to the nitrogen a second heteroatom selected from oxygen and nitrogen.

[0036] Advantageously, R 5 represents a hydrogen atom or a methyl group. More preferably, R 5 represents a hydrogen atom.

[0037] In the preferred compounds of the invention, R 6 represents a hydrogen atom or a methyl group.

[0038] R 7 preferably represents a hydrogen atom, a methyl group, or a -CH 2 -Cy 4 group. Preferably, Cy 4 represents a phenyl group or a dihydroindolyl group.

[0039] Preferred compounds of the invention are: 3-[(4-hydroxy-1-{[(3R,4R)-1-{[3-methyl-5-(pyridin-4-yl)thiophen-2-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-methyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(1-{[(3R,4R)-1-{[5-(6-aminopyridin-3-yl)-3-fluorothiophen-2-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}-4-hydroxypiperidin-4-yl)methyl]-7-methyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 7-cyclopropyl-3-[(1-{[(3R,4R)-1-{[3-fluoro-5-(pyridin-4-yl)thiophen-2-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}-4-hydroxypiperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(1-{[(3R,4R)-1-{[3-fluoro-5-(6-methylpyridin-3-yl)thiophen-2-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}-4-hydroxypiperidin-4-yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(pyridin-3-yl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(thiophen-3-yl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(naphthalen-2-yl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 7-(4-chlorophenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(3-methylphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(4-methylphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 7-(3-chlorophenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 7-(furan-3-yl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 7-(2-fluorophenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 7-(2-chlorophenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 7-[4-(dimethylamino)phenyl]-3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-[4-(4-methylpiperazin-1-yl)phenyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 7-[3-(dimethylamino)phenyl]-3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(1H-pyrrol-1-yl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-{[1-({(3R,4R)-1-[(2-bromo-4-methyl-1,3-thiazol-5-yl)carbonyl]-3-phenylpiperidin-4-yl}carbonyl)-4-hydroxypiperidin-4-yl]methyl}-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 5-(5-{[(3R,4R)-4-({4-hydroxy-4-[(4-oxo-7-phenyl-4,7-dihydro-3H-pyrrolo[2,3-d] pyrimidin-3-yl)methyl]piperidin-1-yl}carbonyl)-3-phenylpiperidin-1-yl]carbonyl}-4-methyl-1,3-thiazol-2-yl)pyridine-2-carbonitrile; 3-[(1-{[(3R,4R)-1-({2-[6-(dimethylamino)pyridin-3-yl]-4-methyl-1,3-thiazol-5-yl}carbonyl)-3-phenylpiperidin-4-yl]carbonyl}-4-hydroxypiperidin-4-yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-({4-methyl-2-[6-(trifluoromethyl)pyridin-3-yl]-1,3-thiazol-5-yl}carbonyl)-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-4-methyl-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(3-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 7-(3-fluorophenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(1-{[(3R,4R)-1-({2-[6-(dimethylamino)pyridin-3-yl]-1,3-thiazol-5-yl}methyl)-3-phenylpiperidin-4-yl]carbonyl}-4-hydroxypiperidin-4-yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 7-(4-fluorophenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(thiophen-3-yl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-({2-[6-(morpholin-4-yl)pyridin-3-yl]-1,3-thiazol-5-yl}methyl)-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(3-methylphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(4-methylphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3 -d]pyrimidin-4-one; 3-[(1-{[(3R,4R)-1-({2-[6-(dimethylamino)pyridin-3-yl]-1,3-thiazol-5-yl}methyl)-3-phenylpiperidin-4-yl]carbonyl}-4-hydroxypiperidin-4-yl)methyl]-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 7-(4-chlorophenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 7-(4-chlorophenyl)-3-[(1-{[(3R,4R)-1-({2-[6-(dimethylamino)pyridin-3-yl]-1,3-thiazol-5-yl}methyl)-3-phenylpiperidin-4-yl]carbonyl}-4-hydroxypiperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-6,8-dimethylpyrimido[5',4':4,5]pyrrolo[1,2-b]pyridazin-4(3H)-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-[3-(morpholin-4-yl)phenyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-[4-(morpholin-4-yl)phenyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 7-(3-chlorophenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methyl-1-oxidopyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-3-phenyl-1-({2-[6-(piperazin-1-yl)pyridin-3-yl]-1,3-thiazol-5-yl}methyl)piperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-3-phenyl-1-({2-[6-(trifluoromethyl)pyridin-3-yl]-1,3-thiazol-5-yl}methyl)piperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 7-(3,4-dichlorophenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 5-(5-{[(3R,4R)-4-({4-hydroxy-4-[(4-oxo-7-phenyl-4,7-dihydro-3H-pyrrolo[2,3-d] pyrimidin-3-yl)methyl]piperidin-1-yl}carbonyl)-3-phenylpiperidin-1-yl]methyl}-1,3-thiazol-2-yl)pyridine-2-carbonitrile; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(3-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(pyridin-2-yl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-[4-(hydroxymethyl)phenyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(thiophen-2-yl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 7-(3,4-dimethoxyphenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 7-(3,4-dimethoxyphenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(pyridin-3-yl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 5-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-1-phenyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one; 7-(3,5-dimethoxyphenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 7-(3,5-dimethoxyphenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 7-(4-fluorophenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 4-{3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl}benzonitrile; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(1-methyl-1H-pyrazol-4-yl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(1-methyl-1H-pyrazol-4-yl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-[3-(hydroxymethyl)phenyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 7-[3-(hydroxymethyl)phenyl]-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 7-(4-chloro-3-fluorophenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 5-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-1-phenyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(1-methyl-1H-pyrazol-4-yl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-[3-(hydroxymethyl)phenyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 7-(4-fluorophenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 7-(4-chloro-3-fluorophenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 7-(3-chloro-5-methoxyphenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 7-(3-chloro-5-methoxyphenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 7-(4-fluoro-3-methoxyphenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 7-(4-fluoro-3-methoxyphenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 7-(4-fluoro-3-methoxyphenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 7-(4-chloro-3-methoxyphenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 7-(4-chloro-3-methoxyphenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 7-(4-chlorophenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 7-(5-chlorothiophen-2-yl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 7-(5-chlorothiophen-2-yl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 7-bromo-3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]pyrrolo[2,1-f][1,2,4]triazin-4(3H)-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(5-methylthiophen-2-yl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(5-methylthiophen-2-yl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(5-methylthiophen-2-yl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 7-[4-(hydroxymethyl)phenyl]-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-[4-(hydroxymethyl)phenyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-phenylpyrrolo[2,1-f] [1,2,4]triazin-4(3H)-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-phenylpyrrolo[2,1-f][1,2,4]triazin-4(3H)-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(thiophen-2-yl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(thiophen-2-yl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-phenylthieno[3,4-d]pyrimidin-4(3H)-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-phenylthieno[3,4-d] pyrimidin-4(3H)-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-phenyl-3,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-phenyl-3,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-phenyl-3,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(3-methylphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(4-methylphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(thiophen-3-yl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-[3-(morpholin-4-yl)phenyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-[3-(morpholin-4-yl)phenyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-{[1-({(3R,4R)-1-[(2-bromo-1,3-thiazol-5-yl)methyl]-3-phenylpiperidin-4-yl}carbonyl)-4-hydroxypiperidin-4-yl]methyl}-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(4-hydroxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(4-hydroxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-hydroxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(4-hydroxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-hydroxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-({2-[6-(hydroxymethyl)pyridin-3-yl]-1,3-thiazol-5-yl}methyl)-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-[3-(trifluoromethyl)phenyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-[3-(trifluoromethyl)phenyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 7-[4-(difluoromethyl)phenyl]-3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 7-[4-(difluoromethyl)phenyl]-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 7-[4-(difluoromethyl)phenyl]-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 7-[1-(difluoromethyl)-1H-pyrazol-4-yl]-3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 7-[1-(difluoromethyl)-1H-pyrazol-4-yl]-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(3-methyl-3H-imidazo[4,5-b]pyridin-6-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(3-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 7-[3-(dimethylamino)phenyl]-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 7-(3-fluorophenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(1-{[(3R,4R)-1-{[2-(5-fluoro-6-hydroxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}-4-hydroxypiperidin-4-yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 5-(5-{[(3R,4R)-4-({4-hydroxy-4-[(4-oxo-7-phenyl-4,7-dihydro-3H-pyrrolo[2,3-d] pyrimidin-3-yl)methyl]piperidin-1-yl}carbonyl)-3-phenylpiperidin-1-yl]methyl}-1,3-thiazol-2-yl)pyridine-3-carboxamide; 3-[(4-hydroxy-1-{[(3R,4R)-1-({2-[5-(hydroxymethyl)pyridin-3-yl]-1,3-thiazol-5-yl}methyl)-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-3-phenyl-1-({2-[6-(tetrahydro-2H-pyran-4-yloxy)pyridin-3-yl]-1,3-thiazol-5-yl}methyl)piperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(1-{[(3R,4R)-1-{[2-(5-amino-6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}-4-hydroxypiperidin-4-yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-{[1-({(3R,4R)-1-[(2-bromo-1,3-thiazol-5-yl)methyl]-3-phenylpiperidin-4-yl}carbonyl)-4-hydroxypiperidin-4-yl]methyl}-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-3-phenyl-1-{[2-(thiophen-2-yl)-1,3-thiazol-5-yl]methyl}piperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-3-phenyl-1-{[2-(pyrimidin-5-yl)-1,3-thiazol-5-yl]methyl}piperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(1-methyl-1H-pyrazol-5-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(1-methyl-1H-pyrazol-4-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(1-methyl-1H-pyrrol-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-3-phenyl-1-{[2-(thiophen-3-yl)-1,3-thiazol-5-yl]methyl}piperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 7-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 7-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(3-hydroxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-{[1-({(3R,4R)-1-[(2-bromopyridin-4-yl)carbonyl]-3-phenylpiperidin-4-yl}carbonyl)-4-hydroxypiperidin-4-yl]methyl}-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-{[1-({(3R,4R)-1-[(5-bromopyridin-3-yl)carbonyl]-3-phenylpiperidin-4-yl}carbonyl)-4-hydroxypiperidin-4-yl]methyl}-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 7-(3-chlorophenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-hydroxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(1-{[(3R,4R)-1-{[2-(furan-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}-4-hydroxypiperidin-4-yl)methyl]-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(1-{[(3R,4R)-1-{[2-(furan-2-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}-4-hydroxypiperidin-4-yl)methyl]-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-3-phenyl-1-{[2-(thiophen-2-yl)-1,3-thiazol-5-yl]methyl}piperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(3-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-3-phenyl-1-{[2-(pyrimidin-5-yl)-1,3-thiazol-5-yl]methyl}piperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(3-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(1-methyl-1H-pyrazol-5-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(3-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(1-methyl-1H-pyrazol-4-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(3-methoxyphenyl)-3,7-dihydro-4H-pyrro10[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(1-methyl-1H-pyrrol-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(3-methoxyphenyl)-3,7-dihydro-4H-pyrro10[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-3-phenyl-1-{[2-(thiophen-3-yl)-1,3-thiazol-5-yl]methyl}piperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(3-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(1-{[(3R,4R)-1-{[2-(furan-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}-4-hydroxypiperidin-4-yl)methyl]-7-(3-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(1-{[(3R,4R)-1-{[2-(furan-2-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}-4-hydroxypiperidin-4-yl)methyl]-7-(3-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 7-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(3,4,5-trimethoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(3,4,5-trimethoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 7-(1,3-benzodioxol-5-yl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 7-(1,3-benzodioxol-5-yl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 7-(1,3-benzodioxol-5-yl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-{[1-({(3R,4R)-1-[(5-bromopyridin-3-yl)methyl]-3-phenylpiperidin-4-yl}carbonyl)-4-hydroxypiperidin-4-yl]methyl}-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(3,4,5-trimethoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-3-phenyl-1-(pyridin-3-ylmethyl)piperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d] pyrimidin-4-one; 3-{[4-hydroxy-1-({(3R,4R)-1-[(6'-methyl-3,3'-bipyridin-5-yl)carbonyl]-3-phenylpiperidin-4-yl}carbonyl)piperidin-4-yl]methyl}-7-phenyl-3,7-dihydro-4H-pyrrolo [2,3 -d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(3-hydroxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[-(pyridin-4-ylmethyl)piperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d] pyrimidin-4-one; 5-[5-({(3R,4R)-4-[(4-hydroxy-4-{[7-(3-methoxyphenyl)-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-3-yl]methyl}piperidin-1-yl)carbonyl]-3-phenylpiperidin-1-yl}methyl)-1,3-thiazol-2-yl]pyridine-2-carbonitrile; 5-[5-({(3R,4R)-4-[(4-{[7-(4-chlorophenyl)-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d] pyrimidin-3-yl]methyl}-4-hydroxypiperidin-1-yl)carbonyl]-3-phenylpiperidin-1-yl}methyl)-1,3-thiazol-2-yl]pyridine-2-carbonitrile; 5-[5-({(3R,4R)-4-[(4-hydroxy-4-{[7-(4-methoxyphenyl)-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-3-yl]methyl}piperidin-1-yl)carbonyl]-3-phenylpiperidin-1-yl}methyl)-1,3-thiazol-2-yl]pyridine-2-carbonitrile; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(morpholin-4-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-({2-[6-(2-methoxyethoxy)pyridin-3-yl]-1 ,3-thiazol-5-yl}methyl)-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(4-methylpiperazin-1-yl)-1 ,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-hydroxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(3-hydroxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-{[4-hydroxy-1-({(3R,4R)-1-[(4-methyl-1,3-thiazol-5-yl)carbonyl]-3-phenylpiperidin-4-yl}carbonyl)piperidin-4-yl]methyl}-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-{[4-hydroxy-1-({(3R,4R)-1-[(2-methyl-1,3-thiazol-5-yl)carbonyl]-3-phenylpiperidin-4-yl}carbonyl)piperidin-4-yl]methyl}-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-{[1-({(3R,4R)-1-[(2-chloro-1,3-thiazol-5-yl)carbonyl]-3-phenylpiperidin-4-yl}carbonyl)-4-hydroxypiperidin-4-yl]methyl}-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-3-phenyl-1-(pyrazin-2-ylmethyl)piperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d] pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-3-phenyl-1-(1,3-thiazol-5-ylmethyl)piperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d] pyrimidin-4-one; 5-[5-({(3R,4R)-4-[(4-{[7-(4-fluorophenyl)-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d] pyrimidin-3-yl]methyl}-4-hydroxypiperidin-1-yl)carbonyl]-3-phenylpiperidin-1-yl}methyl)-1,3-thiazol-2-yl]pyridine-2-carbonitrile; methyl 3-{[(3R,4R)-4-({4-hydroxy-4-[(4-oxo-7-phenyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-3-yl)methyl]piperidin-1-yl}carbonyl)-3-phenylpiperidin-1-yl]carbonyl}benzoate; 5-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-1-(4-methoxyphenyl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one; 5-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-1-(4-methoxyphenyl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one; 5-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-1-(4-methoxyphenyl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one; 3-{[4-hydroxy-1-({(3R,4R)-1-[(2-{6-[(2-methoxyethyl)amino]pyridin-3-yl}-1,3-thiazol-5-yl)methyl]-3-phenylpiperidin-4-yl}carbonyl)piperidin-4-yl]methyl}-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-{[4-hydroxy-1-({(3R,4R)-1-[(1-methyl-1H-pyrazol-4-yl)methyl]-3-phenylpiperidin-4-yl}carbonyl)piperidin-4-yl]methyl}-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-3-phenyl-1-(pyrazin-2-ylmethyl)piperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-{[4-hydroxy-1-({(3R,4R)-1-[(5-methyl-1,3-thiazol-2-yl)methyl]-3-phenylpiperidin-4-yl}carbonyl)piperidin-4-yl]methyl}-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-{[1-({(3R,4R)-1-[(5-bromopyridin-3-yl)methyl]-3-phenylpiperidin-4-yl}carbonyl)-4-hydroxypiperidin-4-yl]methyl}-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; methyl 5-{[(3R,4R)-4-({4-hydroxy-4-[(4-oxo-7-phenyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-3-yl)methyl]piperidin-1-yl}carbonyl)-3-phenylpiperidin-1-yl]carbonyl}pyridine-3-carboxylate; 1-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl} -3-phenylpiperidin-4-yl] carbonyl}piperidin-4-yl)methyl]-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one; 1-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl] carbonyl}piperidin-4-yl)methyl]-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one; 3-{[4-hydroxy-1-({(3R,4R)-1-[(5-methyl-1,3-thiazol-2-yl)methyl]-3-phenylpiperidin-4-yl}carbonyl)piperidin-4-yl]methyl}-7-phenyl-3,7-dihydro-4H-pyrrolo [2,3 -d]pyrimidin-4-one; 3-{[4-hydroxy-1-({(3R,4R)-1-[(3-methyl-1,2-oxazol-5-yl)methyl]-3-phenylpiperidin-4-yl}carbonyl)piperidin-4-yl]methyl}-7-phenyl-3,7-dihydro-4H-pyrrolo [2,3 -d]pyrimidin-4-one; 3-{[1-({(3R,4R)-1-[(2,4-dimethyl-1,3-thiazol-5-yl)methyl]-3-phenylpiperidin-4-yl}carbonyl)-4-hydroxypiperidin-4-yl]methyl}-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-[(4-hydroxy-1-{[(3R,4R)-1-(1,3-oxazol-4-ylmethyl)-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 3-{[4-hydroxy-1-({(3R,4R)-1-[(5-methyl-1,3-oxazol-2-yl)methyl]-3-phenylpiperidin-4-yl}carbonyl)piperidin-4-yl]methyl}-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 5-{[(3R,4R)-4-({4-hydroxy-4-[(4-oxo-7-phenyl-4,7-dihydro-3H-pyrrolo[2,3-d] pyrimidin-3-yl)methyl]piperidin-1-yl}carbonyl)-3-phenylpiperidin-1-yl]methyl}pyridine-2-carbonitrile; 3-[[4-hydroxy-1-[(3R,4R)-1-[4-methyl-2-(6-methyl-3-pyridyl)thiazole-5-carbonyl]-3-phenyl-piperidine-4-carbonyl]-4-piperidyl]methyl]-7-[4-(hydroxymethyl)phenyl]pyrrolo[2,1-f][1,2,4]triazin-4-one; 3-[[4-hydroxy-1-[(3R,4R)-1-[4-methyl-2-(6-methyl-3-pyridyl)thiazole-5-carbonyl]-3-phenyl-piperidine-4-carbonyl]-4-piperidyl]methyl]-7-[4-(hydroxymethyl)phenyl]thieno [3,4-d]pyrimidin-4-one; 3-[[4-hydroxy-1-[(3R,4R)-1-[2-(6-methyl-3-pyridyl)thiazole-5-carbonyl]-3-phenylpiperidine-4-carbonyl]-4-piperidyl]methyl]-7-(3-methoxyphenyl)pyrrolo[2,3-d] pyrimidin-4-one; 3-[[3,3-difluoro-4-hydroxy-1-[(3R,4R)-1-[4-methyl-2-(6-methyl-3-pyridyl)thiazole-5-carbonyl]-3-phenyl-piperidine-4-carbonyl]-4-piperidyl]methyl]-7-phenyl-pyrrolo[2,3-d]pyrimidin-4-one; 3-[[3,3-difluoro-4-hydroxy-1-[(3R,4R)-1-[4-methyl-2-(6-methyl-3-pyridyl)thiazole-5-carbonyl]-3-phenyl-piperidine-4-carbonyl]-4-piperidyl]methyl]-7-(4-methoxyphenyl)pyrrolo[2,3-d]pyrimidin-4-one; 3-[[4-hydroxy-1-[(3R,4R)-1-[(2-methoxypyrimidin-4-yl)methyl]-3-phenylpiperidine-4-carbonyl]-4-piperidyl]methyl]-7-phenyl-pyrrolo[2,3-d]pyrimidin-4-one; 3-[[4-hydroxy-1-[(3R,4R)-1-[(2-methoxypyrimidin-4-yl)methyl]-3-phenylpiperidine-4-carbonyl]-4-piperidyl]methyl]-7-(4-methoxyphenyl)pyrrolo[2,3-d] pyrimidin-4-one; 3-[[4-hydroxy-1-[(3R,4R)-1-[(5-methylpyrazin-2-yl)methyl]-3-phenyl-piperidine-4-carbonyl]-4-piperidyl]methyl]-7-phenyl-pyrrolo[2,3-d]pyrimidin-4-one; 3-[[4-hydroxy-1-[(3R,4R)-1-[(5-methylpyrazin-2-yl)methyl]-3-phenyl-piperidine-4-carbonyl]-4-piperidyl]methyl]-7-(4-methoxyphenyl)pyrrolo[2,3-d]pyrimidin-4-one; 3-[[4-hydroxy-1-[(3R,4R)-3-phenyl-1-(pyrimidin-2-ylmethyl)piperidine-4-carbonyl]-4-piperidyl]methyl]-7-phenyl-pyrrolo[2,3-d]pyrimidin-4-one; 3-[[4-hydroxy-1-[(3R,4R)-3-phenyl-1-(pyrimidin-2-ylmethyl)piperidine-4-carbonyl]-4-piperidyl]methyl]-7-(4-methoxyphenyl)pyrrolo[2,3-d]pyrimidin-4-one; 3-[[4-hydroxy-1-[(3R,4R)-1-[(2-methylpyrimidin-4-yl)methyl]-3-phenylpiperidine-4-carbonyl]-4-piperidyl]methyl]-7-phenyl-pyrrolo[2,3-d]pyrimidin-4-one; 3-[[4-hydroxy-1-[(3R,4R)-1-[(2-methylpyrimidin-4-yl)methyl]-3-phenylpiperidine-4-carbonyl]-4-piperidyl]methyl]-7-(4-methoxyphenyl)pyrrolo[2,3-d] pyrimidin-4-one; 3-[[4-hydroxy-1-[(3R,4R)-1-[(6-methoxypyridazin-3-yl)methyl]-3-phenylpiperidine-4-carbonyl]-4-piperidyl]methyl]-7-(4-methoxyphenyl)pyrrolo[2,3-d] pyrimidin-4-one; 3-[[4-hydroxy-1-[(3R,4R)-1-[(5-methylpyrazin-2-yl)methyl]-3-phenyl-piperidine-4-carbonyl]-4-piperidyl]methyl]-7-phenyl-thieno[3,4-d]pyrimidin-4-one; 3-[[4-hydroxy-1-[(3R,4R)-1-[(2-methylpyrimidin-4-yl)methyl]-3-phenylpiperidine-4-carbonyl]-4-piperidyl]methyl]-7-phenyl-thieno[3,4-d]pyrimidin-4-one.

[0040] The invention relates also to a process for the preparation of compounds of formula (I), which process is characterized in that there is used as starting material the compound of formula (II): wherein R 2 and n are as defined for formula (I), which is subjected to coupling with a compound of formula (III): wherein R 1 is as defined for formula (I), and PG represents a protecting group of the amine function, to yield the compound of formula (IV): wherein R 1 , R 2 , n and PG are as defined hereinbefore, compound of formula (IV) which is further converted to an epoxide compound of formula (V): wherein R 1 , R 2 , n and PG are as defined hereinbefore, compound of formula (V) which is further subjected to coupling with compound of formula (VI): wherein W is as defined for formula (I), to yield the compound of formula (VII): wherein R 1 , R 2 , n, W and PG are as defined hereinbefore, compound of formula (VII) which, after a reaction removing the protecting group PG, is further subjected to: ▪ either coupling with compound of formula (VIII): wherein J is as defined in formula (I), K' represents a -Cy 1 - group, Y represents a hydroxy group or a halogen atom, and Z represents a halogen atom, to yield the compound of formula (IX): wherein R 1 , R 2 , J, K', n, W and Z are as defined hereinbefore, compound of formula (IX) which is further subjected to coupling with compound of formula (X): wherein L is as defined for formula (I), and R B1 and R B2 represent a hydrogen atom, a linear or branched (C 1 -C 6 ) alkyl group, or R B1 and R B2 are linked together by a linear or branched (C 2 -C 6 )alkylene group, to yield the compound of formula (I-a), a particular case of the compounds of formula (I): wherein R 1 , R 2 , J, K', L, n and W are as defined hereinbefore, ▪ or coupling with compound of formula (XI): wherein J, K and L are as defined in formula (I), and Y represents a hydroxy group or a halogen atom, to yield the compound of formula (I), compound of formula (I) or compound of formula (I-a), which is a particular case of compound of formula (I), may then be purified according to a conventional separation technique, which is converted, if desired, into its addition salts with a pharmaceutically acceptable acid or base and which is optionally separated into its isomers according to a conventional separation technique, it being understood that at any moment considered appropriate during the course of the process described above, some groups (hydroxy, amino...) of the starting reagents or of the synthesis intermediates can be protected, subsequently deprotected and functionalized, as required by the synthesis.

[0041] In another embodiment of the invention, compounds of formula (I) may be obtained using an alternative process, which process is characterized in that there is used as starting material the compound of formula (XII): wherein R 1 is as defined for formula (I), and PG represents a protecting group of the carboxylic acid function, which is subjected to: ▪ either coupling with compound of formula (VIII): wherein J is as defined in formula (I), K' represents a -Cy 1 - group, Y represents a hydroxy group or a halogen atom, and Z represents a halogen atom, to yield the compound of formula (XIII): wherein R 1 , J, K', Z and PG are as defined hereinbefore, compound of formula (XIII) which is further subjected to coupling with compound of formula (X): wherein L is as defined for formula (I), and R B1 and R B2 represent a hydrogen atom, a linear or branched (C 1 -C 6 ) alkyl group, or R B1 and R B2 are linked together by a linear or branched (C 2 -C 6 )alkylene group, to yield the compound of formula (XIV): wherein R 1 , J, K', L and PG are as defined hereinbefore, ▪ or coupling with compound of formula (XI): wherein J, K and L are as defined in formula (I), and Y represents a hydroxy group or a halogen atom, to yield the compound of formula (XV), wherein R 1 , J, K, L and PG are as defined hereinbefore, compounds of formula (XIV) and (XV) which, after a reaction removing the protecting group PG, are further subjected to coupling with a compound of formula (II), to yield the compound of formula (XVI): wherein R 1 , R 2 , J, L and n are as defined hereinbefore, and K" is either K' or K as defined hereinbefore, compound of formula (XVI) which is further converted to an epoxide compound of formula (XVII): wherein R 1 , R 2 , J, K", L and n are as defined hereinbefore, compound of formula (XVII) which is further subjected to coupling with compound of formula (VI): wherein W is as defined for formula (I), to yield the compound of formula (I), which may be purified according to a conventional separation technique, which is converted, if desired, into its addition salts with a pharmaceutically acceptable acid or base and which is optionally separated into its isomers according to a conventional separation technique, it being understood that at any moment considered appropriate during the course of the process described above, some groups (hydroxy, amino...) of the starting reagents or of the synthesis intermediates can be protected, subsequently deprotected and functionalized, as required by the synthesis.

[0042] The compounds of formulae (II), (III), (VI), (VIII), (X), (XI) and (XII) are either commercially available or can be obtained by the person skilled in the art using conventional chemical reactions described in the literature.

[0043] Pharmacological studies of the compounds of the invention have shown pro-apoptotic and / or anti-proliferative properties. The ability to reactivate the apoptotic process in cancerous cells is of major therapeutic interest in the treatment of cancers and of immune and auto-immune system diseases.

[0044] Among the cancer treatments envisaged there may be mentioned, without implying any limitation, treatment of cancers of the bladder, brain, breast and uterus, chronic lymphoid leukemia, cancer of the colon, esophagus and liver, lymphoblastic leukemia, acute myeloid leukemia, lymphomas, melanomas, malignant haemopathies, myelomas, ovarian cancer, non-small-cell lung cancer, prostate cancer, pancreatic cancer and small-cell lung cancer. More especially, the compounds according to the invention will be useful in the treatment of chemo-, targeted therapy- or radio-resistant cancers.

[0045] The present invention relates also to pharmaceutical compositions comprising at least one compound of formula (I) in combination with one or more pharmaceutically acceptable excipients.

[0046] Among the pharmaceutical compositions according to the invention there may be mentioned more especially those that are suitable for oral, parenteral, nasal, per- or trans-cutaneous, rectal, perlingual, ocular or respiratory administration, especially tablets or dragées, sublingual tablets, sachets, paquets, capsules, glossettes, lozenges, suppositories, creams, ointments, dermal gels, and drinkable or injectable ampoules.

[0047] The pharmaceutical compositions according to the invention comprise one or more excipients or carriers selected from diluents, lubricants, binders, disintegration agents, stabilisers, preservatives, absorbents, colorants, sweeteners, flavourings etc.By way of non-limiting example there may be mentioned:

[0048] ◆ as diluents: lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, glycerol, ◆ as lubricants: silica, talc, stearic acid and its magnesium and calcium salts, polyethylene glycol, ◆ as binders: magnesium aluminium silicate, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and polyvinylpyrrolidone, ◆ as disintegrants: agar, alginic acid and its sodium salt, effervescent mixtures.

[0049] The dosage varies according to the sex, age and weight of the patient, the administration route, the nature of the therapeutic indication, or of any associated treatments, and ranges from 0.01 mg to 1 g per 24 hours in one or more administrations.

[0050] Furthermore, the present invention relates also to the combination of a compound of formula (I) with anti-cancer agents selected from genotoxic agents, mitotic poisons, antimetabolites, proteasome inhibitors, kinase inhibitors, protein-protein interaction inhibitors, immunomodulators, E3 ligase inhibitors, chimeric antigen receptor T-cell therapy and antibodies, and also to pharmaceutical compositions comprising that type of combination and their use in the manufacture of medicaments for use in the treatment of cancer.

[0051] The combination of a compound of formula (I) with an anticancer agent may be administered simultaneously or sequentially. The administration route is preferably the oral route, and the corresponding pharmaceutical compositions may allow the instantaneous or delayed release of the active ingredients. The compounds of the combination may moreover be administered in the form of two separate pharmaceutical compositions, each containing one of the active ingredients, or in the form of a single pharmaceutical composition, in which the active ingredients are in admixture.

[0052] The compounds of formula (I) may also be used in combination with radiotherapy in the treatment of cancer.

[0053] The following Preparations and Examples illustrate the invention but do not limit it in any way.General Procedures

[0054] All reagents obtained from commercial sources were used without further purification. Anhydrous solvents were obtained from commercial sources and used without further drying.

[0055] Flash chromatography was performed on ISCO CombiFlash Rf 200i with pre-packed silica-gel cartridges (RediSep® R f Gold High Performance).

[0056] Thin layer chromatography was conducted with 5 x 10 cm plates coated with Merck Type 60 F254 silica-gel.

[0057] Microwave heating was performed in an Anton Parr MonoWave or CEM Discover® instrument.

[0058] Preparative HPLC purifications were performed on an HANBON NP7000 Liquid Chromatography system with a Gemini-NX® 5µM C18, 250 mm × 50 mm i.d. column running at a flow rate of 99.9 mL min -1< with UV diode array detection (210 - 400 nm) using 5 mM aqueous NH 4 HCO 3 solution and MeCN as eluents unless specified otherwise.

[0059] Analytical LC-MS: The compounds of the present invention were characterized by high performance liquid chromatography-mass spectroscopy (HPLC-MS) on Agilent HP1200 with Agilent 6140 quadrupole LC / MS, operating in positive or negative ion electrospray ionization mode. Molecular weight scan range is 100 to 1350. Parallel UV detection was done at 210 nm and 254 nm. Samples were supplied as a 1 mM solution in MeCN, or in THF / H 2 O (1:1) with 5 µL loop injection. LCMS analyses were performed on two instruments, one of which was operated with basic, and the other with acidic eluents.

[0060] Basic LCMS: Gemini-NX, 3 µm, C18, 50 mm × 3.00 mm i.d. column at 23 °C, at a flow rate of 1 mL min -1< using 5 mM ammonium bicarbonate (Solvent A) and acetonitrile (Solvent B) with a gradient starting from 100 % Solvent A and finishing at 100 % Solvent B over various / certain duration of time.

[0061] Acidic LCMS: ZORBAX Eclipse XDB-C18, 1.8 µm, 50 mm × 4.6 mm i.d. column at 40 °C, at a flow rate of 1 mL min -1< using 0.02 % v / v aqueous formic acid (Solvent A) and 0.02 % v / v formic acid in acetonitrile (Solvent B) with a gradient starting from 100% Solvent A and finishing at 100 % Solvent B over various / certain duration of time.

[0062] 1< H-NMR measurements were performed on Bruker Avance III 500 MHz spectrometer and Bruker Avance III 400 MHz spectrometer, using DMSO-d 6 or CDCl 3 as solvent. 1< H NMR data is in the form of delta values, given in part per million (ppm), using the residual peak of the solvent (2.50 ppm for DMSO-d 6 and 7.26 ppm for CDCl 3 ) as internal standard. Splitting patterns are designated as: s (singlet), d (doublet), t (triplet), q (quartet), quint (quintet), sept (septet), m (multiplet), brs (broad singlet), brd (broad doublet), brt (broad triplet), brq (broad quartet), brm (broad multiplet), vbrs (very broad singlet), dd (doublet of doublets), td (triplet of doublets), dt (doublet of triplets), dq (doublet of quartet), ddd (doublet of doublet of doublets), dm (doublet of multiplets), tm (triplet of multiplets), qm (quartet of multiplets).

[0063] Combination gas chromatography and low resolution mass spectrometry were performed on Agilent 6850 gas chromatograph and Agilent 5975C mass spectrometer using 15 m × 0.25 mm column with 0.25 µm HP-5MS coating and helium as carrier gas. Ion source: EI +< , 70 eV, 230 °C, quadrupole: 150 °C, interface: 300 °C.

[0064] HRMS were determined on a Shimadzu IT-TOF, ion source temperature 200 °C, ESI + / -, ionization voltage: (+-)4.5 kV. Mass resolution min. 10000.

[0065] Elementary analyses were performed on a Thermo Flash EA 1112 Elemental Analyzer.List of abbreviations

[0066] Abbreviation Name abs.absoluteaq.aqueousArargonAtaPhos ∗< PdCl 2 bis(di-tert-butyl(4-dimethylaminophenyl)phosphine) dichloropalladium(II)Boctert-butoxycarbonylcc.concentratedDCMdichloromethaneDEEdiethyl etherDIPOdiisopropyl oxidedisp.dispersionDMEDAN,N'-dimethylethylenediamineDMFdimethylformamideEDC.HClN-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochlorideEEOethyl ethanoateeq.equivalentLCliquid chromatographyLDAlithium diisopropylamidemCPBAmeta-chloro-perbenzoic acidMeCNacetonitrileMSMmethylsulfinylmethaneMTBEtert-butyl methyletherNMPN-methylpyrrolidonePDOp-dioxaner.t.room temperaturesat.saturatedSEMtrimethylsilylethoxymethylTBAFtetrabutylammonium fluorideTFAtrifluoroacetic acidTHFtetrahydrofuranTMP.MgCl.LiCl2,2,6,6-tetramethylpiperidine-magnesium chloride-lithium chloride (1:1) complex General Procedure 1 Step 1:

[0067] To a stirred solution of 4-chloro-7H-pyrrolo[2,3-d]pyrimidine (Preparation R1a; 1.84 g, 12 mmol, 1 eq.) in abs. DMF (15 ml) sodium-hydride (720 mg, 60 % disp. in mineral oil, 18 mmol, 1.5 eq.) was added, and stirred for 10 minutes at r.t. under Ar. Alkylating agent (13.18 mmol) was added to the reaction mixture and stirred for 1-6 hours at r.t. The mixture was poured into water (150 ml), then it was extracted with EEO (3 x 150 ml). The combined organic layers were washed with water, brine, dried over MgSO 4 , and evaporated.Step 2:

[0068] A part of the compound obtained in Step 1 above (1.36 mmol) and lithium-hydroxide monohydrate (571 mg, 13.62 mmol, 10 eq.) were stirred in PDO-water (40 ml, 1:1 v / v) mixture at 110 °C for 7-36 hours. The reaction mixture was neutralized with 1 N aq. HCl solution and the resulted precipitate was filtered off, washed with water and dried.General Procedure 2 Step 1:

[0069] Preparation R1a (460 mg, 3 mmol, 1 eq.), heteroaryl / aryl-boronic acid (7.5 mmol) and copper(II)-acetate (817 mg, 4.5 mmol) were stirred in pyridine (10 ml) at 50-60 °C for 16-72 hours.Work-up 1:

[0070] The mixture was evaporated to Celite and purified by flash chromatography (heptane-EEO, gradient).Work-up 2:

[0071] The mixture was filtered and the resulted filtrate was purified by preparative LC (on C-18 Gemini-NX 5µm column, 5 mM aqueous NH 4 HCO 3 -MeCN, gradient).Step 2:

[0072] The resulted compound obtained in Step 1 above (1.36 mmol) and lithium-hydroxide monohydrate (571 mg, 13.62 mmol, 10 eq.) were stirred in PDO-water (40 ml, 1:1 v / v) mixture at 110 °C for 7-24 hours. The reaction mixture was neutralized with 1 N aq. HCl solution, the resulted precipitate was filtered off, washed with water, dried.General Procedure 3 Step 1:

[0073] Preparation R1b (746 mg, 5 mmol, 1 eq.), heteroaryl / aryl-iodide (10 mmol), CuI (286 mg, 1.5 mmol, 0.3 eq.), R,R-diaminocyclohexane (171 mg, 1.5 mmol, 0.3 eq.), anhydrous K 3 PO 4 (4.24 g, 20 mmol, 4 eq.) was stirred in diglyme (15 ml) for 6-16 hours at 120 °C under N 2 atmosphere.Work-up 1:

[0074] After the reaction completed, the mixture was diluted with water (200 ml) (or. 25% aq. NH 3 ) and cooled to r.t. The mixture was filtered, washed with water (3 x 30 ml), aq. NH 3 solution (40 ml, 25%), water (3 x 50 ml), heptane (50 then 30 ml) and dried in vacuum.Work-up 2:

[0075] The reaction mixture was evaporated to Celite and purified by flash chromatography (heptane:EEO, gradient).Step 2:

[0076] The corresponding 4-methoxy-7-heteroaryl / aryl-pyrrolo[2,3-d]pyrimidine obtained in Step 1 above (61.3 mmol, 1 eq.), cc. HCl aqueous solution (10 ml, ∼12.2 M, 122.5 mmol, 2 eq.) and PDO (70 ml) was stirred at 100 °C for 0.5-2 hours. After the reaction completed, the mixture was partially evaporated. The formed suspension was filtered and the solid on the filter was washed with water and dried.General Procedure 4 Step 1:

[0077] Preparation R1a (154 mg, 1 mmol, 1 eq.), di-tert-butyl-diazodicarboxylate (690 mg, 3 mmol, 3 eq.), triphenylphosphine (786 mg, 3 mmol, 3 eq.) and corresponding alcohol (3 mmol, 3 eq.) were stirred in abs. toluene (10 ml) under Ar atmosphere at 50 °C for 2 hours. The reaction mixture was evaporated, taken in THF and purified by preparative LC (on C-18 Gemini-NX 5µm column, 5 mM aqueous NH 4 HCO 3 -MeCN, gradient).Step 2:

[0078] A part of 4-chloro-7-aryl / alkyl-pyrrolo[2,3-d]pyrimidine obtained in Step 1 above (1.36 mmol) and lithium-hydroxide monohydrate (571 mg, 13.62 mmol) were stirred in PDO-water (40 ml, 1:1 v / v) mixture at 110 °C for 7-24 hours. The reaction mixture was neutralized with 1 N aq. HCl solution, the resulted precipitate was filtered off, washed with water and dried.General Procedure 5 Step 1:

[0079] Pyrimidine-4-one derivative (1 mmol), epoxide compound Preparation R1f (1 mmol) and K 2 CO 3 (276.4 mg, 2 mmol, 2 eq.) were stirred in DMF (5 ml) at 75 °C for 2-8 hours.Work-up 1:

[0080] The mixture was poured into ice-water mixture and the resulted precipitate was filtered off, washed with water and dried.Work-up 2:

[0081] The reaction mixture was filtered and the solid was washed with DMF. The resulted filtrate was purified by preparative LC (on C-18 Gemini-NX 5µm column, 5 mM aqueous NH 4 HCO 3 -MeCN, gradient).Step 2:

[0082] A part of the compound obtained in Step 1 above (1 mmol) was stirred in aq. HCl solution (1 N, 10 ml, 10 mmol, 10 eq.) and PDO (5 ml) for 1-3 hours at 75 °C.Work-up 1:

[0083] The mixture was cooled to about 0-5 °C with ice bath and the white precipitate was filtered off and dried in vacuum (resulted HCl salt).Work-up 2:

[0084] The mixture was totally evaporated and was used to the further step (resulted HCl salt).Work-up 3:

[0085] The mixture was purified by preparative LC (on C-18 Gemini-NX 5µm column, 5 mM aqueous NH 4 HCO 3 -MeCN, gradient, resulted free base).General Procedure 6

[0086] Compound obtained in General Procedure 5 (1 mmol, 1 eq.), aryl / heteroaryl-CH 2 -X (1 mmol, 1 eq.; wherein X represents a halogen atom) and K 2 CO 3 (483 mg, 3.5 mmol, 3.5 eq.) were stirred in DMF (10 ml) at r.t. for 4-16 hours.Work-up 1:

[0087] The mixture was poured into ice-water mixture and the resulted precipitate was filtered off, washed with water and dried.Work-up 2:

[0088] The mixture was filtered and the filtrate was injected to preparative LC (on C-18 Gemini-NX 5µm column, 5 mM aqueous NH 4 HCO 3 -MeCN, gradient).General Procedure 7

[0089] Compound obtained in General Procedure 5 (2.7 mmol), EDC.HCl (1.183 g, 6.172 mmol) and corresponding carboxylic acid (2.7 mmol) were stirred in pyridine (25 ml) at r.t. for 16 hours.Work-up 1:

[0090] The reaction mixture was evaporated, the residue was taken in DMF and injected to preparative LC (on C-18 Gemini-NX 5µm column, 5 mM aqueous NH 4 HCO 3 -MeCN, gradient).Work-up 2:

[0091] The reaction mixture was evaporated. The residue was triturated with water and the resulted solid was filtered off.General Procedure 8

[0092] Compound obtained in General Procedure 5 (1 mmol, 1 eq.), corresponding sulfonyl chloride (2 mmol, 2 eq.) and K 2 CO 3 (553 mg, 4 mmol, 4 eq.) were stirred in DMF (10 ml) at r.t. for 4-28 hours. The mixture was evaporated to Celite and purified by flash chromatography (eluent: DCM-MeOH).General Procedure 9

[0093] The corresponding halogenated component (0.15 mmol, 1 eq.), corresponding boronic acid (0.375 mol, 2.5 eq.), ATAphos ∗< PdCl 2 (10.6 mg, 0.015 mmol, 0.1 eq.), Cs 2 CO 3 (171 mg, 0.525 mmol, 3.5 eq.) was diluted with THF (2.5 ml) and water (2.5 ml). The mixture was flushed with nitrogen and stirred in microwave reactor at 80 °C for 100-150 minutes. The reaction mixture was injected through syringe filter to preparative LC (on C-18 Gemini-NX 5µm column, 5 mM aqueous NH 4 HCO 3 -MeCN, gradient).General Procedure 10

[0094] To the stirred solution of the corresponding O-benzyl or O-methyl containing compound (0.17 mmol) in DCM (5 ml), boron-tribromide (0.3 ml, 440 mg, 1.7 mmol, 10 eq.) was added dropwise at r.t. After 3 hours of stirring, the reaction mixture was quenched with EtOH and evaporated. The residue was purified by preparative LC (on C-18 Gemini-NX 5µm column, 5 mM aqueous NH 4 HCO 3 -MeCN, gradient).General Procedure 11

[0095] The procedure is the same as described under General procedure 5 using Preparation R1m as epoxide component. The residue was purified by preparative LC (on C-18 Gemini-NX 5µm column, 5 mM aqueous NH 4 HCO 3 -MeCN, gradient).General Procedure 12

[0096] The mixture of the nitro compound (1.45 mmol), tin(II)-chloride dihydrate (1.64 g, 7.45 mmol, 5 eq.) in EtOH (30 ml) and HCl (1 N, 5 ml, aq.) was stirred for 20 hours at 80 °C. To the reaction mixture sat. aqueous NaHCO 3 (50 ml) was added, then the mixture was evaporated to Celite and purified by flash chromatography (DCM-MeOH).General Procedure 13

[0097] To a stirred mixture of amino / amide compound (0.105 mmol), K 2 CO 3 (22 mg, 0.158 mmol, 1.5 eq.) in DMF (1 ml) iodomethane (10 µl) was added at r.t. After 18 hours of stirring the reaction mixture was filtered and injected to preparative LC (on C-18 Gemini-NX 5µm column, 5 mM aqueous NH 4 HCO 3 -MeCN, gradient).General Procedure 14

[0098] The N-Boc compound (0.1 mmol) was stirred in aq. HCl solution (1 N, 3 ml, 3 mmol, 30 eq.) and PDO (2 ml) for 2-5 hours at 75 °C. The mixture was purified by preparative LC (on C-18 Gemini-NX 5µm column, 5 mM aqueous NH 4 HCO 3 -MeCN, gradient, resulted as free amine base).General Procedure 15

[0099] The mixture of the corresponding methoxy compound (0.44 mmol), cc. HCl (aq. 37 %, 1.1 ml, 13 mmol, 30 eq.) and PDO (7 ml) was stirred at 100 °C for 3 hours. To the reaction mixture NaOH solution (aq. 2 M, 6.6 ml) was added. The solid compound was filtered off, then purified by preparative LC (on C-18 Gemini-NX 5µm column, 5 mM aqueous NH 4 HCO 3 -MeCN, gradient).Preparation R1b: 4-methoxy-7H-pyrrolo[2,3-d]pyrimidine

[0100] Preparation R1a (100 g, 0.651 mol, 1 eq.), NaOH (31.26 g, 0.781 mol, 1.2 eq.) and MeOH (400 ml) was stirred at 90 °C for 24 hours. The mixture was quenched with water (1200 ml) and cooled to r.t. with ice bath. The mixture is stirred for 30 minutes, and filtered through a glass filter. The precipitate was washed with water (3 x 100 ml) then dried and Preparation R1b was obtained as a white solid. HRMS calculated for C 7 H 7 N 3 O: 149.0589; found 150.0667 [(M+H) +< form]. 1< H-NMR (400 MHz, MSM-d 6 ): δ = 12.02 (vbrs, 1 H), 8.37 (s, 1 H), 7.35 (d, 1 H), 6.47 (d, 1 H), 4.02 (s, 3 H). 13< C-NMR (100 MHz, MSM-d 6 ) δ ppm 162.6, 152.9, 150.8, 124.6, 104.8, 98.3, 53.7.Preparation R1c: 5-[5-(chloromethyl)-1,3-thiazol-2-yl]-2-methylpyridine Step 1: [2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methanol

[0101] 2-Bromothiazole-5-methanol (20 g, 0.103 mol, 1 eq.), 2-methylpyridine-5-boronic acid (18.3 g, 0.134 mol, 1.3 eq.), ATAphos ∗< PdCl 2 (3.65 g, 5.152 mmol, 0.05 eq.), Cs 2 CO 3 (67.14 g, 0.206 mol, 2 eq.) were dissolved in THF (800 ml) and water (800 ml). The mixture was flushed with nitrogen and stirred at 80 °C for 3 hours. The mixture was cooled to r.t. and diluted with EEO (300 ml). The layers were separated, the aqueous layer was extracted with EEO (3x100 ml), the combined organic layer was dried over MgSO 4 and, after filtration, evaporated. The residue was crystallized from EEO / DIPO, filtered and dried in vacuum to give a brown solid. HRMS calculated for C 10 H 10 N 2 OS: 206.0514; found 207.0591 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d 6 ): δ = 2.52 (s, 3 H), 4.72 (d, J = 10.4 Hz, 2 H), 5.67 (t, J = 11.0 Hz, 1 H), 7.38 (d, J = 16.3 Hz, 1 H), 7.77 (s, 1 H), 8.14 (dd, J = 16.0, 4.8 Hz, 1 H), 8.96 (d, J = 4.5 Hz, 1 H).Step 2: Preparation R1c

[0102] [2-(6-Methyl-3-pyridyl)thiazol-5-yl]methanol (18.23 g, 88.38 mmol, 1 eq.) was dissolved in abs. DMF (1.37 ml, 1.29 g, 17.68 mmol, 0.2 eq.) and dry DCM (400 ml). SOCl 2 (8.36 ml, 13.67 g, 114.9 mmol, 1.3 eq.) was dropped to the mixture in DCM (50 ml) solution (∼15 min) at r.t. The mixture was stirred at 50 °C for 2 hours. The mixture was cooled to r.t. Water (50 ml) was dropped slowly to the mixture, then it was neutralized with sat. NaHCO 3 solution (250 ml, pH 7-8). The layers were separated. The aqueous layer was extracted with DCM (4 x 50 ml). The combined organic layer was dried over MgSO 4 , filtered. The solution was diluted with EEO (300 ml) and filtered through silica bed (∼20 g). The mixture was evaporated to give Preparation R1c as a yellow solid. HRMS calculated for C 10 H 9 ClN 2 S: 224.0175; found 225.0247 [(M+H) +< form]. 1< H NMR (500 MHz, MSM-d 6 ): δ = 2.53 (s, 3 H), 5.17 (s, 2 H), 7.41 (d, J = 16.5 Hz, 1 H), 7.98 (s, 1 H), 8.17 (dd, J = 16.0, 5.0 Hz, 1 H), 8.99 (d, J = 5.0 Hz, 1 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 24.5, 38.4, 124.1, 134.4, 144.4, 146.7.Preparation R1d: 4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazole-5-carboxylic acid Step 1: ethyl 4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazole-5-carboxylate

[0103] Ethyl 2-bromo-4-methylthiazole-5-carboxylate (26.9 g, 107.6 mmol, 1 eq.), 2-methylpyridine-5-boronic acid (19.2 g, 139.8 mmol, 1.3 eq.), ATAphos ∗< PdCl 2 (3.05 g, 4.3 mmol, 0.04 eq.), Na 2 CO 3 (34.2 g, 322.65 mmol, 3 eq.) were dissolved in THF (250 ml) and water (250 ml). The mixture was flushed with nitrogen and stirred at 80 °C for 2 hours. After the reaction ended, the mixture was cooled to r.t. and diluted with EEO (250 ml). The layers were separated and the aqueous layer was extracted with EEO (2 x 50 ml). The combined organic layer was dried over MgSO 4 and, after filtration, evaporated. The raw product was dissolved in DCM / EEO / heptane (1:1:1 v / v, 600 ml) and filtered through silica (∼30 g) and washed with DCM / EEO / heptane (1:1:1 v / v, 100 ml). The mixture was evaporated. The residue was recrystallized from DIPO (100 ml) and dried in vacuum to give a beige solid. HRMS calculated for C 13 H 14 N 2 O 2 S: 262.0776; found 263.0852 [(M+H) +< form]. 1< H NMR (500 MHz, MSM-d 6 ): δ = 1.31 (t, J = 17.5 Hz, 3 H), 2.54 (s, 3 H), 2.70 (s, 3 H), 4.30 (q, J = 17.8 Hz, 2 H), 7.42 (d, J = 20.3 Hz, 1 H), 8.24 (dd, J = 20.4, 6.1 Hz, 1 H), 9.04 (d, J=5.4 Hz, 1 H).Step 2: Preparation R1d

[0104] Ethyl 4-methyl-2-(6-methyl-3-pyridyl)thiazole-5-carboxylate (21.07 g, 80.33 mmol, 1 eq.) was dissolved in EtOH (40 ml). NaOH (4.82 g, 120.49 mmol, 1.5 eq.) was dissolved in water (80 ml). The aq. NaOH was added to the organic mixture and stirred at 80 °C for 45 minutes. After the reaction ended, the mixture was cooled to r.t. After 1 week, the black precipitate was sedimented. The mixture was filtered through a silica / Celite bed. The mixture was acidified with cc. HCl solution (to pH∼1), and the resulting precipitate was filtered off, washed with water (50 ml) and dried in vacuum to give Preparation R1d as an off-white solid. HRMS calculated for C 11 H 10 N 2 O 2 S: 234.0463; found 235.0533 [(M+H) +< form]. 1< H NMR (500 MHz, MSM-d 6 ): δ = 2.52 (s, 3 H), 2.63 (s, 3 H), 7.36 (d, J = 16.2 Hz, 1 H), 8.14 (dd, J = 16.2, 4.8 Hz, 1 H), 8.95 (d, J = 4.8 Hz, 1 H).Preparation R1e: tert-butyl 1-oxa-6-azaspiro[2.5]octane-6-carboxylate

[0105] Trimethyl-sulfoxonium iodide (20.0 g, 150 mmol) was dissolved in abs. MSM (75 ml) then sodium-hydride dispersion (60 % in mineral oil, 6 g, 150 mmol) was added sequentially and stirred for 20 minutes at r.t. N-Boc-piperidin-4-one (20.0 g, 100 mmol) solution in MSM (75 ml, abs.) was added to the mixture and stirred for 15 hours at r.t. The reaction mixture was poured into ice-water mixture (200 ml) and extracted with diethyl-ether (4 x 200 ml). The combined organic layer was washed with water, brine, then dried over MgSO 4 and evaporated to give Preparation R1e. HRMS calculated for C 11 H 19 NO 3 : 213.1365; found 158.0811 [(M+H-tBu) +< form]. 1< H NMR (500 MHz, MSM-d 6 ): δ ppm 3.5 / 3.37 (brm+brm, 4 H), 2.65 (s, 2 H), 1.64 / 1.38 (m+m, 4 H), 1.4 (s, 9 H). 13< C NMR (125 MHz, MSM-d 6 ): δ ppm 154.3, 79.3, 57.4, 53.3, 42.7, 33, 28.5.Preparation Rlf: tert-butyl (3R,4R)-4-(1-oxa-6-azaspiro[2.5]oct-6-ylcarbonyl)-3-phenylpiperidine-1-carboxylate Step 1: tert-butyl (3R,4R)-4-[(4-oxopiperidin-1-yl)carbonyl]-3-phenylpiperidine-1-carboxylate

[0106] 4-piperidone hydrochloride hydrate (0.969 g, 6.3 mmol), EDC.HCl (3.623 g, 18.9 mmol) and (3R,4R)-1-tert-butoxycarbonyl-3-phenyl-piperidine-4-carboxylic acid (1.928 g, 6.3 mmol) were dissolved in pyridine (10 mL) and stirred at r.t. for 16 hours. The reaction mixture was evaporated to Celite and purified by flash chromatography (DCM:MeOH, gradient) to give the product of the title. HRMS calculated for C 22 H 30 N 2 O 4 : 386.2206; found 409.2093 [(M+Na) +< form]. 1< H-NMR (500 MHz, MSM-d 6 ): δ 1.42 (s, 9 H), 4.14-1.50 (m, 16 H), 7.32-7.15 (m, 5 H).Step 2: Preparation R1f

[0107] tert-butyl (3R,4R)-4-[(4-oxopiperidin-1-yl)carbonyl]-3-phenylpiperidine-1-carboxylate (60 g, 155 mmol 1 eq.) and trimethylsulfoxonium-iodide (85.41 g, 388 mmol, 2.5 eq.) was charged into a round bottom flask and dissolved / suspended in MeCN (150 ml) and MTBE (150 ml). In parallel, NaOH (15.5 g, 388 mmol, 2.5 eq.) was dissolved in water (21.6 ml) (∼40 % solution). The aq. NaOH solution was added to the mixture and stirred at 60 °C for 2 hours. After the reaction completed, the mixture was cooled to r.t., filtered through a Celite bed and the filter cake was washed with MTBE (2 x 60 ml). Water (150 ml) was added to the organic layer and, after extraction, the layers were separated. The aq. layer was extracted with further MTBE (2 x 60 ml). The combined organic layers were dried over MgSO 4 and after filtration evaporated to give Preparation R1f as beige solid foam. HRMS calculated for C 23 H 32 N 2 O 4 : 400.2362; found 423.2247 [(M+Na) +< form]. 1< H-NMR (500 MHz, MSM-d 6 ): δ = 1.41 (s, 9 H), 1.79-0.86 (m, 6 H), 2.61-2.51 (m, 2 H), 4.16-2.73 (m, 10 H), 7.33-7.18 (m, 5 H).Preparation R1g: 3-fluoro-5-iodo-thiophene-2-carboxylic acid Step 1: 3-fluoro-5-iodo-thiophene-2-carboxylate and methyl 3-fluoro-4,5-diiodo-thiophene-2-carboxylate

[0108] To the solution of methyl 3-fluorothiophene-2-carboxylate (2.42 g, 15.1 mmol) in THF (10 ml) at TMP.MgCl.LiCl (1 N, in THF / toluene, 25 ml, 25 mmol) was added dropwise at -45 °C in 5 minutes. After 30 minutes of stirring iodine (4.04 mg, 15.9 mmol) was added in THF (10 ml) at -45 °C to the mixture. After warming up (1 hour) sat. NH 4 Cl solution (50 ml, aq.) was added to the mixture while stirring. The mixture was extracted with EEO (5 x 10 ml). The combined organic layer was evaporated. The residue was purified by preparative LC (on C-18 Gemini-NX 5µm column, 5 mM aqueous NH 4 HCO 3 -MeCN, gradient) to give 3-fluoro-5-iodo-thiophene-2-carboxylate and methyl 3-fluoro-4,5-diiodo-thiophene-2-carboxylate, separately.Methyl 3-fluoro-5-iodo-thiophene-2-carboxylate

[0109] GC-MS calculated for C 6 H 4 FIO 2 S: 285.8961; found 285.9 [(M, EI) form]. 1< H NMR (500 MHz, MSM-d 6 ): δ ppm 7.52 (s, 1 H), 3.78 (s, 3 H). 13< C NMR (125 MHz, MSM-d 6 ): δ ppm 159.4, 158.8, 128.5, 117.2, 86.4, 52.8.Methyl 3-fluoro-4,5-diiodo-thiophene-2-carboxylate

[0110] GC-MS calculated for C 6 H 4 FIO 2 S: 411.7927; found 411.9 [(M, EI) form]. 1< H NMR (500 MHz, MSM-d 6 ): δ ppm 3.8 (s, 3 H). 13< C NMR (125 MHz, MSM-d 6 ): δ ppm 159, 158.2, 117.4, 96.1, 90.6, 53.1.Step 2: Preparation R1g

[0111] Methyl 3-fluoro-5-iodo-thiophene-2-carboxylate (1.188 g, 4.135 mmol), lithium-hydroxide monohydrate (867 mg, 20.7 mmol) were stirred in methanol (10 ml) and water (10 ml) at 70 °C for 1 hour. The mixture was partially evaporated and the aqueous residue was acidified with 1 N HCl (25 ml, aq.). The resulted precipitate was filtered off, washed with water and dried to give Preparation R1g. GC-MS calculated for C 5 H 2 FIO 2 S: 271.8804; found 271.9 [(M, EI) form]. 1< H NMR (500 MHz, MSM-d 6 ): δ ppm 13.48 (brs), 7.74 (s, 1 H). 13< C NMR (125 MHz, MSM-d 6 ): δ ppm 160.4, 158.3, 128.5, 119, 85.1.Preparation R1h: 3-fluoro-4,5-diiodo-thiophene-2-carboxylic acid

[0112] Methyl 3-fluoro-4,5-diiodo-thiophene-2-carboxylate (614 mg, 1.49 mmol), lithium-hydroxide monohydrate (256 mg, 6 mmol) were stirred in methanol (8 ml) and water (8 ml) at r.t. for 5 hours. The mixture was partially evaporated and the aqueous residue was acidified with 1 N HCl (10 ml, aq.). The resulted precipitate was filtered off, washed with water and dried to give Preparation R1h. HRMS calculated for C 5 HFI 2 O 2 S: 397.7771; found 352.7798 [(M-H-CO 2 ) +< form]. 1< H NMR (500 MHz, MSM-d 6 ): δ ppm 13.72 (brs, 1 H). 13< C NMR (125 MHz, MSM-d 6 ): δ ppm 160, 157.7, 119.1, 95.1, 90.5.Preparation R1i: 3-fluoro-4-iodo-5-methyl-thiophene-2-carboxylic acid Step 1: methyl 3-fluoro-4-iodo-5-methyl-thiophene-2-carboxylate

[0113] To the solution of methyl 3-fluoro-5-iodo-thiophene-2-carboxylate Preparation R1g (286 mg, 1 mmol) in THF (3 ml) TMP.MgCl.LiCl (1 N, in THF / toluene, 1.5 ml, 1.5 mmol) was added dropwise at -45 °C in 5 minutes. After 60 minutes of stirring iodomethane (123 ml, 282 mg, 2 mmol) was added in THF (2 ml) at -45 °C to the mixture and stirred for 2 hours at -40 °C. After warming up, sat.NH 4 Cl solution (5 ml, aq.) was added to the mixture while stirring. The mixture was extracted with EEO (4 x 10 ml). The combined organic layer was evaporated. The residue was purified by preparative LC (on C-18 Gemini-NX 5µm column, 5 mM aqueous NH 4 HCO 3 -MeCN, gradient) to give the product of the title. HRMS calculated for C 7 H 6 FIO 2 S: 299.9117; 300.9200 [(M+H) +< form]. 1< H NMR (500 MHz, MSM-d 6 ): δ ppm 3.8 (s, 3 H), 2.43 (s, 3 H). 13< C NMR (125 MHz, MSM-d 6 ): δ ppm 159.8, 158.5, 145.1, 109.6, 77.2, 52.8, 19.1.Step 2: Preparation R1i

[0114] Methyl 3-fluoro-4-iodo-5-methyl-thiophene-2-carboxylate (40 mg, 0.133 mmol), lithium-hydroxide monohydrate (11 mg, 0.266 mmol) were stirred in methanol (1 ml) and water (1 ml) at r.t. for 3 hours. The mixture was partially evaporated and the aqueous residue was acidified with 1 N HCl (3 ml, aq.). The resulted precipitate was filtered off, washed with water and dried to give Preparation R1i . 1< H NMR (500 MHz, MSM-d 6 ): δ ppm 13.41 (brs, 1 H), 2.41 (s, 3 H). 13< C NMR (125 MHz, MSM-d 6 ): δ ppm 160.8, 158, 144.2, 76.9, 19.1.Preparation R1j: 3-chloro-5-iodo-thiophene-2-carboxylic acid Step 1: 3-chloro-5-iodothiophene-2-carboxylic acid methyl ester

[0115] To the solution of 3-chlorothiophene-2-carboxylic acid methyl ester (353 g, 2 mmol) in THF (5 ml) at TMP.MgCl.LiCl (1 N, in THF / toluene, 3 ml, 3 mmol) was added dropwise at -45 °C. After 20 minutes of stirring iodine (507 mg, 4 mmol) was added in THF (2 ml) at -45 °C to the mixture. After warming up, sat.NH 4 Cl solution (5 ml, aq.) and Na 2 S 2 O 3 solution (5 ml, 10 % aq.) was added to the mixture while stirring. The mixture was extracted with EEO (4 x 10 ml). The combined organic layer was evaporated. The residue was purified by preparative LC (on C-18 Gemini-NX 5µm column, 5 mM aqueous NH 4 HCO 3 -MeCN, gradient) to give the product of the title. HRMS calculated for C 6 H 4 ClIO 2 S: 301.8665; found 301.9000 [(M+H) +< form]. 1< H NMR (500 MHz, MSM-d 6 ): δ ppm 37.55 (s, 1 H), 3.8 (s, 3 H). 13< C NMR (125 MHz, MSM-d 6 ): δ ppm 159.5, 139.4, 130.9, 130.6, 86.8, 53.Step 2: Preparation R1j

[0116] 3-chloro-5-iodothiophene-2-carboxylic acid methyl ester (477 mg, 1.58 mmol), lithium-hydroxide monohydrate (132 mg, 3.16 mmol) were stirred in methanol (5 ml) and water (5 ml) at 50 °C for 2.5 hours. The mixture was partially evaporated and the aqueous residue was acidified with 1 N HCl solution (4 ml, aq.). The resulted precipitate was filtered off, washed with water and dried to give Preparation R1j. GC-MS calculated for C 5 H 2 CHO 2 S: 287.8509; found 243.8 [(M-CO 2 , EI) form]. 1< H NMR (500 MHz, MSM-d 6 ): δ ppm 13.6 (brs, 1 H), 7.51 (s, 1 H). 13< C NMR (125 MHz, MSM-d 6 ): δ ppm 160.6, 139.3, 132.4, 130.1, 85.8.Preparation R1k: 5-chloro-3-fluoro-4-iodo-thiophene-2-carboxylic acid Step 1: methyl 5-chloro-3-fluoro-4-iodo-thiophene-2-carboxylate

[0117] To the solution of methyl 3-fluoro-5-iodo-thiophene-2-carboxylate (286 mg, 1 mmol) in THF (5 ml) at TMP.MgCl.LiCl (1 N, in THF / toluene, 1.5 ml, 1.5 mmol) was added dropwise at -45 °C in 5 minutes. After 30 minutes of stirring hexachloroethane (236 mg, 1 mmol) was added in THF (2 ml) at -45 °C to the mixture. After warming up, sat.NH 4 Cl solution (5 ml, aq.) was added to the mixture while stirring. The mixture was extracted with EEO (4 x 10 ml) and the combined organic layers were evaporated. The residue was purified by preparative LC (on C-18 Gemini-NX 5µm column, 5 mM aqueous NH 4 HCO 3 -MeCN, gradient) to give the product of the title. GC-MS calculated for C 6 H 3 ClFIO 2 S: 319.8571; found 319.9 [(M, EI) form]. 1< H NMR (500 MHz, MSM-d 6 ): δ ppm 3.82 (s, 3 H). 13< C NMR (125 MHz, MSM-d 6 ): δ ppm 159.1, 157.9, 135.9, 111.7, 81.1, 53.2.Step 2: Preparation R1k

[0118] Methyl 5-chloro-3-fluoro-4-iodo-thiophene-2-carboxylate (76 mg, 0.237 mmol), lithium-hydroxide monohydrate (20 mg, 0.474 mmol) were stirred in methanol (4 ml) and water (4 ml) at r.t. for 2 hours. The mixture was partially evaporated and the aqueous residue was acidified with 1 N HCl (2 ml, aq.). The resulted precipitate was filtered off, washed with water and dried to give Preparation R1k. 1< H NMR (400 MHz, MSM-d 6 ): δ ppm 13.88 (brs, 1 H). 19< F NMR (376.5 MHz, MSM-d 6 ): δ ppm -101.7. 13< C NMR (100 MHz, MSM-d 6 ): δ ppm 157.4.Preparation R1l: 5-chloro-3-fluoro-4-methyl-thiophene-2-carboxylic acid Step 1: methyl 5-chloro-3-fluoro-thiophene-2-carboxylate

[0119] To the solution of methyl 3-fluoro-thiophene-2-carboxylate (1826 mg, 11.4 mmol) in THF (5 ml) TMP.MgCl.LiCl (1 N, in THF / toluene, 21 ml, 21 mmol) was added dropwise at -45 °C in 5 minutes. After 30 minutes of stirring at -45 °C, hexachloroethane (2.7g, 11.4 mmol) was added at -45 °C to the mixture and stirred for 1 hour at -40 °C. After warming up, sat.NH 4 Cl solution (10 ml, aq.) was added to the mixture while stirring. The mixture was extracted with EEO (4 x 10 ml) and the combined organic layers were evaporated. The residue was purified by preparative LC (on C-18 Gemini-NX 5µm column, 5 mM aqueous NH 4 HCO 3 -MeCN, gradient) to give the product of the title. GC-MS calculated for C 6 H 4 ClFO 2 S: 193.9604; found 193.9 [(M, EI) form]. 1< H NMR (500 MHz, MSM-d 6 ): δ ppm 7.46 (s, 1 H), 3.81 (s, 3 H). 13< C NMR (125 MHz, MSM-d 6 ): δ ppm 159.5, 157.5, 135.3, 120.2, 111.5, 53.Step 2: methyl 5-chloro-3-fluoro-4-methyl-thiophene-2-carboxylate

[0120] To the solution of methyl 5-chloro-3-fluoro-thiophene-2-carboxylate (579 mg, 3 mmol) in THF (3 ml) TMP.MgCl.LiCl (1 N, in THF / toluene, 6 ml, 6 mmol) was added dropwise at -45 °C in 5 minutes. After 60 minutes of stirring, iodomethane (1.3 ml, 2964 mg, 20.9 mmol) was added in THF (2 ml) at -45 °C to the mixture and stirred for 2 hours at - 40 °C. After warming up, sat.NH 4 Cl solution (5 ml, aq.) was added to the mixture while stirring. The mixture was extracted with EEO (4 x 10 ml) and the combined organic layers were evaporated. The residue was purified by preparative LC (on C-18 Gemini-NX 5µm column, 5 mM aqueous NH 4 HCO 3 -MeCN, gradient) to give the product of the title. GC-MS calculated for C 7 H 6 ClFO 2 S: 207.9761; found 207.9 found [(M, EI) form]. 1< H NMR (500 MHz, MSM-d 6 ): δ ppm 3.81 (s, 3 H), 2.09 (s, 3 H). 13< C NMR (125 MHz, MSM-d 6 ): δ ppm 159.7, 156.4, 130.8, 127, 109.6, 53, 10.5.Step 3: Preparation R1l

[0121] Methyl 5-chloro-3-fluoro-4-methyl-thiophene-2-carboxylate (316 mg, 1.62 mmol), lithium-hydroxide monohydrate (271 mg, 6.46 mmol) were stirred in methanol (5 ml) and water (5 ml) at r.t. for 4 hours. The mixture was partially evaporated and the aqueous residue was acidified with 1 N HCl (2 ml, aq.). The resulted precipitate was filtered off, washed with water and dried to give Preparation R1l. 1< H NMR (500 MHz, MSM-d 6 ): δ ppm 13.57 (brs, 1 H), 2.07 (s, 3 H) 13< C NMR (125 MHz, MSM-d 6 ): δ ppm 160.7, 155.9, 129.8, 126.9, 111.4, 10.5Preparation R1m: [4-methyl-2-(6-methyl-3-pyridyl)thiazol-5-yl]-[(3R,4R)-4-(2-oxa-6-azaspiro[2.5]octane-6-carbonyl)-3-phenyl-1-piperidyl] methanone Step 1: ethyl (3R,4R)-3-phenylpiperidine-4-carboxylate hydrochloride

[0122] 1-tert-butyl 4-ethyl (3R,4R)-3-phenylpiperidine-1,4-dicarboxylate (10 g, 30 mmol) was stirred in the mixture of MeCN (100 ml) and cc. HCl solution (7.38 ml, 90 mmol, aq.) at 80 °C for 30 minutes. The reaction mixture was evaporated, and dried over vacuum to give the product of the title.Step 2: ethyl (3R,4R)-1-[(2-bromo-4-methyl-1,3-thiazol-5-yl)carbonyl]-3-phenylpiperidine-4-carboxylate

[0123] Ethyl (3R,4R)-3-phenylpiperidine-4-carboxylate hydrochloride (7.89 g, 29.9 mmol), 2-bromo-4-methyl-thiazole-5-carboxylic acid (6.64 g, 29.9 mmol) and EDC.HCl (17.2 g, 89.7 mmol) was dissolved in pyridine (200 ml) and stirred at r.t. for 23 hours. The reaction mixture was evaporated. To the residue, water (200 ml) was added and extracted with DCM (3 x 50 ml). The combined organic layer was dried over MgSO 4 and evaporated to give the product of the title. HRMS calculated for C 19 H 21 BrN 2 O 3 S: 436.0456; found 437.0546 [(M+H) +< form]. 1< H NMR (500 MHz, MSM-d 6 ): δ ppm 7.36-7.19 (m, 5 H), 4.96-2.74 (vbrs, 4 H), 3.82 (q, 2 H), 3.03 (m, 1 H), 2.87 (m, 1 H), 2.34 (s, 3 H), 1.98 / 1.62 (m+m, 2 H), 0.86 (t, 3 H). 13< C NMR (125 MHz, MSM-d 6 ): δ ppm 160.5, 151.6, 136.3, 129.2, 60.1, 47.3, 45.3, 29.2, 16.4, 14.2.Step 3: ethyl (3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidine-4-carboxylate

[0124] In 8 separated microwave tubes, ethyl (3R,4R)-1-[(2-bromo-4-methyl-1,3-thiazol-5-yl)carbonyl]-3-phenylpiperidine-4-carboxylate (8 x 1.87 g, 34.2 mmol), 2-methylpyridine-5-boronic acid (8 x 1.17 g, 68.4 mmol), ATAphos ∗< PdCl 2 (8 x 303 mg, 3.4 mmol) and Cs 2 CO 3 (8 x 4.18 g, 102.6 mmol) were dissolved in THF (8 x 25 ml) and water (8 x 15 ml). The 8 tubes were microwave irradiated at once at 80 °C for 2 hours (Anton-Paar Multiwave Pro). The organic layers of 8 tubes were combined, partially evaporated and purified by preparative LC (on C-18 Gemini-NX 5µm column, 5 mM aqueous NH 4 HCO 3 -MeCN, gradient) to give the product of the title. HRMS calculated for C 25 H 27 N 3 O 3 S: 449.1773; found 450.1860[(M+H) +< form]. 1< H NMR (400 MHz, MSM-d 6 ): δ ppm 8.98 (d, 1 H), 8.17 (dd, 1 H), 7.4 (d, 1 H), 7.36-7.16 (m, 5 H), 5-2.75 (vbrs, 4 H), 3.83 (q, 2 H), 3.05 (m, 1 H), 2.87 (m, 1 H), 2.53 (s, 3 H), 2.43 (s, 3 H), 2.01 / 1.64 (dm+qm, 2 H), 0.87 (t, 3 H). 13< C NMR (100 MHz, MSM-d 6 ): δ ppm 146.7, 134.4, 124, 60.1, 47.3, 45.5, 29.2, 24.3, 16.5, 14.2.Step 4: (3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl)-3-phenylpiperidine-4-carboxylic acid

[0125] Ethyl (3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenyl piperidine-4-carboxylate (7.48 g, 16.64 mmol) and lithium-hydroxide hydrate (1.75 g, 41.6 mmol) were stirred in the mixture of EtOH (30 ml) and water (10 ml) at 75 °C for 3.5 hours. The reaction mixture was partially evaporated, to residue was acidified (to pH = 4.5-5.5) with HCl solution (1 N, aq.) and the resulted suspension was filtered. The solid compound on the filter was washed with water and dried to give the product of the title. HRMS calculated for C 23 H 23 N 3 O 3 S: 421.146; found 422.1544 [(M+H) +< form]. 1< H NMR (400 MHz, MSM-d 6 ): δ ppm 11.82 (brs, 1 H), 8.97 (d, 1 H), 8.15 (dd, 1 H), 7.39 (d, 1 H), 7.35-7.18 (m, 5 H), 4.34-4.05 (brm, 4 H), 3.01-2.84 (m, 2 H), 2.54 (s, 3 H), 2.44 (s, 3 H), 2.06 / 1.66 (m+m, 2 H). 13< C NMR (100 MHz, MSM-d 6 ): δ ppm 146.8, 134.4, 123.8, 29.5, 24.3, 16.5.Step 5: 1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl)piperidin-4-one

[0126] (3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenyl piperidine-4-carboxylic acid (3786 mg, 8.98 mmol), piperidin-4-one hydrate hydrochloride (1518 mg, 9.88 mmol) and EDC.HCl (5.16 g, 26.94 mmol) were stirred in pyridine (30 ml) at r.t. for 16 hours. The reaction mixture was evaporated, the residue was taken in MeOH (20 ml) and poured into water (120 ml) and extracted with DCM (3 x 60 ml). The combined organic layer was washed with water, brine, dried over MgSO 4 and evaporated to give the product of the title. HRMS calculated for C 23 H 23 N 3 O 3 S: 502.2039; found 503.2088 [(M+H) +< form]. 1< H NMR (400 MHz, MSM-d 6 ): δ ppm 8.98 (brs, 1 H), 8.17 (dd, 1 H), 7.4 (d, 1 H), 7.36-7.13 (m, 5 H), 4.92-2.76 (m, 10 H), 2.53 (s, 3 H), 2.45 (s, 3 H), 2.25-1.52 (m, 6 H).Step 6: Preparation R1m

[0127] 1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenyl piperidin-4-yl]carbonyl}piperidin-4-one (3.89 g, 7.74 mmol) and trimethylsulfoxonium-iodide (2.09 g, 9.3 mmol) was stirred in MeCN (19 ml) at r.t. and solution of NaOH (309 mg, 9.3 mmol) in water (0.4 ml) was added to the mixture. Then the reaction mixture was stirred at 70 °C for 2 hours. The reaction mixture was poured into water (200 ml) and neutralized with aqueous HCl solution (1 N, 9 ml) and extracted with DCM (3 x 80 ml). The combined organic layer was washed with water and brine and evaporated to give Preparation R1m as solid foam. HRMS calculated for C 29 H 32 N 4 O 3 S: 516.2195; found 517.2267 [(M+H) +< form]. 1< H NMR (500 MHz, MSM-d 6 ): δ ppm 8.98 (brs, 1 H), 8.17 (dd, 1 H), 7.4 (d, 1 H), 7.37-7.15 (brs / brs, 5 H), 3.82-0.88 (m, 14 H), 3.53 (m, 1 H), 2.97 (brm, 1 H), 2.56 (m, 2 H), 2.53 (s, 3 H), 2.44 (s, 3 H). 13< C NMR (125 MHz, MSM-d 6 ): δ ppm 164.1, 160.8, 152.4, 146.8, 134.5, 125.6, 124.1, 57.4 / 57.1, 53.4 / 53.1, 42.9 / 42.8, 24.5, 16.7.Preparation R1n: 3-[[4-Hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]-4-piperidyl]methyl]-7-(2-trimethylsilylethoxymethyl)pyrrolo[2,3-d]pyrimidin-4-one Step 1: 2-[(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)methoxy]ethyl-trimethyl-silane

[0128] Preparation R1a (2.81 g, 18.3 mmol) was dissolved in THF (25 ml) cooled to 0 °C, and NaH (60 % disp., 1.1 g, 27.4 mmol) was added to the mixture and stirred for 1 hour. Then SEM-Cl (8.1 ml, 45.76 mmol) was added to the mixture and allowed to warm up to r.t. After 2.5 hours, water (25 ml) was added to the reaction mixture and extracted with EEO (2 x 30 ml). The combined organic layer was dried over MgSO 4 and evaporated. The residue was purified by flash chromatography (220 g Silica Gold column, heptane-EEO gradient) to give the product of the title.Step 2: 7-(2-Trimethylsilylethoxymethyl)-3H-pyrrolo[2,3-d]pyrimidin-4-one

[0129] 2-[(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)methoxy]ethyl-trimethyl-silane (3.5 g, 12.3 mmol) and lithium-hydroxide hydrate (5.17 g, 123 mmol) were stirred at 100 °C for 116 hours in the mixture of PDO (20 ml) and water (20 ml). The reaction mixture was filtered, the filtrate was acidified with aqueous HCl solution (1 N, 80 ml), and the resulted solid compound was filtered off, washed with water and dried to give the product of the title.Step 3: tert-Butyl 4-hydroxy-4-[[4-oxo-7-(2-trimethylsilylethoxymethyl)pyrrolo[2,3-d] pyrimidin-3-yl]methyl]piperidine-1-carboxylate

[0130] 7-(2-Trimethylsilylethoxymethyl)-3H-pyrrolo[2,3-d]pyrimidin-4-one (3.11g, 11.7 mmol), Preparation R1e (2.75 g, 2.9 mmol) and K 2 CO 3 (1.78 g, 12.9 mmol) were stirred in DMF (70 ml) at 60 °C for 40 hours. To the reaction mixture water was added, the resulted solid compound was filtered off, washed with water to give the product of the title. HRMS calculated for C 23 H 38 N 4 O 5 Si: 478.2611; found 479.2694 [(M+H) +< form].Step 4: 3-[(4-Hydroxy-4-piperidyl)methyl]-7-(2-trimethylsilylethoxymethyl)pyrrolo[2,3-d] pyrimidin-4-one

[0131] tert-Butyl 4-hydroxy-4-[[4-oxo-7-(2-trimethylsilylethoxymethyl)pyrrolo[2,3-d]pyrimidin-3-yl]methyl]piperidine-1-carboxylate (1.84 g, 3.86 mmol) was dissolved in DCM (50 ml) and formic acid (5 ml) and TFA (1317 mg, 0.885 ml, 11.58 mmol) were added then the mixture was stirred for 4 days at r.t. To the reaction mixture aqueous sodium-hydroxide solution (1 N, 100 ml) was added, then extracted with DCM (50 ml). The organic layer was dried over MgSO 4 , filtered, evaporated to give the product of the title. HRMS calculated for C 18 H 30 N 4 O 3 Si: 378.2087; found 379.2176 [(M+H) +< form].Step 5: tert-Butyl (3R,4R)-4-[4-hydroxy-4-[[4-oxo-7-(2-trimethylsilylethoxymethyl) pyrrolo[2,3-d]pyrimidin-3-yl]methyl]piperidine-1-carbonyl]-3-phenyl-piperidine-1-carboxylate

[0132] 3-[(4-hydroxy-4-piperidyl)methyl]-7-(2-trimethylsilylethoxymethyl)pyrrolo[2,3-d] pyrimidin-4-one (1.527 g, 3.77 mmol), (3R,4R)-1-tert-butoxycarbonyl-3-phenylpiperidine-4-carboxylic acid (1.152 g, 3.77 mmol) and EDC.HCl (1.446 g, 7.54 mmol) were stirred in pyridine (15 ml) overnight at r.t. The reaction mixture was evaporated to Celite, and purified by flash chromatography (DCM-MeOH) to give the product of the title. HRMS calculated for C 35 H 51 N 5 O 6 Si: 665.3609; found 666.3696 [(M+H) +< form].Step 6: Preparation R1n

[0133] The solution of tert-butyl (3R,4R)-4-[4-hydroxy-4-[[4-oxo-7-(2-trimethylsilylethoxy methyl)pyrrolo[2,3-d]pyrimidin-3-yl]methyl]piperidine-1-carbonyl]-3-phenyl-piperidine-1-carboxylate (1.6 g, 2.4 mmol), formic acid (3 ml) and TFA (820 mg, 0.55 ml, 7.2 mmol) in DCM (30 ml) was stirred at r.t. for 4 days. To the reaction mixture potassium-carbonate (15 g) was added as aqueous solution and extracted with DCM. The organic layer was evaporated to give Preparation R1n. HRMS calculated for C 30 H 43 N 5 O 4 Si: 565.3084; found 566.3138 [(M+H) +< form].Preparation R1o: 5-bromo-4-(tert-butoxycarbonylamino)thiophene-2-carboxylic acid

[0134] 4-Amino-5-bromo-thiophene-2-carboxylic acid (500 mg, 2.25 mmol) was dissolved in the mixture of PDO (2 ml) and water (2 ml) and sodium-hydroxide (194 mg, 4.8 mmol) was added to the mixture at 0 °C. Then di-tert-butyl dicarbonate (1768 mg, 8.1 mmol) was added to the mixture and stirred at 0 °C for 3 hours, then the reaction mixture was allowed to warm up to r.t. and stirred for 116 hours. The reaction mixture water was added and acidified by aqueous HCl solution (1 N, 4 ml). The resulted solid was filtered off washed with water and dried. The residue was purified by preparative LC (on C-18 Gemini-NX 5µm column, 5 mM aqueous NH 4 HCO 3 -MeCN, gradient, resulted as ammonium salt) to give Preparation R1o. 1< H NMR (500 MHz, MSM-d 6 ): δ ppm 8.71 (s, 1 H), 7.44 (brs, 4 H), 7.24 (s, 1 H), 1.44 (s, 9 H). 13< C NMR (125 MHz, MSM-d 6 ): δ ppm 125.8, 28.5. 15< N NMR (470.6 MHz, MSM-d 6 ): δ ppm 99.Preparation R1p: 4-nitro-5-(4-pyridyl)thiophene-2-carboxylic acid

[0135] Using General Procedure 9 starting from methyl 5-chloro-4-nitro-thiophene-2-carboxylate and 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine as reactant, the crude product (200 mg, 0.75 mmol) was stirred with lithium-hydroxide hydrate (60 mg, 1.5 mmol) in mixture of water (2 ml) and methanol (10 ml) at r.t. for 4 hours. The reaction mixture was neutralized with aqueous HCl solution (1 N, 1.5 ml). The resulted precipitate was filtered off, washed with water and dried to give Preparation R1p. 1< H NMR (500 MHz, MSM-d 6 ): δ ppm 14.18 (vbrs, 1 H), 8.74 (brs, 2 H), 8.19 (s, 1 H), 7.65 (m, 2 H). 13< C NMR (125 MHz, MSM-d 6 ): δ ppm 161.8, 150.4, 145.9, 143.6, 138.2, 134.4, 129.2, 124.3.Preparation R1g-(3S,4R): (3S,4R)-1-benzyl-3-(2-thienyl)piperidine-4-carboxylic acid andPreparation R1q-(3R,4S): (3R,4S)-1-benzyl-3-(2-thienyl)piperidine-4-carboxylic acid

[0136] To a stirred suspension of sodium-hydride (60 % disp., 1.4 g, 35.1 mmol) in abs. DEE (135 ml) ethyl 1-benzyl-3-oxo-piperidine-4-carboxylate hydrochloride (3.54 g, 11.9 mmol) was added at 0 °C. After 30 minutes of stirring trifluoromethanesulfonic anhydride (3.88 g, 2.28 ml, 13.5 mmol) was added dropwise to the reaction mixture and stirred for 3 hours while temperature allowed to warm up to r.t. To the reaction mixture water (100 ml) was added, the layers were separated, the aqueous layer was washed with DEE. The DEE layer was dried over MgSO 4 , and evaporated.

[0137] From a part of the prepared ethyl 1-benzyl-5-(trifluoromethylsulfonyloxy)-3,6-dihydro-2H-pyridine-4-carboxylate (2.184 g, 5.55 mmol), 2-thienylboronic acid (925 mg, 7.23 mmol), ATAphos ∗< PdCl 2 (400 mg, 0.55 mmol), Cs 2 CO 3 (3.63 g, 11.1 mol) was dissolved in THF (11 ml) and water (11 ml). The mixture was flushed with nitrogen and microwave irradiated at 82 °C for 140 minutes. The layers were separated, the organic layer was evaporated to Celite and purified by flash chromatography (Heptane-EEO, gradient).

[0138] The previously prepared ethyl 1-benzyl-5-(trifluoromethylsulfonyloxy)-3,6-dihydro-2H-pyridine-4-carboxylate (2.184 g, 5.55 mmol), 2-thienylboronic acid (925 mg, 7.23 mmol), ATAphos ∗< PdCl 2 (400 mg, 0.55 mmol), and Cs 2 CO 3 (3.63 g, 11.1 mol) were dissolved in the mixture of THF (11 ml) and water (11 ml). The mixture was flushed with nitrogen and microwave irradiated at 82 °C for 140 minutes. The layers were separated, the organic layer was evaporated to Celite and purified by flash chromatography (Heptane-EEO, gradient).

[0139] The resulted ethyl 1-benzyl-5-(2-thienyl)-3,6-dihydro-2H-pyridine-4-carboxylate (2.85 g, 8.7 mmol), Pd on carbon (3 x 1.5 g, 10 %), HCl solution (1 N in ether, 8.7 ml, 8.7 mmol) and EtOH (65 ml) were added into an autoclave. The autoclave was closed, inertized, vacuumized and filled with hydrogen (8 bar) and the reaction mixture was stirred in autoclave at 90 °C for 420 hours. During the curse of reaction, the catalyst was filtered out and replaced twice by fresh one. The reaction mixture was removed from the autoclave and filtered through Celite and the filtrate was evaporated. The residue was purified by preparative LC (on C-18 Gemini-NX 5µm column, 5 mM aqueous NH 4 HCO 3 -MeCN, gradient).

[0140] The resulted methyl cis-1-benzyl-3-(2-thienyl)piperidine-4-carboxylate (664 mg, 2 mmol) was dissolved in NaOEt solution (1 N, in EtOH, freshly prepared, 10 ml, 10 mmol) and stirred at 75 °C for 3 hours. Then water (5 ml) was added to the reaction mixture and continued stirring at 75 °C for 4 hours. The reaction mixture was partially evaporated, then neutralized by aqueous 1 N HCl solution, the solid was filtered off, washed with water and dried. The two enantiomers were separated by chiral LC to give Preparation R1q-(3S,4R) and Preparation R1q-(3R,4S). HRMS calculated for C 17 H 19 NO 2 S: 301.1136; found 302.1217 [(M+H) +< form]. 1< H NMR (400 MHz, MSM-d 6 ): δ ppm 12.15 (brs, 1 H), 7.37-7.19 (m, 5 H), 7.32 (dd, 1 H), 6.91 (dd, 1 H), 6.88 (dd, 1 H), 3.51 (s, 2 H), 3.24 (tm, 1 H), 2.9-2.05 (m, 4 H), 2.39 (tm, 1 H), 1.91-1.67 (dm / qm, 2 H).Preparation R1s: (4-methyl-2-phenyl-thiazol-5-yl)-[(3R,4R)-4-(2-oxa-6-azaspiro[2.5]octane-6-carbonyl)-3-phenyl-1-piperidyl]methanone Step 1: 1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]piperidin-4-one hydrochloride

[0141] tert-butyl (3R,4R)-4-(4-oxopiperidine-1-carbonyl)-3-phenylpiperidine-1-carboxylate (obtained in Step 1 of the Preparation R1f, 4.77 g, 12.34 mmol) was stirred in PDO (20 ml) and aqueous HCl solution (20 ml, 1 N) at 70 °C for 1 hour. The reaction mixture was evaporated and dried to give the product of the title. HRMS calculated for C 17 H 22 N 2 O 2 : 286.1681; found 287.1755 [(M+H) +< form]. 1< H NMR (400 MHz, MSM-d 6 ): δ ppm 9.68 (brd, 1 H), 9.14 (brq, 1 H), 7.40-7.18 (m, 5H), 3.73 / 3.31 (m / m, 2 H), 3.73 / 3.31 (m / m, 2 H), 3.56 (m, 1 H), 3.33 / 3.10 (m / m, 2 H), 3.31-3.13 (m, 2 H), 3.26 (m, 1 H), 2.17 / 1.56 (m / m, 2 H), 2.15 / 1.81 (m / m, 2 H), 2.03-1.87 (m, 2 H).Step 2: 1-[(3R,4R)-]-(4-methyl-2-phenyl-thiazole-5-carbonyl)-3-phenyl-piperidine-4-carbonyl]piperidin-4-one

[0142] 1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]piperidin-4-one hydrochloride (3.42 g, 10.6 mmol), EDC.HCl (6.64 g, 34.6 mmol) and 4-methyl-2-phenyl-thiazole-5-carboxylic acid (2.32 g, 10.6 mmol) were stirred in pyridine (60 ml) at r.t. for 20 hours. The reaction mixture was evaporated to Celite and purified by flash chromatography (DCM-MeOH / DCM, gradient) to give the product of the title. HRMS calculated for C 28 H 29 N 3 O 3 S: 487.1930; found 488.1991 [(M+H) +< form]. 1< H NMR (400 MHz, MSM-d 6 ): δ ppm 7.93 / 7.51 (brs / brs, 5 H), 7.35 / 7.15 (brs / brs, 5 H), 4.80-2.80 (brm, 4H), 3.74 / 3.63 (m / brm, 2 H), 3.74 / 3.32 (m / m, 2 H), 3.56 (td, 1 H), 2.99 (td, 1 H), 2.44 (s, 3 H), 2.19 / 1.61 (m / m, 2 H), 2.16 / 1.84 (m / m, 2 H), 1.89 / 1.66 (brm / brm, 2 H).Step 3: Preparation R1s

[0143] To the stirred suspension of 1-[(3R,4R)-1-(4-methyl-2-phenyl-thiazole-5-carbonyl)-3-phenyl-piperidine-4-carbonyl]piperidin-4-one (4.5 g, 9.23 mmol) and trimethylsulfoxonium-iodide (2.44 g, 11.1 mmol) in MeCN (25 ml) aqueous sodium-hydroxide (40 w %, 443 mg NaOH / 0.664 ml water) was added at r.t., stirred for 160 minutes. The reaction mixture was diluted with water (20 ml) and MeCN was evaporated. The residue was extracted with DCM and the organic layer was evaporated to give Preparation R1s. HRMS calculated for C 29 H 31 N 3 O 3 S: 501.2086; found 502.2160 [(M+H) +< form]. 1< H NMR (400 MHz, MSM-d 6 ): δ ppm 7.93 (m, 2 H), 7.51 (m, 3 H), 7.40-7.10 (brs / brs, 5 H), 4.88-2.88 (brm, 4H), 3.82 - 2.97 (m, 4 H), 3.54 (m, 1 H), 2.97 (m, 1 H), 2.56 (m, 2 H), 2.43 (s, 3 H), 1.83 / 1.63 (brd / brq, 2 H), 1.45-0.86 (m, 2 H).Preparation R1t: 1-ethenyl-1H-indole-2-carboxylic acid

[0144] The mixture of ethyl indole-2-carboxylate (2 g, 10.57 mmol), palladium(II)-acetate (119 mg, 0.53 mmol), copper(II)-bromide (2.37 g, 10.57 mmol), vinyl-acetate (20 ml, 248.7 mmol) and sodium-acetate (2.6 g, 31.7 mmol) was heated at 80 °C for 28 hours. The reaction mixture was evaporated to Celite and purified by flash chromatography (heptane-EEO, 0-5% gradient).

[0145] The mixture of the resulted ester (1.08 g, 5.017 mmol), lithium-hydroxide hydrate (1.05 g, 25.1 mmol) in ethanol and water (10-10 ml) was stirred at 80 °C for 90 minutes. The reaction mixture was acidified with aqueous HCl solution (1 N, 30 ml) at 0-5 °C, the formed precipitate was filtered off, washed with water (5 x 20 ml) and dried to give Preparation R1t. 1< H NMR (400 MHz, MSM-d6): δ ppm 13.22 (s, 1 H), 7.75 (m, 3 H), 7.51 (m, 1 H), 7.22 (t, 1 H), 5.48 (d, 1 H), 5.28 (d, 1 H)Preparation R1u: 5-bromo-1-vinyl-pyrrole-2-carboxylic acid

[0146] The mixture of methyl 5-bromo-1H-pyrrole-2-carboxylate (1.2 g, 5.88 mmol), palladium(II)-acetate (132 mg, 0.588 mmol), copper(II)-bromide (2.63 g, 11.76 mmol), vinyl-acetate (27 ml, 294 mmol) and sodium-acetate (2.9 g, 35.3 mmol) was heated at 80 °C for 28 hours. The reaction mixture was evaporated to Celite and purified by flash chromatography (heptane-EEO, 0-25% gradient).

[0147] The mixture of the resulted ester (403 mg, 1.75 mmol), lithium-hydroxide hydrate (368 mg, 8.75 mmol) in ethanol and water (4-4 ml) was stirred at 80 °C for 60 minutes. The reaction mixture was acidified with aqueous HCl solution (1 N, 10 ml) at 0-5 °C. The formed precipitate was filtered off, washed with water (5 x 20 ml) and dried to give Preparation R1u . 1< H NMR (400 MHz, MSM-d6): δ ppm 12.63 (s, 1 H), 7.11 (m, 1 H), 6.94 (d, 1 H), 6.45 (d, 1 H), 5.42 (m, 2 H)Preparation R1v: 4-bromo-1-vinyl-pyrrole-2-carboxylic acid

[0148] The mixture of methyl 4-bromo-1H-pyrrole-2-carboxylate (1.2 g, 5.88 mmol), palladium(II)-acetate (132 mg, 0.588 mmol), copper(II)-bromide (2.63 g, 11.76 mmol), vinyl-acetate (27 ml, 294 mmol) and sodium-acetate (2.9 g, 35.3 mmol) was heated at 80 °C for 21 hours. The reaction mixture was evaporated to Celite and purified by flash chromatography (heptane-EEO, 0-5% gradient).

[0149] The mixture of the resulted ester (338 mg, 1.47 mmol), lithium-hydroxide hydrate (908 mg, 7.35 mmol) in ethanol and water (3.5-3.5 ml) was stirred at 80 °C for 105 minutes. The reaction mixture was acidified with aqueous HCl solution (1 N, 9 ml) at 0-5 °C. The formed precipitate was filtered off, washed with water (2 x 5 ml) and dried to give Preparation R1v. 1< H NMR (500 MHz, MSM-d6): δ ppm 12.93 (brs, 1 H), 7.85 (d, 1 H), 7.84 (dd, 1 H), 6.94 (d, 1 H), 5.5 / 4.9 (dd+dd, 2 H). 13< C NMR (125 MHz, MSM-d6): δ ppm 131.4, 124.1, 123.4, 120.3, 102.8, 97.9Preparation R1w: 4,5-dichloro-3-fluoro-thiophene-2-carboxylic acid Step 1: methyl 4,5-dichloro-3-fluoro-thiophene-2-carboxylate

[0150] To the solution of methyl 3-fluoro-thiophene-2-carboxylate (1826 mg, 11.4 mmol) in THF (5 ml) TMP.MgCl.LiCl (1 N, in THF / toluene, 21 ml, 21 mmol) was added dropwise at -45 °C in 5 minutes. After 30 minutes of stirring at -45 °C, hexachloroethane (2.7g, 11.4 mmol) was added at -45 °C to the mixture and stirred for 1 hour at -40 °C. After warming up, sat.NH 4 Cl solution (10 ml, aq.) was added to the mixture while stirring. The mixture was extracted with EEO (4 x 10 ml). The combined organic layer was evaporated. The residue was purified by preparative LC (on C-18 Gemini-NX 5µm column, 5 mM aqueous NH 4 HCO 3 -MeCN, gradient) to give the product of the title. GC-MS calculated for C 6 H 3 Cl 2 FO 2 S: 227.9215; found 227.9 found [(M, EI) form]. 1< H NMR (500 MHz, MSM-d 6 ): δ ppm 3.85 (s, 3 H). 13< C NMR (125 MHz, MSM-d 6 ): δ ppm 159, 152.8, 130.5, 115.5, 110.8, 53.4.Step 2: Preparation R1w

[0151] Methyl 4,5-dichloro-3-fluoro-thiophene-2-carboxylate (130 mg, 0.567 mmol), lithium-hydroxide monohydrate (95 mg, 2.27 mmol) were stirred in methanol (3 ml) and water (3 ml) at r.t. for 3 hours. The mixture was partially evaporated and the aqueous residue was acidified with 1 N HCl (4 ml, aq.). The resulted precipitate was filtered off, washed with water and dried to give Preparation R1w. 13< C NMR (125 MHz, MSM-d 6 ): δ ppm 160, 152.3, 129.5, 115.3, 112.8.Preparation Rlx: 2-(6-methyl-3-pyridyl)thiazole-5-carboxylic acid

[0152] Ethyl 2-(6-methyl-3-pyridyl)thiazole-5-carboxylate (745 mg, 3 mmol), lithium-hydroxide monohydrate (630 mg, 15 mmol) were stirred in ethanol (5 ml) and water (5 ml) at r.t. for 8 hours. The mixture was partially evaporated and the aqueous residue was acidified with 1N HCl (15 ml, aq.). The resulted precipitate was filtered off, washed with water and dried to give Preparation Rlx. HRMS calculated for C 10 H 8 N 2 O 2 S: 220.0307; found 221.0379 [(M+H) +< form]. 1< H NMR (500 MHz, MSM-d 6 ): δ ppm 13.69 (brs, 1 H), 9.07 (d, 1 H), 8.45 (s, 1 H), 8.26 (dd, 1 H), 7.44 (d, 1 H), 2.55 (s, 3 H). 13< C NMR (125 MHz, MSM-d 6 ): δ ppm 149.3, 147.1, 134.9, 124.2, 24.5Preparation R2b: 7-methyl-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0153] Using General Procedure 1 starting from Preparation R1a and iodomethane as alkylating agent, Preparation R2b was obtained. HRMS calculated for C 7 H 7 N 3 O: 149.0589; found 150.0668 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ (ppm) 11.85 (brs, 1 H), 7.88 (brs, 1 H), 7.09 (d, 1 H), 6.44 (d, 1 H), 3.70 (m, 1 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 158.7, 147.7, 143.8, 125.1, 108.1, 101.7, 31.8.Preparation R2c: 7-ethyl-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0154] Using General Procedure 1 starting from Preparation R1a and iodoethane as reagents, Preparation R2c was obtained. HRMS calculated for C 8 H 9 N 3 O: 163.0746; found 164.0823 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ (ppm) 11.38 (brs, 1 H), 7.87 (d, J=2.0 Hz, 1 H), 7.16 (d, J=3.4 Hz, 1 H), 6.45 (d, J=3.4 Hz, 1 H), 4.14 (q, J=7.1 Hz, 2 H), 1.34 (t, J=7.1 Hz, 3 H).Preparation R2d: 7-(propan-2-yl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0155] Using General Procedure 1 starting from Preparation R1a and 2-iodopropane as reagents, Preparation R2d was obtained. HRMS calculated for C 9 H 11 N 3 O: 177.0902; found 178.0979 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ (ppm) 11.83 (brs, 1 H), 7.87 (s, 1 H), 7.24 (d, 1 H), 6.47 (d, 1 H), 4.85 (sept., 1 H), 1.42 (d, 6 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 158.8, 146.8, 143.5, 120.7, 108.2, 102, 46.5, 23. 15< N-NMR (50.6 MHz, MSM-d6): δ (ppm) 168.Preparation R2g: 7-cyclopropyl-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0156] Using General Procedure 2 starting from Preparation R1a and cyclopropylboronic acid as reagents, Preparation R2g was obtained. HRMS calculated for C 9 H 9 N 3 O: 175.0746; found 176.0819 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ (ppm) 11.88 (brs, 1 H), 7.89 (brs, 1 H), 7.05 (d, 1 H), 6.4 (d, 1 H), 3.53 (m, 1 H), 1.06-0.92 (m, 4 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 158.7, 148.9, 143.8, 123.4, 108.8, 101.6, 27.5, 6.6.Preparation R2h: 7-cyclobutyl-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0157] Using General Procedure 1 starting from Preparation R1a and cyclobutyl bromide as reagents, Preparation R2h was obtained. HRMS calculated for C 10 H 11 N 3 O: 189.0902; found 190.0974 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ (ppm) 11.85 (brs, 1 H), 7.88 (brs, 1 H), 7.09 (d, 1 H), 6.44 (d, 1 H), 3.70 (m, 1 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 158.7, 147.7, 143.8, 125.1, 108.1, 101.7, 31.8.Preparation R2i: 7-cyclopentyl-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0158] Using General Procedure 4 starting from Preparation R1a and cyclopentanol as reagents, Preparation R2i was obtained. HRMS calculated for C 11 H 13 N 3 O: 203.1059; found 204.1139 [(M+H) +< form]. 1< H-NMR (400 MHz, MSM-d6): δ (ppm) 11.84 (brs, 1 H), 7.87 (d, 1 H), 7.21 (d, 1 H), 6.46 (d, 1 H), 4.97 (m, 1 H), 2.16-1.57 (m, 8 H). 13< C-NMR (100 MHz, MSM-d6): δ (ppm) 143.5, 121.3, 102, 55.6.Preparation R2i: 7-cyclohexyl-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0159] Using General Procedure 4 starting from Preparation R1a and cyclohexanol as reagents, Preparation R2j was obtained. HRMS calculated for C 12 H 15 N 3 O: 217,1215; found 218.1293 [(M+H) +< form]. 1< H-NMR (400 MHz, MSM-d6): δ (ppm) 11.83 (brs, 1 H), 7.86 (d, 1 H), 7.23 (d, 1 H), 6.46 (d, 1 H), 4.45 (m, 1 H), 1.97-1.13 (m, 10 H). 13< C-NMR (100 MHz, MSM-d6): δ (ppm) 143.4, 121.1, 101.8, 53.8.Preparation R2k: 7-(1-methylpiperidin-4-yl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0160] Using General Procedure 4 starting from Preparation R1a and 4-hydroxy-1-methylpiperidine as reagents, Preparation R2k was obtained. HRMS calculated for C 12 H 16 N 4 O: 232.1324; found 233.1405 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ (ppm) 11.82 (brs, 1 H), 7.86 (d, 1 H), 7.29 (d, 1 H), 6.46 (d, 1 H), 4.44 (m, 1 H), 2.89 / 2.05 (m, 4 H), 2.22 (s, 3 H), 2.02 / 1.82 (m, 4 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 143.9, 121.2, 102.1, 55.1, 52.1, 46.1, 32.3.Preparation R2l: 7-(tetrahydro-2H-pyran-4-yl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one

[0161] Using General Procedure 4 starting from Preparation R1a and tetrahydro-4-pyranol as reagents, Preparation R2l was obtained. HRMS calculated for C 11 H 13 N 3 O 2 : 219.1008; found 220.1082 [(M+H) +< form]. 1< H-NMR (400 MHz, MSM-d6): δ (ppm) 11.88 (brs, 1 H), 7.88 (d, 1 H), 7.29 (d, 1 H), 6.48 (d, 1 H), 4.71 (m, 1 H), 3.98 / 3.49 (m+m, 4 H), 2.05 / 1.82 (m+m, 4 H). 13< C-NMR (100 MHz, MSM-d6): δ (ppm) 143.5, 121.2, 102, 66.7, 51.3, 33.3.Preparation R2m: 7-(prop-2-yn-1-yl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0162] Using General Procedure 1 starting from Preparation R1b (instead of Preparation R1a) and 3-bromoprop-1-yne as reagents (without the hydrolysis step), the crude methoxypyrimidine product (400 mg, 2.3 mmol) was dissolved in PDO (4 ml) and aqueous HCl solution (37 %, 0.18 ml) was added. The mixture was heated for 100 °C for 30 minutes in a Schlenk tube. After cooling DIPO (4 ml) was added to the reaction mixture, the resulted precipitate was filtered off and dried to give Preparation R2m. HRMS calculated for C 9 H 7 N 3 O: 173.0589; found 174.0665 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ (ppm) 11.98 (brs, 1 H), 7.93 (s, 1 H), 7.19 (d, 1 H), 6.5 (d, 1 H), 4.98 (d, 2 H), 3.42 (t, 1 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 158.6, 147.3, 144.3, 123.6, 102.5, 79.4, 76, 34.1.Preparation R2n: 7-(2-methylpropyl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0163] Using General Procedure 1 starting from Preparation R1a and 1-bromo-2-methylpropane as reagents, Preparation R2n was obtained. HRMS calculated for C 10 H 13 N 3 O: 191.1059; found 192.1132 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ (ppm) 11.84 (brs, 1 H), 7.86 (s, 1 H), 7.12 (d, 1 H), 6.45 (d, 1 H), 3.92 (d, 2 H), 2.1 (sept., 1 H), 0.82 (d, 6 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 158.8, 147.7, 143.7, 124.5, 108, 101.6, 52, 29.6, 20.2.Preparation R2o: 7-(2,2,2-trifluoroethyl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0164] Using General Procedure 1 starting from Preparation R1a and 2,2,2-trifluoroethyl trifluoromethanesulfonate as reagents, Preparation R2o was obtained. HRMS calculated for C 8 H 6 N 3 OF 3 : 217.0463; found 218.0543 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ (ppm) 12.08 (brs, 1 H), 7.97 (s, 1 H), 7.19 (d, 1 H), 6.57 (d, 1 H), 5.06 (q, 2 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 158.5, 148.4, 144.9, 124.7, 124.4, 108.8, 103.2, 45.1. 19< F-NMR (376.5 MHz, MSM-d6): δ (ppm) -70.3.Preparation R2p: 7-(2,2-difluoroethyl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0165] Using General Procedure 1 starting from Preparation R1a and 2-iodo-1,1-difluoroethane as reagents, Preparation R2p was obtained. HRMS calculated for C 8 H 7 N 3 OF 2 : 199.0557; found 200.0634 ((M+H) +< form]. 1< H-NMR (400 MHz, MSM-d6) δ ppm 11.99 (brs, 1 H), 7.93 (s, 1 H), 7.16 (d, 1 H), 6.53 (d, 1 H), 6.37 (tt, 1 H), 4.6 (td, 2 H). 13< C-NMR (400 MHz, MSM-d6) δ ppm 144.4, 124.8, 114.3, 102.5, 46.2.Preparation R2q: 7-(cyclopropylmethyl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0166] Using General Procedure 1 starting from Preparation R1a and cyclopropylmethyl bromide as reagents, Preparation R2q was obtained. HRMS calculated for C 10 H 11 N 3 O: 189.0902; found 190.0980 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ (ppm) 11.84 (s, 1 H), 7.87 (s, 1 H), 7.2 (d, 1 H), 6.45 (d, 1 H), 3.97 (d, 2 H), 1.21 (m, 1 H), 0.52-0.35 (m, 4 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 158.7, 147.3, 143.7, 124, 108.1, 101.7, 49, 12.3, 4.07.Preparation R2r: 7-(cyclobutylmethyl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0167] Using General Procedure 1 starting from Preparation R1a and (bromomethyl)cyclobutane as reagents, Preparation R2r was obtained. HRMS calculated for C 11 H 13 N 3 O: 203.1059; found 204.1134 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ (ppm) 11.83 (brs, 1 H), 7.87 (d, 1 H), 7.12 (d, 1 H), 6.43 (d, 1 H), 4.13 (d, 2 H), 2.72 (m, 1 H), 1.92 / 1.74 (m+m, 4 H), 1.82 (m, 2 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 143.7, 124.2, 101.7, 49.6, 36, 25.6, 18.Preparation R2s : 7-(buta-2,3-dien-1-yl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0168] Using General Procedure 1 starting from Preparation R1b (instead of Preparation R1a) and 4-bromobuta-1,2-diene as reagents (without the hydrolysis step), the crude methoxypyrimidine product (300 mg, 1.65 mmol) was dissolved in PDO (4 ml) and aqueous HCl solution (37 %, 0.18 ml) was added. The mixture was heated for 100 °C for 30 minutes in a Schlenk tube. After cooling, the reaction mixture was evaporated to give Preparation R2s . HRMS calculated for C 10 H 9 N 3 O: 187.0745; found 188.0821 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ (ppm) 11.91 (brs, 1 H), 7.89 (s, 1 H), 7.12 (d, 1 H), 6.46 (d, 1 H), 5.48 (m, 1 H), 4.87 (m, 2 H), 4.73 (m, 2 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 208.3, 158.7, 147.4, 143.9, 123.9, 108.2, 102.1, 88.3,78.1,43.Preparation R2t: 7-[3-(dimethylamino)propyl]-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0169] Using General Procedure 1 starting from Preparation R1a and 3-dimethylaminopropyl chloride hydrochloride as reagents, Preparation R2t was obtained. HRMS calculated for C 11 H 16 N 4 O: 220.1324; found 221.1401 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ (ppm) 11.84 (brs, 1 H), 7.88 (s, 1 H), 7.13 (d, 1 H), 6.44 (d, 1 H), 4.12 (t, 2 H), 2.15 (t, 2 H), 2.1 (s, 6 H), 1.85 (quint, 2 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 158.8, 147.4, 143.8, 124.2, 108.2, 101.7, 56.4, 45.6, 43, 28.6.Preparation R2u: 7-(2-fluoroethyl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0170] Using General Procedure 1 starting from Preparation R1a and 1-fluoro-2-iodoethane as reagents, Preparation R2u was obtained. HRMS calculated for C 8 H 8 NOF: 181.0651; found 182.0728 [(M+H) +< form]. 1< H-NMR (400 MHz, MSM-d6) δ ppm 11.91 (brs, 1 H), 7.9 (s, 1 H), 7.17 (d, 1 H), 6.49 (d, 1 H), 4.74 (dt, 2 H), 4.43 (dt, 2 H). 13< C-NMR (100 MHz, MSM-d6) δ ppm 144, 124.3, 102, 83.1, 45.1.Preparation R2v: 7-[2-(dimethylamino)ethyl]-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0171] Using General Procedure 1 starting from Preparation R1a and 2-bromo-N,N-dimethylethylamine hydrobromide as reagents, Preparation R2v was obtained. HRMS calculated for C 10 H 14 N 4 O: 206.1168; found 207.1242 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ (ppm) 11.84 (brs, 1 H), 7.88 (brd, 1 H), 7.16 (d, 1 H), 6.44 (d, 1 H), 4.19 (t, 2 H), 2.6 (t, 2 H), 2.16 (s, 6 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 158.7, 147.5, 143.7, 124.4, 108.1, 101.7, 59.2, 45.5,42.6.Preparation R2w: 7-(2-hydroxyethyl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0172] Using General Procedure 1 starting from Preparation R1a and 2-chloroethanol as reagents, Preparation R2w was obtained. 1< H-NMR (400 MHz, MSM-d6): δ (ppm) 11.83 (brs, 1 H), 7.86 (d, J=2.4 Hz, 1 H), 7.12 (d, J=3.92 Hz, 1 H), 6.43 (d, J=3.14 Hz, 1 H), 4.92 (t, J=5.49 Hz, 1 H), 4.15 (t, J=6.28 Hz, 2 H), 3.68 (q, J=5.49 Hz, 2 H).Preparation R2x: 7-[(4-chlorophenyl)methyl]-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0173] Using General Procedure 1 starting from Preparation R1a and 4-chlorobenzyl bromide as reagents, Preparation R2x was obtained. HRMS calculated for C 13 H 10 CN 3 O: 259.0512; found 260.0583 [(M+H) +< form]. 1< H-NMR (400 MHz, MSM-d6): δ (ppm) 11.93 (s, 7.9 (s, 1 H), 7.39 (m, 2 H), 7.23 (m, 2 H), 7.22 (d, 1 H), 6.51 (d, 1 H), 5.34 (s, 2 H). 13< C-NMR (100 MHz, MSM-d6): δ (ppm) 158.7, 147.4, 144.2, 137.5, 132.5, 129.5, 129, 124.2, 108.3, 102.4, 47.5.Preparation R2y: 7-[(3-chlorophenyl)methyl]-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0174] Using General Procedure 1 starting from Preparation R1a and 3-chlorobenzyl bromide as reagents, Preparation R2y was obtained. HRMS calculated for C 13 H 10 ClN 3 O: 259.0512; found 260.0580 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ (ppm) 11.94 (brs, 1 H), 7.92 (d, 1 H), 7.35 (m, 1 H), 7.35 (m, 1 H), 7.28 (t, 1 H), 7.25 (d, 1 H), 7.16 (dm, 1 H), 6.51 (d, 1 H), 5.35 (s, 2 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 158.7, 147.6, 144.3, 140.9, 133.6, 131.1, 128, 127.5, 126.4, 124.3, 108.4, 102.4, 47.5.Preparation R2z: 7-benzyl-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0175] Using General Procedure 1 starting from Preparation R1a and benzyl bromide as reagents, Preparation R2z was obtained. HRMS calculated for C 13 H 11 N 3 O: 225.0902; found 226.0986 [(M+H) +< form]. 1< H-NMR (400 MHz, MSM-d6): δ (ppm) 11.91 (brs, 1 H), 7.91 (s, 1 H), 7.36-7.17 (m, 5 H), 7.2 (d, 1 H), 6.49 (d, 1 H), 5.34 (s, 2 H). 13< C-NMR (100 MHz, MSM-d6): δ (ppm) 144.1, 124.3, 102.2, 48.1.Preparation R2aa: 7-[(2-chlorophenyl)methyl]-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0176] Using General Procedure 1 starting from Preparation R1a and 2-chlorobenzyl bromide as reagents, Preparation R2aa was obtained. HRMS calculated for C 13 H 10 ClN 3 O: 2590512; found 260.0587 [(M+H) +< form]. 1< H-NMR (400 MHz, MSM-d6): δ (ppm) 11.95 (brs, 1 H), 7.89 (d, 1 H), 7.5 (dm, 1 H), 7.32 (m, 1 H), 7.26 (m, 1 H), 7.17 (d, 1 H), 6.72 (dm, 1 H), 6.55 (d, 1 H), 5.44 (s, 2 H). 13< C-NMR (100 MHz, MSM-d6): δ (ppm) 144.3, 129.8, 129.8, 128.8, 128.1, 124.5, 102.5, 46.Preparation R2ab: 7-(2-oxopyrrolidin-1-yl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one

[0177] Preparation R1b (1.74 g, 11.67 mmol) was dissolved in DMF (80 ml) and cooled to 0 °C, sodium hydride (60 % disp., 1.87 g, 46.67 mmol) was slowly added and stirred for 30 minutes at 0 °C. Hydroxylamine-O-sulfonic acid (2.11 g, 18.67 mmol) was added to the reaction mixture and allowed to warm up to r.t. and stirred for 20 hours. Water (100 ml) was added to the reaction mixture and extracted with DCM (4 x 50 ml). The combined organic layer was washed with water and dried over MgSO 4 and evaporated. The residue was dissolved in MSM and purified by preparative LC (on C-18 Gemini-NX 5µm column, 5 mM aqueous NH 4 HCO 3 -MeCN, gradient).

[0178] A part of the resulted N-amine compound (500 mg, 3.05 mmol) was dissolved in DCM (20 ml) and TEA (850 µl, 6.09 mmol, 2 eq.) and 4-chlorobutyryl chloride was (409 µl, 515 mg, 3.65 mmol, 1.2 eq.) added dropwise and stirred for 20 hours at r.t. Then the reaction mixture was evaporated, sat. NaHCO 3 solution (5 ml, aq.), MeCN (20 ml) and water (20 ml) were added to the residue and the mixture was stirred for 3 hours at 80 °C. The reaction mixture was evaporated and water (50 ml) was added. The solution was extracted with DCM (3 x 10 ml) and the combined organic layers were evaporated. The residue was purified by preparative LC (on C-18 Gemini-NX 5µm column, 5 mM aqueous NH 4 HCO 3 -MeCN, gradient).

[0179] The resulted pyrrolidone (200 mg, 0.862 mmol) was dissolved in HCl solution (4 ml, 1 N, aq.) and PDO (80 ml) and stirred at 60 °C for 6 hours. The reaction mixture was evaporated and the residue was purified by preparative LC (on C-18 Gemini-NX 5µm column, 5 mM aqueous NH 4 HCO 3 -MeCN, gradient) gave Preparation R2ab. HRMS calculated for C 10 H 10 N 4 O 2 : 218.0804; found 219.0883 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ (ppm) 12.11 (brs, 1 H), 7.91 (s, 1 H), 7.2 (d, 1 H), 6.53 (d, 1 H), 3.77 (t, 2 H), 2.47 (t, 2 H), 2.17 (quint., 2 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 173.7, 158.4, 146.6, 145.2, 124.2, 107, 101.3, 49.8,28.4, 16.9.Preparation R2ac: 7-(3,4,5-trimethoxyphenyl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0180] Using General Procedure 3 starting from Preparation R1b and 5-iodo-1,2,3-trimethoxybenzene as reagents, Preparation R2ac was obtained. HRMS calculated for C 15 H 15 N 3 O 4 : 301.1063; found 302.1138 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ (ppm) 12.07 (brs, 1 H), 7.95 (d, 1 H), 7.49 (d, 1 H), 6.99 (s, 2 H), 6.66 (d, 1 H), 3.82 (s, 6 H), 3.7 (s, 3 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 144.5, 124.6, 103.2, 103, 60.6, 56.6.Preparation R2ad: 7-(3,S-dichlorophenyl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0181] Using General Procedure 2 starting from Preparation R1a and 3,5-dichlorophenylboronic acid as reagents, Preparation R2ad was obtained. HRMS calculated for C 12 H 7 Cl 2 N 3 O: 278.9966; found 280.0040 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ (ppm) 12.03 (vbrs, 1 H), 8.03 (s, 1 H), 7.95 (d, 2 H), 7.64 (t, 1 H), 7.63 (d, 1 H), 6.71 (d, 1 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 145.3, 126.7, 123.8, 122.7, 104.4.Preparation R2ae: 7-(3-chloro-5-methoxyphenyl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0182] Using General Procedure 2 starting from Preparation R1a and 3-chloro-5-methoxyphenylboronic acid as reagents, Preparation R2ae was obtained. HRMS calculated for C 13 H 10 ClN 3 O 2 : 275.0461; found 276.0541 [(M+H) +< form]. 1< H-NMR (400 MHz, MSM-d6): δ (ppm) 12.18 (s, 1 H), 8 (d, 1 H), 7.6 (d, 1 H), 7.51 (t, 1 H), 7.33 (t, 1 H), 7.08 (t, 1 H), 6.69 (d, 1 H), 3.85 (s, 3 H). 13< C-NMR(100 MHz, MSM-d6): δ (ppm) 161, 158.7, 147.5, 145, 139.7, 134.5, 124, 116.3, 112.7, 110.2, 109.4, 104, 56.4Preparation R2af: 7-(3,5-dimethoxyphenyl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0183] Using General Procedure 2 starting from Preparation R1a and 2-(3,5-dimethoxy)-phenyl-4,4,5,5-tetramethyl-(1,3,2)-dioxaborolane as reagents, Preparation R2af was obtained. HRMS calculated for C 14 H 13 N 3 O 3 : 271.0957; found 272.1030 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ (ppm) 12.11 (s, 1 H), 7.95 (d, 1 H), 7.52 (d, 1 H), 6.91 (d, 2 H), 6.66 (d, 1 H), 6.54 (t, 1 H), 3.8 (s, 6 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 144.5, 124.2, 103.5, 103.1, 98.9.Preparation R2ag: 7-(3,4-dichlorophenyl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0184] Using General Procedure 3 starting from Preparation R1b and 3,4-dichlorophenylboronic acid as reagents, Preparation R2ag was obtained. HRMS calculated for C 12 H 7 Cl 2 N 3 O: 278.9966; found 280.003 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ (ppm) 12.21 (brs, 1 H), 8.15 (t, 1 H), 8.02 (brs, 1 H), 7.82 (d, 1 H), 7.82 (d, 1 H), 7.61 (d, 1 H), 6.72 (d, 1 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 145.1, 131.5, 125.9, 124.3, 123.8, 104.2.Preparation R2ah: 7-(4-chloro-3-fluorophenyl)-3,7-dihydro-4H-pyrrolo[2,3-d] pyrimidin-4-one

[0185] Using General Procedure 3 starting from Preparation R1b and 4-chloro-3-fluoroiodobenzene as reagents, Preparation R2ah was obtained. HRMS calculated for C 12 H 7 ClFN 3 O: 263.0262; found 264.0339 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ (ppm) 12.21 (s, 1 H), 8.02 (d, 1 H), 7.97 (dd, 1 H), 7.77 (dd, 1 H), 7.72 (dd, 1 H), 7.6 (d, 1 H), 6.72 (d, 1 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 145.1, 131.5, 123.7, 121.5, 112.8, 104.2.Preparation R2ai: 7-(4-chloro-3-methoxyphenyl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0186] Using General Procedure 3 starting from Preparation R1b and 2-chloro-5-iodoanisole as reagents, Preparation R2ai was obtained. HRMS calculated for C 13 H 10 ClN 3 O 2 : 275.0461; found 276.0537 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ (ppm) 12.15 (brs, 1 H), 7.98 (brs, 1 H), 7.58 (d, 1 H), 7.57 (d, 1 H), 7.49 (d, 1 H), 7.36 (dd, 1 H), 6.7 (d, 1 H), 3.93 (s, 3 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 158.7, 155.3, 147.4, 144.8, 137.7, 130.5, 124.2, 119.8, 117.3, 110, 109.4, 103.7, 56.9.Preparation R2aj: 7-(4-fluoro-3-methoxyphenyl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0187] Using General Procedure 3 starting from Preparation R1b and 1-fluoro-4-iodo-2-methoxybenzene as reagents, Preparation R2aj was obtained. HRMS calculated for C 13 H 10 N 3 O 2 F: 259.0757; found 260.0818 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ (ppm) 12.1 (s, 1 H), 7.95 (s, 1 H), 7.51 (d, 1 H), 7.48 (dd, 1 H), 7.38 (dd, 1 H), 7.27 (ddd, 1 H), 6.68 (d, 1 H), 3.9 (s, 3 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 144.7, 124.5, 117, 116.5, 111, 103.4,56.8.Preparation R2ak: 7-(3,4-dimethoxyphenyl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0188] Using General Procedure 3 starting from Preparation R1b and 3,4-dimethoxyphenylboronic acid pinacol ester as reagents, Preparation R2ak was obtained. HRMS calculated for C 14 H 13 N 3 O 3 : 271.0957; found 272.103 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ (ppm) 7.92 (d, 1 H), 7.43 (d, 1 H), 7.25 (d, 1 H), 7.19 (dd, 1 H), 7.08 (d, 1 H), 6.65 (d, 1 H), 3.8 (s, 6 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 144.5, 124.6, 116.9, 112.2, 109.3, 103.1, 56.3.Preparation R2am: 7-(4-methylphenyl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0189] Using General Procedure 3 starting from Preparation R1b and 4-iodotoluene as reagents, Preparation R2am was obtained. HRMS calculated for C 13 H 11 N 3 O: 225.0902; found 226.0987 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ (ppm) 12.06 (brs, 1 H), 7.93 (s, 1 H), 7.58 (dm, 1 H), 7.44 (d, 1 H), 7.33 (dm, 1 H), 6.66 (d, 1 H), 2.37 (s, 3 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 158.8, 147.3, 144.5, 136.8, 135.4, 130.1, 124.5, 124.1, 109.6, 103.4, 21.Preparation R2an: 4-{4-oxo-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-7-yl}benzonitrile

[0190] Using General Procedure 3 starting from Preparation R1b and 4-iodobenzonitrile as reagents, Preparation R2an was obtained. HRMS calculated for C 13 H 8 N 4 O: 236.0698; found 237.0775 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ (ppm) 12.25 (brs, 1 H), 8.05 (m, 2 H), 8.03 (m, 2 H), 8.02 (brs, 1 H), 7.66 (d, 1 H), 6.75 (d, 1 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 147.6, 145.2, 141.5, 134, 124.6, 123.6, 119, 110.6, 109.4, 104.7.Preparation R2ao: 7-[4-(trifluoromethyl)phenyl]-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0191] Using General Procedure 3 starting from Preparation R1b and 4-iodobenzotrifluoride as reagents, Preparation R2ao was obtained. HRMS calculated for C 13 H 8 F 3 N 3 O: 279.0619; found 280.0691 [(M+H) form]. 1< H-NMR (500 MHz, MSM-d6): δ (ppm) 12.23 (brs, 1 H), 8.02 (m, 2 H), 8.01 (d, 1 H), 7.92 (m, 2 H), 7.63 (d, 1 H), 6.74 (d, 1 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 158.7, 147.6, 145.1, 126.9, 124.7, 123.8, 110.4, 104.5 15< N-NMR (50.6 MHz, MSM-d6): δ (ppm) 170.9.Preparation R2ap: 7-[4-(difluoromethyl)phenyl]-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0192] Using General Procedure 3 starting from Preparation R1b and 1-(difluoromethyl)-4-iodobenzene as reagents, Preparation R2ap was obtained. HRMS calculated for C 13 H 9 F 2 N 3 O: 261.0714; found 262.0784 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ (ppm) 12.17 (brs, 1 H), 7.99 (d, 1 H), 7.91 (m, 2 H), 7.75 (m, 2 H), 7.58 (d, 1 H), 7.12 (t, 1 H), 6.72 (d, 1 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 144.9, 127.2, 124.7, 123.9, 115.1, 104.1.Preparation R2aq: 7-[4-(hydroxymethyl)phenyl]-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0193] Using General Procedure 3 starting from Preparation R1b and 4-iodobenzyl alcohol as reagents, Preparation R2aq was obtained. HRMS calculated for C 13 H 11 N 3 O 2 : 241.0851; found 242.0925 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ (ppm) 12.07 (brs, 1 H), 7.94 (s, 1 H), 7.66 (m, 2 H), 7.47 (m, 2 H), 7.45 (d, 1 H), 6.67 (d, 1 H), 5.31 (t, 1 H), 4.56 (d, 2 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 158.9, 147.4, 144.6, 142.2, 136.6, 127.6, 124.3, 124.2, 109.9, 103.5, 62.8.Preparation R2ar: 7-(4-chlorophenyl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0194] Using General Procedure 3 starting from Preparation R1b and 1-chloro-4-iodobenzene as reagents, Preparation R2ar was obtained. HRMS calculated for C 12 H 8 ClN 3 O: 245.0356; found 246.0427 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ (ppm) 12.15 (brs, 1 H), 7.97 (d, 1 H), 7.78 (dm, 1 H), 7.61 (dm, 1 H), 7.53 (d, 1 H), 6.7 (d, 1 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 158.7, 147.3, 144.8, 136.7, 131.7, 129.6, 126.1, 123.9, 109.9, 103.9.Preparation R2as: 7-(4-fluorophenyl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0195] Using General Procedure 3 starting from Preparation R1b and 4-fluoroiodobenzene as reagents, Preparation R2as was obtained. HRMS calculated for C 12 H 8 FN 3 O: 229.0651; found 230.0714 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ (ppm) 12.12 (brs, 1 H), 7.95 (d, 1 H), 7.74 (m, 2 H), 7.48 (d, 1 H), 7.39 (m, 2 H), 6.68 (d, 1 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 144.7, 126.8, 124.2, 116.4, 103.5.Preparation R2at: 7-[4-(dimethylamino)phenyl]-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0196] Using General Procedure 2 starting from Preparation R1a and 4-(dimethylamino)phenylboronic acid as reagents, Preparation R2at was obtained. HRMS calculated for C 14 H 14 N 4 O: 254.1168; found 255.1243 [(M+H) +< form]. 1< H-NMR (400 MHz, MSM-d6): δ (ppm) 11.98 (brs, 1 H), 7.89 (d, 1 H), 7.43 (m, 2 H), 7.33 (d, 1 H), 6.82 (m, 2 H), 6.61 (d, 1 H), 2.94 (s, 6 H). 13< C-NMR (100 MHz, MSM-d6): δ (ppm) 144.1, 125.6, 124.3, 112.7, 102.7, 40.6.Preparation R2au: 7-[4-(4-methylpiperazin-1-yl)phenyl]-3H,4H,7H-pyrrolo[2,3-d] pyrimidin-4-one

[0197] Using General Procedure 2 starting from Preparation R1a and 4-(4-methylpiperazin-1-yl)phenylboronic acid pinacol ester as reagents, Preparation R2au was obtained. HRMS calculated for C 17 H 19 N 5 O: 309.1590; found 310.1674 [(M+H) +< form]. 1< H-NMR (400 MHz, MSM-d6): δ (ppm) 12.01 (brs, 1 H), 7.9 (d, 1 H), 7.49 (m, 2 H), 7.37 (d, 1 H), 7.06 (m, 2 H), 6.63 (d, 1 H), 3.2 (brm, 4 H), 2.51 (brm, 4 H), 2.27 (s, 3 H). 13< C-NMR (100 MHz, MSM-d6): δ (ppm) 144.3, 125.4, 124.2, 115.9, 102.9, 54.8, 48.3, 45.9.Preparation R2av: 7-[4-(morpholin-4-yl)phenyl]-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0198] Using General Procedure 2 starting from Preparation R1a and 4-morpholinophenylboronic acid as reagents, Preparation R2av was obtained. HRMS calculated for C 16 H 16 N 4 O 2 : 296.1273; found 297.1361 [(M+H) +< form]. 1< H-NMR (400 MHz, MSM-d6): δ (ppm) 12.01 (brs, 1 H), 7.9 (s, 1 H), 7.51 (m, 2 H), 7.38 (d, 1 H), 7.07 (m, 2 H), 6.63 (d, 1 H), 3.76 (m, 4 H), 3.16 (m, 4 H). 13< C-NMR (100 MHz, MSM-d6): δ (ppm) 484.8, 144.3, 125.4, 124.2, 115.7, 103, 66.5.Preparation R2ax: 7-(4-methoxyphenyl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0199] Using General Procedure 3 starting from Preparation R1b and 4-iodoanisole as reagents, Preparation R2ax was obtained. HRMS calculated for C 13 H 11 N 3 O 2 : 241.0851; found 242.0929 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ (ppm) 12.04 (brs, 1 H), 7.92 (d, 1 H), 7.58 (dd, 1 H), 7.4 (d, 1 H), 7.08 (d, 1 H), 6.65 (d, 1 H), 3.81 (s, 3 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 158.8, 158.8, 147.3, 144.4, 130.9, 126.1, 124.4, 114.8, 109.4, 103.1, 55.9.Preparation R2ay: 7-[4-(trifluoromethoxy)phenyl]-3H,4H,7H-pyrrolo[2,3-d] pyrimidin-4-one

[0200] Using General Procedure 3 starting from Preparation R1b and 1-iodo-4-(trifluoromethoxy)benzene as reagents, Preparation R2ay was obtained. HRMS calculated for C 13 H 8 F 3 N 3 O 2 : 295.0569; found 296.0648 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ (ppm) 12.15 (s, 1 H), 7.97 (d, 1 H), 7.86 (m, 2 H), 7.56 (m, 2 H), 7.54 (m, 1 H), 6.71 (d, 1 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 144.8, 126.4, 124.1, 122.5, 103.9.Preparation R2az: 7-[4-(benzyloxy)phenyl]-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0201] Using General Procedure 3 starting from Preparation R1b and 4-benzyloxyiodobenzene as reagents, Preparation R2az was obtained. HRMS calculated for C 19 H 15 N 3 O 2 : 317.1164; found 318.1243 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ (ppm) 12.05 (brs, 1 H), 7.92 (d, 1 H), 7.59 (dm, 2 H), 7.48 (dm, 2 H), 7.41 (d, 1 H), 7.41 (tm, 2 H), 7.35 (tm, 1 H), 7.16 (dm, 2 H), 6.65 (d, 1 H), 5.18 (s, 2 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 158.8, 157.6, 147.3, 144.4, 137.4, 131, 129, 128.4, 128.2, 126.1, 124.3, 115.7, 109.4, 103.1, 69.9.Preparation R2ba: 7-(5-methylthiophen-2-yl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0202] Using General Procedure 3 starting from Preparation R1b and 2-iodo-5-methylthiophene as reagents, Preparation R2ba was obtained. HRMS calculated for C 11 H 9 N 3 OS: 231.0466; found 232.0541 [(M+H) +< form]. 1< H-NMR (400 MHz, MSM-d6): δ (ppm) 12.17 (brs, 1 H), 7.99 (d, 1 H), 7.49 (d, 1 H), 7.14 (d, 1 H), 6.76 (dq, 1 H), 6.67 (d, 1 H), 2.46 (d, 3 H). 13< C-NMR (100 MHz, MSM-d6): δ (ppm) 145, 124.2, 123.9, 119.4, 103.9, 15.4.Preparation R2bb: 7-(5-chlorothiophen-2-yl)-3H,4H,7H-pyrrolo [2,3-d]pyrimidin-4-one

[0203] Using General Procedure 3 starting from Preparation R1b and 2-chloro-5-iodothiophene as reagents, Preparation R2bb was obtained. HRMS calculated for C 10 H 6 N 3 OSCl: 250.9920; found 252.0005 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 12.28 (brs, 1 H), 8.07 (d, 1 H), 7.67 (d, 1 H), 7.3 (d, 1 H), 7.13 (d, 1 H), 6.72 (d, 1 H) 13< C-NMR (125 MHz, MSM-d6) δ ppm 158.4, 146.8, 145.6, 136.4, 125.5, 124.6, 123.3, 117.5, 109.3, 104.6Preparation R2bc: 7-(2,3-dihydro-1,4-benzodioxin-6-yl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one

[0204] Using General Procedure 2 starting from Preparation R1a and 1,4-benzodioxane-6-boronic acid as reagents, Preparation R2bc was obtained. HRMS calculated for C 14 H 11 N 3 O 3 : 269.0800; found 270.0881 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ (ppm) 12.05 (brs, 1 H), 7.92 (d, 1 H), 7.4 (d, 1 H), 7.22 (d, 1 H), 7.13 (dd, 1 H), 6.99 (d, 1 H), 6.63 (d, 1 H), 4.33-4.25 (m, 4 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 144.4, 124.3, 117.7, 117.6, 113.8, 103.2.Preparation R2bd: 7-(2H-1,3-benzodioxol-5-yl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0205] Using General Procedure 2 starting from Preparation R1a and 3,4-methylenedioxyphenylboronic acid as reagents, Preparation R2bd was obtained. HRMS calculated for C 13 H 9 N 3 O 3 : 255.0644; found 256.0719 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ (ppm) 12.05 (brs, 1 H), 7.92 (d, 1 H), 7.4 (d, 1 H), 7.29 (d, 1 H), 7.12 (dd, 1 H), 7.05 (d, 1 H), 6.63 (d, 1 H), 6.11 (s, 2 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 144.5, 124.5, 118.2, 108.7, 106.5, 103.1, 102.2.Preparation R2be: 7-(naphthalen-2-yl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0206] Using General Procedure 2 starting from Preparation R1a and 2-naphthaleneboronic acid as reagents, Preparation R2be was obtained. HRMS calculated for C 16 H 11 N 3 O: 261.0902; found 262.0982 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ (ppm) 12.14 (s, 1 H), 8.25 (d, 1 H), 8.09 (d, 1 H), 8.01 (m, 1 H), 8.01 (m, 1 H), 8 (s, 1 H), 7.91 (dd, 1 H), 7.63 (d, 1 H), 7.6 (tm, 1 H), 7.57 (tm, 1 H), 6.74 (d, 1 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 158.8, 147.6, 144.8, 135.4, 133.4, 132, 129.4, 128.4, 128.2, 127.4, 126.9, 124.4, 123.5, 122.3, 109.9, 103.8.Preparation R2bf: 7-(3-methylphenyl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0207] Using General Procedure 3 starting from Preparation R1b and 3-iodotoluene as reagents, Preparation R2bf was obtained. HRMS calculated for C 13 H 11 N 3 O: 225.0902; found 226.098 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ (ppm) 12.08 (brs, 1 H), 7.95 (d, 1 H), 7.52 (brs, 1 H), 7.49 (dm, 1 H), 7.46 (d, 1 H), 7.41 (t, 1 H), 7.22 (brd, 1 H), 6.67 (d, 1 H), 2.39 (s, 3 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 158.8, 147.3, 144.6, 139.2, 137.8, 129.5, 128.1, 125.2, 124.2, 121.8, 109.7, 103.5, 21.4.Preparation R2bg: 7-[3-(trifluoromethyl)phenyl]-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0208] Using General Procedure 3 starting from Preparation R1b and 3-iodobenzotrifluoride as reagents, Preparation R2bg was obtained. HRMS calculated for C 13 H 8 F 3 N 3 O: 279.0620; found 280.0699 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ (ppm) 12.19 (brs, 1 H), 8.18 (brs, 1 H), 8.07 (dm, 1 H), 8.02 (d, 1 H), 7.79 (t, 1 H), 7.77 (dm, 1 H), 7.65 (d, 1 H), 6.73 (d, 1 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 145.1, 131.1, 128.3, 124, 123.9, 121, 104.1.Preparation R2bh: 7-{3-[(4-methylpiperazin-1-yl)methyl]phenyl}-3H,4H,7H-pyrrolo [2,3-d]pyrimidin-4-one

[0209] Using General Procedure 3 starting from Preparation R1b and 3-(4-methyl-1-piperazinylmethyl)benzeneboronic acid pinacol ester as reagents, Preparation R2bh was obtained. HRMS calculated for C 18 H 21 N 5 O: 323.1746; found 324.1828 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ (ppm) 12.37 / 12.2 / 11.95 (brs, 3 H), 8.04 (brs, 1 H), 7.98 (s, 1 H), 7.91 (dm, 1 H), 7.67 (dm, 1 H), 7.63 (d, 1 H), 7.62 (t, 1 H), 6.72 (d, 1 H), 4.49 (brs, 2 H), 3.8-3.3 (brm, 8 H), 2.8 (brs, 3 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 144.8, 130.3, 130, 127.3, 125.7, 124, 103.9, 58.7, 42.7.Preparation R2bi: 7-[3-(hydroxymethyl)phenyl]-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0210] Using General Procedure 3 starting from Preparation R1b and 3-iodobenzyl alcohol as reagents, Preparation R2bi was obtained. HRMS calculated for C 13 H 11 N 3 O 2 : 241.0851; found 242.0935 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ (ppm) 12.11 (brs, 1 H), 7.95 (d, 1 H), 7.64 (brt, 1 H), 7.55 (dm, 1 H), 7.48 (t, 1 H), 7.46 (d, 1 H), 7.35 (dm, 1 H), 6.68 (d, 1 H), 4.58 (s, 2 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 158.8, 147.4, 144.6, 144.4, 137.7, 129.4, 125.4, 124.2, 123, 122.5, 109.7, 103.5, 62.9.Preparation R2bj: 7-(3-chlorophenyl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0211] Using General Procedure 3 starting from Preparation R1b and 1-chloro-3-iodobenzene as reagents, Preparation R2bj was obtained. HRMS calculated for C 12 H 8 ClN 3 O: 245.0356; found 246.0437 [(M+H) +< form]. 1< H-NMR (400 MHz, MSM-d6): δ (ppm) 12.17 (brs, 1 H), 8 (d, 1 H), 7.92 (m, 1 H), 7.74 (dm, 1 H), 7.58 (d, 1 H), 7.57 (t, 1 H), 7.47 (dm, 1 H), 6.7 (d, 1 H). 13< C-NMR (100 MHz, MSM-d6): δ (ppm) 145, 131.3, 127.2, 124.1, 123.9, 122.9, 104.Preparation R2bk: 7-(3-fluorophenyl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0212] Using General Procedure 3 starting from Preparation R1b and 1-fluoro-3-iodobenzene as reagents, Preparation R2bk was obtained. HRMS calculated for C 12 H 8 N 3 OF: 229.0651; found 230.0729 [(M+H) +< form]. 1< H-NMR (400 MHz, MSM-d6): δ (ppm) 12.17 (brs, 1 H), 7.99 (d, 1 H), 7.72 (dm, 1 H), 7.64 (m, 1 H), 7.58 (d, 1 H), 7.58 (m, 1 H), 7.25 (m, 1 H), 6.71 (d, 1 H). 13< C-NMR (100 MHz, MSM-d6): δ (ppm) 144.9, 131.4, 130.9, 123.9, 120.2, 114, 111.6. 19< F-NMR (376.5 MHz, MSM-d6): δ (ppm) -111.7.Preparation R2bl: 7-[3-(dimethylamino)phenyl]-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0213] Using General Procedure 2 starting from Preparation R1a and 3-(N,N-dimethylamino)phenylboronic acid as reagents, Preparation R2bl was obtained. HRMS calculated for C 14 H 14 N 4 O: 254.1168; found 255.1229 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ (ppm) 12.04 (brs, 1 H), 7.92 (d, 1 H), 7.45 (d, 1 H), 7.3 (t, 1 H), 6.94 (m, 1 H), 6.93 (dm, 1 H), 6.74 (dm, 1 H), 6.65 (d, 1 H), 2.95 (s, 6 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 144.3, 129.9, 124.4, 112.4, 111.4, 108.6, 103.1, 40.5.Preparation R2bm: 7-[3-(morpholin-4-yl)phenyl]-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0214] Using General Procedure 2 starting from Preparation R1a and 3-(morpholino)phenylboronic acid as reagents, Preparation R2bm was obtained. 1< H-NMR (400 MHz, MSM-d6): δ (ppm) 12.05 (brs, 1 H), 7.93 (s, 1 H), 7.47 (d, J=3.53 Hz, 1 H), 7.36 (t, J=8.13 Hz, 1 H), 7.19 (t, J=2.20 Hz, 1 H), 7.11 (dd, J=1.27, 7.93 Hz, 1 H), 6.98 (dd, J=1.96, 8.49 Hz, 1 H), 6.65 (d, J=3.5 Hz, 1 H), 3.75 (t, J=4.61 Hz, 4 H), 3.18 (t, J=4.61 Hz, 4 H).Preparation R2bo: 7-(3-methoxyphenyl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0215] Using General Procedure 3 starting from Preparation R1b and 3-iodoanisole as reagents, Preparation R2bo was obtained. HRMS calculated for C 13 H 11 N 3 O 2 : 241.0851; found 242.0928 [(M+H) +< form]. 1< H-NMR (400 MHz, MSM-d6): δ (ppm) 12.1 (brs, 1 H), 7.95 (d, 1 H), 7.51 (d, 1 H), 7.44 (t, 1 H), 7.31 (m, 1 H), 7.3 (m, 1 H), 6.98 (dm, 1 H), 6.67 (d, 1 H), 3.82 (s, 3 H). 13< C-NMR (100 MHz, MSM-d6): δ (ppm) 144.6, 130.4, 124.2, 116.7, 112.9, 110.5, 103.5.Preparation R2bp: 7-[3-(trifluoromethoxy)phenyl]-3H,4H,7H-pyrrolo[2,3-d] pyrimidin-4-one

[0216] Using General Procedure 3 starting from Preparation R1b and 3-(trifluoromethoxy)iodobenzene as reagents, Preparation R2bp was obtained. HRMS calculated for C 13 H 8 F 3 N 3 O 2 : 295.0569; found 296.0651 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ (ppm) 12.91 (s, 1 H), 8 (s, 1 H), 7.87 (t, 1 H), 7.82 (ddd, 1 H), 7.68 (t, 1 H), 7.6 (d, 1 H), 7.41 (ddd, 1 H), 6.71 (d, 1 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 145.1, 131.5, 123.9, 123.2, 119.5, 117.1, 104.1.Preparation R2bq: 7-[3-(benzyloxy)phenyl]-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0217] Using General Procedure 3 starting from Preparation R1b and 1-benzyloxy-3-iodobenzene as reagents, Preparation R2bq was obtained. HRMS calculated for C 19 H 15 N 3 O 2 : 317.1164; found 318.1235 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ (ppm) 12.1 (brs, 1 H), 7.95 (d, 1 H), 7.51 (d, 1 H), 7.51-7.31 (m, 5 H), 7.44 (t, 1 H), 7.41 (m, 1 H), 7.32 (dm, 1 H), 7.05 (dm, 1 H), 6.68 (d, 1 H), 5.18 (s, 2 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 144.6, 130.5, 124.1, 116.8, 113.6, 111.4, 103.6, 70.Preparation R2br: 7-(6-methylpyridin-2-yl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0218] Using General Procedure 3 starting from Preparation R1b and 2-iodo-6-methylpyridine as reagents, Preparation R2br was obtained. HRMS calculated for C 12 H 10 N 4 O: 226.0855; found 227.0933 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ (ppm) 12 (brs, 1 H), 8.25 (dm, 1 H), 8.05 (s, 1 H), 7.9 (t, 1 H), 7.88 (d, 1 H), 7.25 (dm, 1 H), 6.68 (d, 1 H), 2.52 (s, 3 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 144.9, 139.5, 122, 121.8, 113.8, 103.7, 24.4.Preparation R2bs: 7-(6-methoxypyridin-2-yl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0219] The mixture of Preparation R1a (1.0 g, 6.51 mmol), 2-iodo-6-methoxy-pyridine (2.35 g, 9.77 mmol, 1.5 eq.), copper(I)-iodide (125 mg, 0.65 mmol, 0.1 eq.), potassium-phosphate tribasic (2.76 g, 13 mmol, 2 eq.), (1R,2R)-(-)-1,2-diaminocyclohexane (74 mg, 0.65 mmol, 0.1 eq.) in PDO (50 ml) was stirred under inert atmosphere for 4 hours at 100 °C. The inorganics were filtered off, the filtrate was evaporated, and the resulted residue was purified by flash chromatography (DCM).

[0220] The obtained arylated product (920 mg, 3.5 mmol) and lithium-hydroxide monohydrate (1.48 g, 35 mmol) were stirred in the mixture of PDO (15 ml) and water (15 ml) at 110 °C for 24 hours. The residue was acidified by aqueous HCl solution (1 N, 50 ml), the resulted precipitate was filtered off and dried to give Preparation R2bs.

[0221] HRMS calculated for C 12 H 10 N 4 O 2 : 242.0804; found 243.0884 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ (ppm) 12.21 (brs, 1 H), 8.08 (dd, 1 H), 8.03 (s, 1 H), 7.94 (d, 1 H), 7.9 (t, 1 H), 6.78 (dd, 1 H), 6.7 (d, 1 H), 3.94 (s, 3 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 163.2, 158.5, 147.6, 147.4, 144.9, 141.9, 121.9, 111.2, 108.4, 108.4, 103.8, 53.9.Preparation R2bt: 7-(naphthalen-1-yl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0222] Using General Procedure 2 starting from Preparation R1a and 1-naphthaleneboronic acid as reagents, Preparation R2bt was obtained. HRMS calculated for C 16 H 11 N 3 O: 261.0902; found 262.0984 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ (ppm) 12.04 (s, 1 H), 8.12 (d, 1 H), 8.09 (d, 1 H), 7.78 (d, 1 H), 7.67 (t, 1 H), 7.61 (dm, 1 H), 7.6 (t, 1 H), 7.51 (tm, 1 H), 7.39 (d, 1 H), 7.21 (t, 1 H), 6.77 (d, 1 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 158.9, 149.2, 144.6, 134.2, 134.1, 130.4, 129.5, 128.7, 127.8, 127.2, 126.4, 126.3, 126, 123, 108.7, 103.1Preparation R2bu: 7-phenyl-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0223] Using General Procedure 3 starting from Preparation R1b and iodobenzene as reagents, Preparation R2bu was obtained. HRMS calculated for C 12 H 9 N 3 O: 211.0746; found 212.083 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ (ppm) 12.1 (brs, 1 H), 7.95 (d, 1 H), 7.71 (m, 2 H), 7.54 (m, 2 H), 7.5 (d, 1 H), 7.4 (m, 1 H), 6.69 (d, 1 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 158.8, 147.3, 144.6, 137.8, 129.7, 127.4, 124.6, 124.1, 109.8, 103.6.Preparation R2bv: 7-(2-methylphenyl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0224] Using General Procedure 2 starting from Preparation R1a and 2-methylphenylboronic acid as reagents, Preparation R2bv was obtained. HRMS calculated for C 13 H 11 N 3 O: 225.0902; found 226.098 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ (ppm) 12 (brs, 1 H), 7.83 (d, 1 H), 7.41 (m, 1 H), 7.41 (m, 1 H), 7.35 (m, 1 H), 7.3 (d, 1 H), 7.21 (d, 1 H), 6.66 (d, 1 H), 2.01 (s, 3 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 158.9, 148.2, 144.4, 136.9, 135.6, 131.2, 129.2, 128.5, 127.1, 125.3, 108.6, 102.9, 17.9.Preparation R2bw: 7-(2-chlorophenyl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0225] Using General Procedure 2 starting from Preparation R1a and 2-chlorophenylboronic acid as reagents, Preparation R2bw was obtained. HRMS calculated for C 12 H 8 ClN 3 O: 245.0356; found 246.0437 [(M+H) +< form]. 1< H-NMR (400 MHz, MSM-d6): δ (ppm) 12.06 (brs, 1 H), 7.86 (d, 1 H), 7.73-7.48 (m, 4 H), 7.27 (d, 1 H), 6.68 (d, 1 H). 13< C-NMR (100 MHz, MSM-d6): δ (ppm) 144.7, 125.4, 102.2.Preparation R2bx: 7-(2-fluorophenyl)-3H,4H,7H-pyrrolo [2,3-d]pyrimidin-4-one

[0226] Using General Procedure 2 starting from Preparation R1a and 2-fluorophenylboronic acid as reagents, Preparation R2bx was obtained. HRMS calculated for C 12 H 8 N 3 OF: 229.0651; found 230.0730 [(M+H) +< form]. 1< H-NMR (400 MHz, MSM-d6): δ (ppm) 12.09 (brs, 1 H), 7.9 (d, 1 H), 7.61 (m, 1 H), 7.54 (m, 1 H), 7.48 (m, 1 H), 7.38 (m, 1 H), 7.34 (dd, 1 H), 6.7 (d, 1 H). 13< C-NMR (100 MHz, MSM-d6): δ (ppm) 144.8, 130.6, 129.6, 125.4, 125.3, 117, 103.5.Preparation R2by: 7-[2-(dimethylamino)phenyl]-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0227] Using General Procedure 2 starting from Preparation R1a and dimethyl[2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]amine as reagents, Preparation R2by was obtained. HRMS calculated for C 14 H 14 N 4 O: 254.1168; found 255.1237 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ (ppm) 12 (brs, 1 H), 7.85 (d, 1 H), 7.36 (m, 1 H), 7.24 (dm, 1 H), 7.2 (d, 1 H), 7.13 (dm, 1 H), 7.02 (m, 1 H), 6.64 (d, 1 H), 2.36 (s, 6 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 144.4, 130.1, 129.4, 125.5, 121.1, 119, 102.9, 42.4.Preparation R2bz: 7-(2-methoxyphenyl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0228] Using General Procedure 2 starting from Preparation R1a and 2-methoxyphenylboronic acid as reagents, Preparation R2bz was obtained. HRMS calculated for C 13 H 11 N 3 O 2 : 241.0851; found 242.092 [(M+H) +< form]. 1< H-NMR (400 MHz, MSM-d6): δ (ppm) 11.96 (brs, 1 H), 7.82 (d, 1 H), 7.46 (m, 1 H), 7.37 (dm, 1 H), 7.24 (dm, 1 H), 7.18 (d, 1 H), 7.08 (m, 1 H), 6.6 (d, 1 H), 3.74 (s, 3 H). 13< C-NMR (100 MHz, MSM-d6): δ (ppm) 144.2, 130.2, 129.3, 126, 120.8, 113.1, 102.4.Preparation R2ca: 7-(pyridin-2-yl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0229] Using General Procedure 3 starting from Preparation R1b and 2-iodopyridine as reagents, Preparation R2ca was obtained. HRMS calculated for C 11 H 8 N 4 O: 212.0698; found 213.0774 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ (ppm) 12.29 (s, 1 H), 8.55 (dd, 1 H), 8.47 (dd, 1 H), 8.06 (brs, 1 H), 8.03 (t, 1 H), 7.9 (d, 1 H), 7.4 (t, 1 H), 6.7 (d, 1 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 149.1, 145, 139.4, 122.5, 122, 116.9, 104. 15< N-NMR (50.6 MHz, MSM-d6): δ (ppm) 171.2.Preparation R2cb: 7-(pyridin-3-yl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0230] Using General Procedure 2 starting from Preparation R1a and pyridine-3-boronic acid as reagents, Preparation R2cb was obtained. HRMS calculated for C 11 H 8 N 4 O: 212.0698; found 213.0774 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ (ppm) 12.29 (s, 1 H), 8.55 (dd, 1 H), 8.47 (dd, 1 H), 8.06 (brs, 1 H), 8.03 (t, 1 H), 7.9 (d, 1 H), 7.4 (t, 1 H), 6.7 (d, 1 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 149.1, 145, 139.4, 122.5, 122, 116.9, 104. 15< N-NMR (50.6 MHz, MSM-d6): δ (ppm) 171.2.Preparation R2cc: 7-(thiophen-2-yl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0231] Using General Procedure 3 starting from Preparation R1b and 2-iodothiophene as reagents, Preparation R2cc was obtained. HRMS calculated for C 10 H 7 N 3 OS: 217.0310; found 218.0384 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ (ppm) 12.2 (brs, 1 H), 8.03 (s, 1 H), 7.58 (d, 1 H), 7.43 (dd, 1 H), 7.39 (dd, 1 H), 7.07 (dd, 1 H), 6.69 (d, 1 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 158.5, 147.2, 145.3, 138.7, 126, 124.3, 122.8, 119.2, 109.4, 104.2.Preparation R2cd: 7-(pyridin-4-yl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0232] Using General Procedure 2 starting from Preparation R1a and pyridine-4-boronic acid pinacol ester as reagents, Preparation R2cd was obtained. HRMS calculated for C 11 H 8 N 4 O: 212.0698; found 213.0773 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ ppm 12.31 (brs, 1 H), 8.69 (m, 2 H), 8.05 (s, 1 H), 7.99 (m, 2 H), 7.73 (d, 1 H), 6.76 (d, 1 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 151.3, 145.6, 122.8, 117.3, 105.Preparation R2ce: 7-(furan-3-yl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0233] Using General Procedure 2 starting from Preparation R1a and 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)furan as reagents, Preparation R2ce was obtained. HRMS calculated for C 10 H 7 N 3 O 2 : 201.0538; found 202.0617 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ (ppm) 12.13 (brs, 1 H), 8.32 (dd, 1 H), 8 (d, 1 H), 7.8 (dd, 1 H), 7.52 (d, 1 H), 7.17 (dd, 1 H), 6.66 (d, 1 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 158.6, 147.1, 145, 143.9, 133.8, 126, 123, 109.6, 106.5, 103.8.Preparation R2cf: 7-(thiophen-3-yl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0234] Using General Procedure 2 starting from Preparation R1a and thiophene-3-boronic acid pinacol ester as reagents, Preparation R2cf was obtained. HRMS calculated for C 10 H 7 N 3 OS: 217.0310; found 218.0390 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ (ppm) 12.14 (s, 1 H), 7.99 (d, 1 H), 7.92 (dd, 1 H), 7.71 (dd, 1 H), 7.68 (dd, 1 H), 7.57 (d, 1 H), 6.66 (d, 1 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 158.6, 147, 144.8, 136.3, 127, 123.8, 123.3, 115.1, 109.5, 103.5.Preparation R2cg: 7-(1-methyl-1H-imidazol-4-yl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0235] Using General Procedure 3 starting from Preparation R1b and 4-iodo-1-methyl-1H-imidazole as reagents, Preparation R2cg was obtained. HRMS calculated for C 10 H 9 N 5 O: 215.0807; found 216.0879 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ (ppm) 9.24-7.3 (vbrs, 3 H), 7.51 (d, 1 H), 6.72 (brs, 1 H), 3.77 (s, 3 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 121.7, 103.5, 35. 15< N-NMR (50.6 MHz, MSM-d6): δ (ppm) 153.Preparation R2ch: 7-(1-methyl-1H-pyrazol-4-yl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0236] Using General Procedure 3 starting from Preparation R1b and 4-iodo-1-methyl-1H-pyrazole as reagents, Preparation R2ch was obtained. HRMS calculated for C 10 H 9 N 5 O: 215.0807; found 216.0889 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ (ppm) 12.12 (brs, 1 H), 8.27 (s, 1 H), 7.96 (s, 1 H), 7.91 (d, 1 H), 7.42 (d, 1 H), 6.63 (d, 1 H), 3.89 (s, 3 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 158.6, 146.9, 144.7, 132.1, 124.3, 123.4, 121.4, 109, 103.4,38.5.Preparation R2ci: 7-[1-(difluoromethyl)-1H-pyrazol-4-yl]-3H,4H,7H-pyrrolo[2,3-d] pyrimidin-4-one

[0237] Using General Procedure 3 starting from Preparation R1b and 1-(difluoromethyl)-4-iodo-1H-pyrazole as reagents, Preparation R2ci was obtained. HRMS calculated for C 10 H 7 F 2 N 5 O: 251.0619; found 252.0682 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ (ppm) 11.88 (brs, 1 H), 8.83 (d, 1 H), 8.4 (d, 1 H), 8.03 (s, 1 H), 7.91 (t, 1 H), 7.58 (d, 1 H), 6.69 (d, 1 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 145.2, 136.2, 123.2, 121.3, 111, 104.Preparation R2cj: 7-(pyrimidin-2-yl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0238] Preparation R1b (300 mg, 2.011 mmol, 1 eq.), 2-chloropyrimidine (2.413 mmol, 1.2 eq.) and anhydrous K 2 CO 3 (417 mg, 3.017 mmol, 1.5 eq.) was heated in DMF (10 ml) at 150 °C for 2 hours. The reaction mixture was filtered and purified by preparative LC (on C-18 Gemini-NX 5µm column, 5 mM aqueous NH 4 HCO 3 -MCN, gradient) to give 4-methoxy-7-pyrimidin-2-yl-pyrrolo[2,3-d]pyrimidine.

[0239] Then the obtained product (0.633 mmol, 1 eq.), 1M HCl aqueous solution (3 ml) and PDO (60 ml) were stirred at 100 °C for 1 hour. After the reaction completed, the mixture was evaporated and purified by preparative LC (on C-18 Gemini-NX 5µm column, 5 mM aqueous NH 4 HCO 3 -MCN, gradient) to give Preparation R2cj. HRMS calculated for C 10 H 7 N 5 O: 213.0651; found 214,0735 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ (ppm) 12.19 (brs, 1 H), 8.94 (d, 1 H), 8.01 (s, 1 H), 7.78 (d, 1 H), 7.54 (t, 1 H), 6.71 (d, 1 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 159.7, 158.7, 156, 148.1, 145.2, 123.3, 120.1, 111.4, 104.5.Preparation R2ck: 7-(1,3-thiazol-2-yl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0240] Using General Procedure 3 starting from Preparation R1b and 2-iodothiazole as reagents, Preparation R2ck was obtained. HRMS calculated for C 9 H 6 N 4 OS: 218.0262; found 219.0335 [(M+H) +< form]. 1< H-NMR (500 MHz, MeCN-d3) δ ppm 8.5 (s, 1 H), 7.62 (d, 1 H), 7.52 (d, 1 H), 7.22 (d, 1 H), 6.51 (d, 1 H). 13< C-NMR (125 MHz, MeCN-d3) δ ppm 154.5, 137.9, 116.8, 114.8, 104.2.Preparation R2cl: 7-(1H-indol-1-yl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0241] Preparation R1b (1.74 g, 11.67 mmol) was dissolved in DMF (80 ml) and cooled to 0 °C. Sodium hydride (60 % disp., 1.87 g, 46.67 mmol) was slowly added and stirred for 30 minutes at 0 °C. Hydroxylamine-O-sulfonic acid (2.11 g, 18.67 mmol) was added to the reaction mixture, allowed to warm up to r.t. and stirred for 20 hours. Water (100 ml) was added to the reaction mixture and extracted with DCM (4 x 50 ml). The combined organic layers were washed with water and dried over MgSO 4 and evaporated. The residue was dissolved in MSM and purified by preparative LC (on C-18 Gemini-NX 5µm column, 5 mM aqueous NH 4 HCO 3 -MeCN, gradient).

[0242] A part of the resulted N-amino compound (500 mg, 3.05 mmol) was dissolved in PDO (5 ml) and 2,5-dimethoxy-tetrahydrofurane (454 ml, 462 mg, 3.5 mmol) was added. The mixture was stirred at 100 °C for 115 hours. The reaction mixture was diluted with aqueous HCl solution (5 N, 2 ml) and purified by preparative LC (on C-18 Gemini-NX 5µm column, 5 mM aqueous NH 4 HCO 3 -MeCN, gradient) to give Preparation R2cl. HRMS calculated for C 14 H 10 N 4 O: 250.0854; found 250.2000 [(M form)]. 1< H-NMR (500 MHz, MSM-d6): δ (ppm) 12.22 (brs, 1 H), 7.86 (s, 1 H), 7.71 (d, 1 H), 7.68 (m, 1 H), 7.58 (d, 1 H), 7.17 (m, 1 H), 7.17 (m, 1 H), 6.86 (m, 1 H), 6.73 (d, 1 H), 6.68 (dd, 1 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 158.5, 147.9, 145.9, 137, 129.7, 126.3, 125.4, 123.5, 121.5, 121.5, 109, 107, 102.3, 101.8.Preparation R2cm: 7-(1H-pyrrol-1-yl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0243] Preparation R1b (1.74 g, 11.67 mmol) was dissolved in DMF (80 ml) and cooled to 0 °C. Sodium hydride (60 % disp., 1.87 g, 46.67 mmol) was slowly added and stirred for 30 minutes at 0 °C. Hydroxylamine-O-sulfonic acid (2.11 g, 18.67 mmol) was added to the reaction mixture, allowed to warm up to r.t. and stirred for 20 hours. Water (100 ml) was added to the reaction mixture and extracted with DCM (4 x 50 ml). The combined organic layers were washed with water and dried over MgSO 4 , evaporated. The residue was dissolved in MSM and purified by preparative LC (on C-18 Gemini-NX 5µm column, 5 mM aqueous NH 4 HCO 3 -MeCN, gradient).

[0244] A part of the resulted N-amino compound (500 mg, 3.05 mmol) was dissolved in PDO (5 ml) and 2,5-dimethoxy-tetrahydrofurane (454 ml, 462 mg, 3.5 mmol) was added. The mixture was stirred at 100 °C for 115 hours. The reaction mixture was diluted with aqueous HCl solution (5 N, 2 ml) and purified by preparative LC (on C-18 Gemini-NX 5µm column, 5 mM aqueous NH 4 HCO 3 -MeCN, gradient).

[0245] To a part of the resulted compound (63 mg, 0.294 mmol) PDO (25 ml) and aqueous HCl solution (1 N, 1.3 ml) was added and stirred at 60 °C for 5 hours. The reaction mixture was evaporated and the residue was purified by preparative LC (on C-18 Gemini-NX 5µm column, 5 mM aqueous NH 4 HCO 3 -MeCN, gradient) to give Preparation R2cm. HRMS calculated for C 10 H 8 N 4 O: 200.0698; found 201.0770 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ (ppm) 12.18 (brs, 1 H), 7.92 (s, 1 H), 7.46 (d, 1 H), 7.12 (m, 2 H), 6.61 (d, 1 H), 6.21 (m, 2 H). 13< C-NMR (125 MHz, MSM-d6): δ (ppm) 158.4, 147.4, 145.8, 125.1, 122.8, 108, 106.7, 101.1.Preparation R2de: 6-methyl-7-phenyl-3H-pyrrolo[2,3-d]pyrimidin-4-one

[0246] Using General Procedure 3 starting from Preparation R1b and iodobenzene as reagents, 4-methoxy-7-phenyl-pyrrolo[2,3-d]pyrimidine was obtained (without hydrolysis). This crude product (450 mg, 2 mmol) was dissolved in THF (18 ml) stirred at -78 °C, then LDA solution (1.8 M, 1.7 ml, 3 mmol) was added. After one hour of stirring at -78 °C, iodomethane (190 µl, 3 mmol) solution in THF (5 ml) was added, and continued stirring for 90 minutes. Then the reaction mixture was diluted with brine (10 ml) and evaporated to Celite and purified by flash chromatography (Hexane-EEO=7-1).

[0247] The resulted crude product (400 mg, 1.6 mmol) was dissolved in cc. HCl aqueous solution (330 µl, ∼12.2 M, 4 mmol) and PDO (5 ml) was stirred at 100 °C for 2 hours. After the reaction completed, the mixture was partially evaporated and the formed suspension was filtered. The solid on the filter was washed with water and dried to give Preparation R2de. HRMS calculated for C 13 H 11 N 3 O: 225.0902; found 226.0985 [(M+H) +< form]. 1< H-NMR(500 MHz, MSM-d6): δ ppm 11.94 (s, 1 H), 7.76 (d, 1 H), 7.55 (tm, 2 H), 7.49 (tm, 1 H), 7.4 (dm, 2 H), 6.41 (d, 1 H), 2.17 (d, 3 H). 13< C-NMR(125 MHz, MSM-d6): δ ppm 158.4, 143.6, 136.2, 132.6, 129.6, 128.7, 128.5, 100.9, 13.3.Preparation R2df: 9-methyl-3H-pyrimido[4,5-b]indol-4-one

[0248] Preparation R1b (500 mg, 3.06 mmol) and 2,5-dimethoxytetrahydrofurane (810 mg, 6.13 mmol, d= 1.02, 795 µl) in PDO (5 ml) were heated up to 100 °C for 102 hours, then 1 N aqueous HCl solution (5 ml) was added. The mixture was dissolved in DMF and purified by preparative LC (on C-18 Gemini-NX 5µm column, 5 mM aqueous NH 4 HCO 3 -MeCN, gradient) to give Preparation R2df. HRMS calculated for C 11 H 9 N 3 O: 199.0746; found 200.0827 [(M+H) +< form]. 1< H-NMR(500 MHz, MSM-d6): δ ppm 12.33 (brs, 1 H), 8.21 (s, 1 H), 7.63 (dm, 1 H), 7.41 (ddd, 1 H), 7.29 (td, 1 H), 3.86 (s, 3 H) 13< C-NMR(125 MHz, MSM-d6): δ ppm 158.5, 153.5, 148.1, 137, 124.6, 122, 121.8, 121, 110.7, 100.1, 28.5Preparation R2dg: 6,8-dimethylpyrimido[5,4-b]indolizin-4(3H)-one

[0249] Preparation R1b (1.74 g, 11.67 mmol) was dissolved in DMF (80 ml) and cooled to 0 °C. Sodium hydride (60 % disp., 1.87 g, 46.67 mmol) was slowly added and stirred for 30 minutes at 0 °C. Hydroxylamine-O-sulfonic acid (2.11 g, 18.67 mmol) was added to the reaction mixture, allowed to warm up to r.t. and stirred for 20 hours. Water (100 ml) was added to the reaction mixture and extracted with DCM (4 x 50 ml). The combined organic layers were washed with water, dried over MgSO 4 and evaporated.

[0250] A part of the resulted N-amino compound (300 mg, 1.83 mmol) and acetylacetone (206 µl, 201 mg 2.01 mmol,) were dissolved in 5 ml acetic acid and heated up to 120 °C for 2.5 hours, then TFA (5 ml) was added. The mixture was heated at 120 °C for 18 hours. Then water (1 ml) and methanol (10 ml) were added and the solution was evaporated. The residue was purified by preparative LC (on C-18 Gemini-NX 5µm column, 5 mM aqueous NH 4 HCO 3 -MeCN, gradient), to give Preparation R2dg. HRMS calculated for C 11 H 10 N 4 O: 214.0855; found 215.0935 [(M+H) +< form]. 1< H-NMR(500 MHz, MSM-d6) δ ppm 12.16 (s, 1 H), 8 (s, 1 H), 6.89 (s, 1 H), 6.68 (d, 1 H), 2.45 (d, 3 H), 2.44 (s, 3 H). 13< C-NMR(125 MHz, MSM-d6) δ ppm 159.7, 152.5, 143.4, 141.2, 138.9, 127.7, 115.5, 109.8, 91.2, 21.9, 17.4.Preparation R2dh: 6-chloro-7-phenyl-3H-pyrrolo[2,3-d]pyrimidin-4-one

[0251] Using General Procedure 3 starting from Preparation R1b and iodobenzene as reagents, 4-methoxy-7-phenyl-pyrrolo[2,3-d]pyrimidine was obtained (without hydrolysis). The crude product (394 mg, 1.75 mmol) was dissolved in THF (14 ml) stirred at -78 °C, then LDA solution (1.8 M, 1.2 ml, 2.16 mmol) was added. After one hour of stirring at -78 °C, hexachloroethane (632 mg, 2.63 mmol) solution in THF (5 ml) was added, and continued stirring for 90 minutes. Then the reaction mixture was diluted with brine (10 ml), evaporated to Celite and purified by flash chromatography (Hexane-EEO=9-1).

[0252] The resulted crude product (110 mg, 0.42 mmol) was dissolved in cc. HCl aqueous solution (82 µl, ∼12.2 M, 1 mmol) and PDO (5 ml) was stirred at 100 °C for 2 hours. After the reaction completed, the mixture was partially evaporated. The formed suspension was filtered and the solid on the filter was washed with water and dried to give Preparation R2dh. HRMS calculated for C 12 H 8 N 3 OCl: 245.0356; found 246.043 [(M+H) +< form]. 1< H-NMR(500 MHz, MSM-d6) δ ppm 12.16 (s, 1 H), 7.88 (s, 1 H), 7.6-7.52 (m, 5 H), 6.78 (s, 1 H). 13< C-NMR(125 MHz, MSM-d6) δ ppm 157.6, 148.2, 145.3, 101.6.Preparation R2di: 6-iodo-7-methyl-3H-pyrrolo[2,3-d]pyrimidin-4-one

[0253] To a stirred solution of Preparation R1a (8 g, 52.1 mmol) in abs. DMF (50 ml) was cooled down to 0 °C, then sodium-hydride (3.13 g, 60 % disp. in mineral oil, 78.2 mmol, 1.5 eq.) was added and stirred for 20 minutes at r.t. under Ar. Methyl iodide (8.2 g, 57.2 mmol, d=2.28, 3.6 ml) was added to the reaction mixture and stirred for 1.5 hours at r.t. The mixture was poured into water (50 ml) to give a solid compound which was filtered off.

[0254] A part of the resulted solid compound (500 mg, 2.98 mmol) was dissolved in 5 ml abs. THF and cooled down to -78 °C. Then 2 M LDA (1.7 ml, 3.4 mmol) was added dropwise. The mixture was stirred at -78°C for 1 hour, then iodide (757 mg, 2.98 mmol) was added. The solution was allowed to warm to r.t. and stirred for 22 hours. Finally, 5 ml water was added and a solid compound was formed, which was filtered off, to give Preparation R2di. HRMS calculated for C 7 H 6 IN 3 O: 274.9556; found 275.9634 [(M+H) +< form]. 1< H-NMR(500 MHz, MSM-d6) δ ppm 11.97 (s, 1 H), 7.85 (s, 1 H), 6.79 (s, 1 H), 3.64 (s, 3 H). 13< C-NMR(125 MHz, MSM-d6) δ ppm 157.3, 149.1, 144.2, 111.4, 110.3, 80.4, 33.2.Preparation R2dj: 5-fluoro-7-methyl-3H-pyrrolo[2,3-d]pyrimidin-4-one

[0255] Using General Procedure 1 starting from 4-chloro-5-fluoro-7H-pyrrolo[2,3-d]pyrimidine (instead of Preparation R1a ) and iodomethane as alkylating agent, Preparation R2dj was obtained. HRMS calculated for C 7 H 6 FN 3 O: 167.0495; found 168.0574 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 11.97 (brs, 1 H), 7.88 (s, 1 H), 7.07 (s, 1 H), 3.64 (s, 3 H). 13< C-NMR (125 MHz, MSM-d6) δ ppm 156.9, 144.6, 144.4, 143.1, 108.1, 97.0, 31.6.Preparation R2dk: 3,6,7,8-tetrahydro-4H-pyrimido[5,4-b]pyrrolizin-4-one Step 1: 4-methoxy-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine

[0256] To a preheated 100 ml two-necked sphere flask equipped with stirring bar and gas inlet, Preparation R1b (2.0 g, 11.4 mmol) was dissolved in abs. THF (45 ml). The solution was cooled to 0 °C, and NaH (0.85 g, 3 eq.) was added. The mixture was stirred for 1 hour, then SEM-C1 (3.55 ml, 1.5 eq.) was added via syringe. Yellow solution and white precipitate formed. The mixture was allowed to warm to r.t., while the color faded away. After losing the color, the reaction was quenched with water (30 ml). The mixture was extracted with EEO (3 x 30 ml) and the collected organic layers were dried on Na 2 SO 4 . After filtration, solvent was evaporated and the crude product was purified with flash chromatography (hexane:EEO = 20:1-9:1) to give the product of the title as a yellowish liquid.Step 2: 6-iodo-4-methoxy-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d] pyrimidine

[0257] To a preheated 250 ml three-necked sphere flask equipped with a magnetic stirring bar and gas inlet, was added abs. THF (30 ml) and diisopropyl amine (2.7 ml, 1.5 eq.) under nitrogen atmosphere. The mixture was cooled to -78°C and n-BuLi (8.0 ml, 1.5 equiv.) was added and stirred for 30 minutes. Then 4-methoxy-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine (3.64 g, 13.05 mmol, 1 eq.) dissolved in abs. THF (100 ml) was added slowly over 30 minutes and stirring was continued for 1 hour. Next, iodine (3.95 g, 1.2 eq.) dissolved in abs. THF (35 ml) was added slowly and stirred for an additional 3 hours. Then the cooling bath was removed and the reaction mixture was left to warm to r.t. Brine (500 ml) was added and the solution was extracted with EEO (150 ml) three times. The organic phases were dried, filtered evaporated and purified by flash chromatography (hexane:EEO - 9:1) to give the product of the title as a yellowish white powder.Step 3: 6-iodo-4-methoxy-7H-pyrrolo[2,3-d]pyrimidine

[0258] In a 100 ml Schlenk bomb, 6-iodo-4-methoxy-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine (4.72 g, 11.65 mmol) was dissolved in THF (50 ml). To the solution TBAF.3H 2 O (11.34 g, 3 eq.) was added with 4Å molecular sieves. The mixture was heated at 95 °C under nitrogen overnight. After cooling, the mixture was filtered through Celite, and the solvent was evaporated. To the resulting brown oil, water was added and an off-white powder precipitated. The precipitation was filtered, washed with water and MeCN (3 x 10 ml). After drying, the product of the title was obtained as an off-white powder.Step 4: 7-allyl-6-iodo-4-methoxy-7H-pyrrolo[2,3-d]pyrimidine

[0259] In a preheated, two-necked 100 ml sphere-flask, equipped with a magnetic stirring bar and a gas inlet, 6-iodo-4-methoxy-7H-pyrrolo[2,3-d]pyrimidine (900 mg, 3.27 mmol) was dissolved in abs. THF (10 ml) under nitrogen. Then, triphenylphosphine (1.048 g, 1.2 eq.) was added. Then, with continuous stirring, allylic alcohol (232 mg, 1.2 eq.) was measured in via syringe. The mixture was cooled to 0 °C and diisopropyl-aza-dicarboxylate (808 mg, 1.2 eq.) was added dropwise via syringe. The mixture was allowed to warm to r.t., and monitored with TLC. After completion, solvent was evaporated, and the crude product was purified by flash chromatography (hexane:EEO=10:1) to give the product of the title as white crystals.Step 5: 4-methoxy-7,8-dihydro-6H-pyrimido[5,4-b]pyrrolizine

[0260] In a preheated 100 ml Schlenk bomb, 7-allyl-6-iodo-4-methoxy-7H-pyrrolo[2,3-d] pyrimidine (1.60 g, 5.1 mmol) was measured in and dissolved in abs. THF (50 ml). 9-Borabicyclo[3.3.1]nonane (1.87 g, 3 eq.) was measured out in a double-manifold glovebox, dissolved in abs. THF (30 ml), and added into the Schlenk bomb via syringe at 0 °C. The reaction was allowed to warm to r.t. and stirred overnight. Then [1,1'-Bis(diphenylphosphino)ferrocene]dichloropalladium(II) (366 mg, 0.1 eq.) and K 2 CO 3 (4.93 g, 7 eq.) were measured in under nitrogen and added to the solution. The mixture was warmed to 85 °C for 4 hours. After completion, the solvent was evaporated and the crude product was purified by flash chromatography (hexane:EEO=3:1) to give the product of the title as a dark red solid.Step 6: Preparation R2dk

[0261] The resulted methoxypyrrolizine obtained in Step 5 above (69.7 mg, 0.37 mmol) and lithium-hydroxide monohydrate (155 mg, 3.7 mmol) diluted in mixture of PDO (2 ml) and water (2 ml) and was stirred at 110 °C for 40 hours. After the reaction completed, the mixture was evaporated, purified by preparative LC (on C-18 Gemini-NX 5µm column, 5 mM aqueous NH 4 HCO 3 -MeCN, gradient) to give Preparation R2dk. MS calculated for C 9 H 9 N 3 O: 175.07; found 175.2 [(M+H) +< EI form].Preparation R2dl: 6,7,8,9-tetrahydro-3H-pyrimido[5,4-b]indolizin-4-one Step 1: 7-(but-3-en-1-yl)-6-iodo-4-methoxy-7H-pyrrolo[2,3-d]pyrimidine

[0262] In a 100 ml sphere-flask, 6-iodo-4-methoxy-7H-pyrrolo[2,3-d]pyrimidine (obtained in Step 3 of Preparation R2dk, 1.99 g, 7.23 mmol) was dissolved in DMSO (70 ml), and KOH (690 mg, 1.7 eq.) was added. The mixture was sonicated for 10 minutes, then homoallyl bromide (2.15 ml, 3 eq.) was added at 0 °C. After warming to r.t., the mixture was stirred until completion. After completion, water (50 ml) was added and the mixture as extracted with EEO (3 x 120 ml). The organic phases were collected, dried over sodium sulfate and evaporated. The crude product was purified by flash chromatography (hexane:EEO=20:1-5:1) to give the product of the title as a white solid.Step 2: 4-methoxy-3,4,6,7,8,9-hexahydropyrimido[5,4-b]indolizine

[0263] 7-But-3-enyl-6-iodo-4-methoxy-pyrrolo[2,3-d]pyrimidine (164 mg, 0.5 mmol) was dissolved in THF (2 ml) in a Schlenk tube under nitrogen atmosphere. The mixture was cooled to 0 °C, and 9-borabicyclo[3.3.1]nonane (305 mg, 2.5 mmol) was added in THF (5 ml) solution via syringe and stirred overnight at r.t. [1,1'-Bis(diphenylphosphino)ferrocene]dichloropalladium(II) (75 mg, 0.1 mmol) and K 2 CO 3 (967 mg, 7 mmol) were added to the reaction mixture and stirred for 3 hours at 80 °C. Then the reaction mixture was evaporated to Celite and purified by flash chromatography (hexane-EEO=3-1).Step 3: Preparation R2dl

[0264] The resulted methoxyindolizine obtained in Step 2 above (104 mg, 0.51 mmol) and lithium-hydroxide monohydrate (215 mg, 5.1 mmol) diluted in mixture of PDO (2 ml) and water (2 ml) and was stirred at 110 °C for 40 hours. After the reaction completed, the mixture was evaporated, purified by preparative LC (on C-18 Gemini-NX 5µm column, 5 mM aqueous NH 4 HCO 3 -MeCN, gradient) to give Preparation R2dl. MS calculated for C 10 H 11 N 3 O: 189.09; found 190 [(M+H) +< EI form].Preparation R3a: 3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]piperidin-4-yl}methyl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0265] Using General Procedure 5 starting from 3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one as reagent, Preparation R3a was obtained. HRMS calculated for C 24 H 29 N 5 O 3 : 435.2270; found 436.2345 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 11.91 / 11.9 (brs, 1 H), 9.36 / 8.86 (brd+brq, 2 H), 8.03 / 7.97 (s, 1 H), 7.32-7.11 (m, 5 H), 7.06 / 7.04 (dd, 1 H), 6.47 / 6.43 (dd, 1 H), 4.09-2.6 (m, 12 H), 1.96-0.62 (m, 6 H).Preparation R3b: 3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]piperidin-4-yl}methyl)-7-methyl-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0266] Using General Procedure 5 starting from Preparation R2b as reagent, Preparation R3b was obtained as HCl salt. HRMS calculated for C 25 H 31 N 5 O 3 : 449.2427; found 450.2517 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.16 / 8.72 (brd / brq, 2 H), 8.02 / 8.07 (s, 1 H), 7.34-7.11 (m, 5 H), 7.11 / 7.13 (d, 1 H), 6.45 / 6.48 (d, 1 H), 4.01 / 3.73 (d / s, 1 H), 4.00-0.58 (m, 16 H), 3.89 (d, 2 H), 3.71 (s, 3 H).Preparation R3c: 7-ethyl-3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]piperidin-4-yl}methyl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0267] Using General Procedure 5 starting from Preparation R2c as reagent, Preparation R3c was obtained as HCl salt. HRMS calculated for C 26 H 33 N 5 O 3 : 463.2583; found 464.2654 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.16 / 8.72 (brd / brq, 2 H), 8.01 / 8.07 (s, 1 H), 7.33-7.09 (m, 5 H), 7.18 / 7.19 (d, 1 H), 6.45 / 6.49 (d, 1 H), 4.13 / 4.15 (q, 2 H), 4.01 / 3.73 (d / s, 1 H), 4.00-0.58 (m, 16 H), 3.89 (d, 2 H), 1.34 / 1.35 (t, 3 H).Preparation R3d: 3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]piperidin-4-yl}methyl)-7-(propan-2-yl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0268] Using General Procedure 5 starting from Preparation R2d as reagent, Preparation R3d was obtained. HRMS calculated for C 27 H 35 N 5 O 3 : 477.274; found 478.2819 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.4 / 8.89 (brd+brq, 1+1 H), 8.08 / 8.03 (s / s, 1 H), 7.32-7.09 (m, 5 H), 7.27 / 7.25 (d / d, 1 H), 6.51 / 6.47 (d / d, 1 H), 4.84 (m, 1 H), 4.05-0.6 (m, 16 H), 3.48 / 3.43 (m / m, 1 H), 3.22 (m, 1 H), 1.43 (d, 6 H). 13< C-NMR (125 MHz, MSM-d6) δ ppm 147.4, 121.1 / 121, 102.3 / 102.2, 46.4, 42.6 / 42.4, 41 / 40.6, 23.1.Preparation R3e: 6-[3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]piperidin-4-yl}methyl)-4-oxo-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-7-yl]-1,2-dihydropyridin-2-one

[0269] Using General Procedure 15 starting from Preparation R3bs as reagent, Preparation R3e was obtained as free base. HRMS calculated for C 29 H 32 N 6 O 4 : 528.2485; found 529.2567 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 8.17 / 8.13 (s / s, 1 H), 7.87 / 7.86 (d / d, 1 H), 7.83 / 7.8 (d / d, 1 H), 7.82 (t, 1 H), 7.26-6.99 (m, 5 H), 6.71 / 6.68 (d / d, 1 H), 6.6 (d, 1 H), 4.85 (brs, 1 H), 4.12-0.75 (m, 16 H), 3.21 / 3.15 (t / t, 1 H), 2.86 (m, 1 H). 13< C-NMR (125 MHz, MSM-d6) δ ppm 148.4, 142, 122.2, 107.9, 107.1, 103.9 / 103.8, 46.4 / 46.3, 43.4 / 42.9.Preparation R3g: 7-cyclopropyl-3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]piperidin-4-yl}methyl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0270] Using General Procedure 5 starting from Preparation R2g as reagent, Preparation R3g was obtained as HCl salt. HRMS calculated for C 27 H 33 N 5 O 3 : 475.2583; found 476.2668 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.26 / 8.78 (brd+brq, 2 H), 8.12-6.38 (m, 8 H), 4.05-0.62 (m, 23 H).Preparation R3h: 7-cyclobutyl-3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]piperidin-4-yl}methyl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0271] Using General Procedure 5 starting from Preparation R2h as reagent, Preparation R3h was obtained. HRMS calculated for C 28 H 35 N 5 O 3 : 489.274; found 490.2796 ((M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 8.92 (vbrs, 2 H), 8.06 / 8.01 (s / s, 1 H), 7.43 / 7.4 (d / d, 1 H), 7.34-7.08 (m, 5 H), 6.53 / 6.49 (d / d, 1 H), 5.09 (m, 1 H), 4.85 (s, 1 H), 4.08-0.55 (m, 16 H), 3.47 / 3.42 (m / m, 1 H), 3.21 (m, 1 H), 2.5 / 2.38 (m+m, 4 H), 1.82 (m, 2 H) 13< C-NMR (500 MHz, MSM-d6) δ ppm 147.6 / 147.5, 122 / 121.9, 102.5 / 102.4, 48.5, 42.6 / 42.5, 41 / 40.6, 31, 14.8Preparation R3k: 3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]piperidin-4-yl}methyl)-7-(1-methylpiperidin-4-yl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0272] Using General Procedure 5 starting from Preparation R2k as reagent, Preparation R3k was obtained as HCl salt. HRMS calculated for C 30 H 40 N 6 O 3 : 532.3162; found 267.1658 [(M+2H) 2+< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 10.87 / 10.67 (brs, 1 H), 9.29 / 8.8 (brq+brd, 2 H), 8.13 / 8.08 (s, 1 H), 7.35-7.11 (m, 5 H), 7.14 / 7.12 (d, 1 H), 6.57 / 6.53 (d, 1 H), 4.82 (brs, 1 H), 4.76 (m, 1 H), 4.08-2.61 (m, 16 H), 2.78 (d, 3 H), 2.47-1.96 (m, 4 H), 1.95-0.59 (m, 6 H).Preparation R3m: 3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl] piperidin-4-yl}methyl)-7-(prop-2-yn-1-yl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0273] Using General Procedure 5 starting from Preparation R2m as reagent, Preparation R3m was obtained as HCl salt. HRMS calculated for C 27 H 31 N 5 O 3 : 473.2427; found 474.2502 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.32 / 8.83 (brd+brq, 2 H), 8.12 / 8.06 (s, 1 H), 7.33-7.12 (m, 12 H), 7.33-7.12 (m, 5 H), 7.22 / 7.2 (d, 1 H), 6.55 / 6.51 (d, 1 H), 5 / 4.98 (d, 2 H), 3.44 / 3.43 (t, 1 H), 1.92-0.62 (m, 6 H).Preparation R3n: 3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]piperidin-4-yl}methyl)-7-(2-methylpropyl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0274] Using General Procedure 5 starting from Preparation R2n as reagent, Preparation R3n was obtained as HCl salt. HRMS calculated for C 28 H 37 N 5 O 3 : 491.2896; found 492.2963 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.3 / 8.81 (brd+brq, 2 H), 8.07 / 8.01 (s, 1 H), 7.33-7.12 (m, 5 H), 7.15 / 7.13 (d, 1 H), 6.49 / 6.46 (d, 1 H), 4.05-2.61 (m, 14 H), 2.12 (m, 1 H), 1.92-0.61 (m, 6 H), 0.84 / 0.83 (d, 6 H).Preparation R3o: 3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]piperidin-4-yl}methyl)-7-(2,2,2-trifluoroethyl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0275] Using General Procedure 5 starting from Preparation R2o as reagent, Preparation R3o was obtained as HCl salt. HRMS calculated for C 26 H 30 F 3 N 5 O 3 : 517.2301; found 518.2386 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.11 / 8.67 (brq+brd, 2 H), 8.16-6.55 (m, 8 H), 5.15-0.6 (m, 20 H), 4.87 (brs, 1 H).Preparation R3p: 7-(2,2-difluoroethyl)-3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]piperidin-4-yl}methyl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0276] Using General Procedure 5 starting from Preparation R2p as reagent, Preparation R3p was obtained as HCl salt. HRMS calculated for C 26 H 31 F 2 N 5 O 3 : 499.2395; found 500.2485 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.28 / 8.8 (brd+brq., 2 H), 8.12 / 8.07 (s / s, 1 H), 7.36-7.11 (m, 5 H), 7.18 / 7.17 (d / d, 1 H), 6.57 / 6.53 (d / d, 1 H), 6.39 (tm, 1 H), 4.6 (m, 2 H), 4.07-0.6 (m, 16 H), 3.48 / 3.42 (m / m, 1 H), 3.22 (m, 1 H). 13< C-NMR (125 MHz, MSM-d6) δ ppm 148.2 / 148.1, 125.2, 114.4, 102.9 / 102.8, 46.1, 42.6 / 42.4, 41 / 40.6.Preparation R3q: 7-(cyclopropylmethyl)-3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]piperidin-4-yl}methyl)-3H,4H,7H-pyrrolo[2,3-d] pyrimidin-4-one

[0277] Using General Procedure 5 starting from Preparation R2q as reagent, Preparation R3q was obtained as HCl salt. HRMS calculated for C 28 H 35 N 5 O 3 : 489.2740; found 490.2817 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.11 / 8.68 (brq+brd, 2 H), 8.06 / 8 (s, 1 H), 7.34-7.1 (m, 5 H), 7.23 / 7.21 (d, 1 H), 6.5 / 6.46 (d, 1 H), 4.07-2.6 (m, 14 H), 1.92-0.63 (m, 7 H), 0.54-0.35 (m, 4 H).Preparation R3r: 7-(cyclobutylmethyl)-3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]piperidin-4-yl}methyl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0278] Using General Procedure 5 starting from Preparation R2r as reagent, Preparation R3r was obtained as HCl salt. HRMS calculated for C 29 H 37 N 5 O 3 : 503.2896; found 504.2957 [(M+H) +< form]. 1< H-NMR (400 MHz, MSM-d6) δ ppm 9.45 / 8.92 (brq+brd), 8.09 / 8.03 (s, 1 H), 7.34-7.08 (m, 5 H), 7.15 / 7.13 (d, 1 H), 6.47 / 6.44 (d, 1 H), 4.19-2.59 (m, 15 H), 2.02-0.56 (m, 12 H).Preparation R3s: 7-(buta-2,3-dien-1-yl)-3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]piperidin-4-yl}methyl)-3H,4H,7H-pyrrolo[2,3-d] pyrimidin-4-one

[0279] Using General Procedure 5 starting from Preparation R2s as reagent, Preparation R3s was obtained as HCl. HRMS calculated for C 28 H 33 N 5 O 3 : 487.2583; found 488.2657 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.28 / 8.8 (brd+brq, 2 H), 8.09 / 8.03 (s, 1 H), 7.34-7.11 (m, 5 H), 7.15 / 7.14 (d, 1 H), 6.51 / 6.47 (d, 1 H), 5.5 (m, 1 H), 4.9 (m, 2 H), 4.88 (s, 1 H), 4.73 (m, 2 H), 4.06-2.63 (m, 12 H), 1.94-0.6 (m, 6 H).Preparation R3t: 7-[3-(dimethylamino)propyl]-3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]piperidin-4-yl}methyl)-3H,4H,7H-pyrrolo[2,3-d] pyrimidin-4-one

[0280] Using General Procedure 5 starting from Preparation R2t as reagent, Preparation R3t was obtained as HCl salt. HRMS calculated for C 29 H 40 N 6 O 3 : 520.3162; found 261.1666 [(M+2H) 2+< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 10.53 (brs, 1 H), 9.33 / 8.83 (brs+brm, 2 H), 8.13 / 8.07 (s / s, 1 H), 7.36-7.14 (m, 5 H), 7.23 / 7.21 (d / d, 1 H), 6.53 / 6.5 (d / d, 1 H), 4.2 (m, 2 H), 4.06-0.55 (m, 16 H), 3.48 / 3.43 (m / m, 1 H), 3.22 (m, 1 H), 3.02 (m, 2 H), 2.72 / 2.71 (s / s, 6 H), 2.17 (m, 2 H). 13< C-NMR (125 MHz, MSM-d6) δ ppm 147.9 / 147.8, 124.4 / 124.3, 102.4, 54.4, 42.6 / 42.4, 42.5, 42, 41 / 40.6, 25.6.Preparation R3u: 7-(2-fluoroethyl)-3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]piperidin-4-yl}methyl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0281] Using General Procedure 5 starting from Preparation R2u as reagent, Preparation R3u was obtained as HCl salt. HRMS calculated for C 25 H 31 FN 5 O 3 : 468.2411; found 482.2555 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.16 / 8.71 (m+m, 2 H), 8.08 / 8.03 (s, 1 H), 7.34-7.11 (m, 5 H), 7.2 / 7.18 (d, 1 H), 6.53 / 6.49 (d, 1 H), 4.82 (brs, 1 H), 4.76 (dt, 2 H), 4.44 (dt, 2 H), 4.11-2.6 (m, 12 H), 1.95-0.6 (m, 6 H).Preparation R3v: 7-[2-(dimethylamino)ethyl]-3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]piperidin-4-yl}methyl)-3H,4H,7H-pyrrolo[2,3-d] pyrimidin-4-one

[0282] Using General Procedure 5 starting from Preparation R2v as reagent, Preparation R3v was obtained as HCl salt. HRMS calculated for C 28 H 38 N 6 O 3 : 506.3005; found 254.1581 [(M+2H) 2+< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 10.48 (brs, 1 H), 9.27 / 8.8 (brs+brm, 2 H), 8.16 / 8.11 (s / s, 1 H), 7.37-7.16 (m, 5 H), 7.25 (d, 1 H), 6.57 / 6.54 (d / d, 1 H), 4.9 (vbrs, 1 H), 4.53 (m, 2 H), 4.13-0.55 (m, 16 H), 3.51 (m, 2 H), 3.48 / 3.43 (brm / brm, 1 H), 3.22 (m, 1 H), 2.8 / 2.79 (d / d, 6 H). 13< C-NMR (125 MHz, MSM-d6) δ ppm 148.1, 124.4, 103, 55.9, 42.9, 42.6 / 42.4, 41 / 40.6, 39.6.Preparation R3w: 3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl] piperidin-4-yl}methyl)-7-(2-hydroxyethyl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0283] Using General Procedure 5 starting from Preparation R2w as reagent, Preparation R3w was obtained. 1< H-NMR (400 MHz, MSM-d6) δ ppm 8.05 / 7.99 (s / s, 1 H), 7.27-7.02 (m, 5 H), 7.16 / 7.14 (d / d, 1 H), 6.47 / 6.45 (d / d, 1 H), 4.94 / 4.93 (t / t, 1 H), 4.83 / 4.8 (s / s, 1 H), 4.15 (m, 2 H), 4.06-0.72 (m, 16 H), 3.71 (m, 2 H), 3.2 / 3.15 (m / m, 1 H), 2.86 (m, 1 H). 13< C-NMR (100 MHz, MSM-d6) δ ppm 147.4, 125.1, 101.8 / 101.7, 60.6, 47.3, 46.5 / 46.4, 43.4.Preparation R3x: 7-[(4-chlorophenyl)methyl]-3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]piperidin-4-yl}methyl)-3H,4H,7H-pyrrolo[2,3-d] pyrimidin-4-one

[0284] Using General Procedure 5 starting from Preparation R2x as reagent, Preparation R3x was obtained as HCl salt. HRMS calculated for C 31 H 34 ClN 5 O 3 : 559.2350; found 560.2418 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.04 / 8.63 (brd+brq, 2 H), 8.07 / 8.02 (s, 1 H), 7.44-7.07 (m, 9 H), 7.26 / 7.24 (d, 1 H), 6.54 / 6.5 (d, 1 H), 5.34 / 5.33 (s, 2 H), 4.81 (brs, 1 H), 4.04-2.61 (m, 12 H), 1.92-0.61 (m, 6 H).Preparation R3y: 7-[(3-chlorophenyl)methyl]-3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]piperidin-4-yl}methyl)-3H,4H,7H-pyrrolo[2,3-d] pyrimidin-4-one

[0285] Using General Procedure 5 starting from Preparation R2y as reagent, Preparation R3y was obtained as HCl salt. HRMS calculated for C 31 H 34 ClN 5 O 3 : 559.2350; found 560.2432 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.1 / 8.67 (brd+brq, 2 H), 8.09 / 8.03 (s, 1 H), 7.4-7.08 (m, 9 H), 7.29 / 7.27 (d, 1 H), 6.55 / 6.52 (d, 1 H), 5.35 / 5.34 (s, 2 H), 4.83 (brs, 1 H), 4.05-2.62 (m, 12 H), 1.91-0.61 (m, 6 H).Preparation R3z: 7-benzyl-3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]piperidin-4-yl}methyl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0286] Using General Procedure 5 starting from Preparation R2z as reagent, Preparation R3z was obtained as HCl salt. HRMS calculated for C 31 H 35 N 5 O 3 : 525.2740; found 526.2822 [(M+H) form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.31 / 8.82 (brd+brq, 2 H), 8.1 / 8.05 (s, 1 H), 7.36-7.09 (m, 10 H), 7.25 / 7.22 (d, 1 H), 6.53 / 6.5 (d, 1 H), 5.34 / 5.33 (s, 2 H), 4.05-2.63 (m, 12 H), 1.92-0.62 (m, 6 H).Preparation R3aa: 7-[(2-chlorophenyl)methyl]-3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]piperidin-4-yl}methyl)-3H,4H,7H-pyrrolo[2,3-d] pyrimidin-4-one

[0287] Using General Procedure 5 starting from Preparation R2aa as reagent, Preparation R3aa was obtained as HCl salt. HRMS calculated for C 31 H 34 ClN 5 O 3 : 559.2350; found 560.2429 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.12 / 8.68 (brd+brq, 2 H), 8.07 / 8.01 (s, 1 H), 7.54-6.76 (m, 9 H), 7.2 / 7.18 (d, 1 H), 6.56 / 6.55 (d, 1 H), 5.44 / 5.43 (s, 2 H), 4.86 / 4.85 (s, 1 H), 4.06-2.61 (m, 12 H), 1.91-0.62 (m, 6 H).Preparation R3ac: 3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]piperidin-4-yl}methyl)-7-(3,4,5-trimethoxyphenyl)-3H,4H,7H-pyrrolo[2,3-d] pyrimidin-4-one

[0288] Using General Procedure 5 starting from Preparation R2ac as reagent, Preparation R3ac was obtained as HCl salt. HRMS calculated for C 33 H 39 N 5 O 6 : 601.2900; found 602.2960 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.55 / 9.01 (brq+brd, 2 H), 8.16 / 8.12 (s, 1 H), 7.54 / 7.51 (d, 1 H), 7.36-7.14 (m, 5 H), 7.01 / 6.99 (s, 2 H), 6.7 / 6.67 (d, 1 H), 4.95 (brs, 1 H), 4.1-2.61 (m, 12 H), 3.83 (s, 6 H), 3.7 (s, 3 H), 1.98-0.62 (m, 6 H).Preparation R3ad: 7-(3,5-dichlorophenyl)-3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]piperidin-4-yl}methyl)-3H,4H,7H-pyrrolo[2,3-d] pyrimidin-4-one

[0289] Using General Procedure 5 starting from Preparation R2ad as reagent, Preparation R3ad was obtained as HCl salt. HRMS calculated for C 30 H 31 N 5 O 3 Cl 2 : 579.1804; found 580.1891 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.06 / 8.65 (brd+brq, 2 H), 8.18 / 8.14 (s, 1 H), 7.98 / 7.97 (d, 2 H), 7.71 / 7.68 (d, 1 H), 7.67 (t, 1 H), 7.34-7.14 (m, 5 H), 6.77 / 6.73 (d, 1 H), 4.88 (brs, 1 H), 4.12-2.62 (m, 12 H), 1.96-0.62 (m, 6 H).Preparation R3ae: 7-(3-chloro-5-methoxyphenyl)-3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]piperidin-4-yl}methyl)-3H,4H,7H-pyrrolo[2,3-d] pyrimidin-4-one

[0290] Using General Procedure 5 starting from Preparation R2ae as reagent, Preparation R3ae was obtained as HCl salt. HRMS calculated for C 31 H 34 ClN 5 O 4 : 575.2299; found 576.2382 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 8.83 (brs, 2 H), 8.15 / 8.1 (s, 1 H), 7.64 / 7.62 (d, 1 H), 7.51 / 7.5 (t, 1 H), 7.36 / 7.34 (t, 1 H), 7.36-7.12 (m, 5 H), 7.09 (t, 1 H), 6.74 / 6.7 (d, 1 H), 4.87 (s, 1 H), 4.11-2.62 (m, 12 H), 3.85 (s, 3 H), 1.94-0.62 (m, 6 H).Preparation R3af: 7-(3,5-dimethoxyphenyl)-3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]piperidin-4-yl}methyl)-3H,4H,7H-pyrrolo[2,3-d] pyrimidin-4-one

[0291] Using General Procedure 5 starting from Preparation R2af as reagent, Preparation R3af was obtained as HCl salt. HRMS calculated for C 32 H 37 N 5 O 5 : 571.2795; found 572.2881 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.11 / 8.68 (brq+brd, 2 H), 8.12 / 8.07 (s, 1 H), 7.57 / 7.55 (d, 1 H), 7.34-7.13 (m, 5 H), 6.93 / 6.91 (d, 2 H), 6.71 / 6.67 (d, 1 H), 6.56 / 6.55 (t, 1 H), 4.86 (brs, 1 H), 4.09-2.62 (m, 12 H), 3.81 (s, 6 H), 1.94-0.64 (m, 6 H).Preparation R3ag: 7-(3,4-dichlorophenyl)-3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]piperidin-4-yl}methyl)-3H,4H,7H-pyrrolo[2,3-d] pyrimidin-4-one

[0292] Using General Procedure 5 starting from Preparation R2ag as reagent, Preparation R3ag was obtained as HCl salt. HRMS calculated for C 30 H 31 Cl 2 N 5 O 3 : 579.18042; found 580.1870 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.16 / 8.71 (brq+brd, 2 H), 8.2-7.79 (m, 3 H), 8.17 / 8.13 (s, 1 H), 7.65 / 7.63 (d, 1 H), 7.35-7.12 (m, 5 H), 6.76 / 6.72 (d, 1 H), 4.85 (brs, 1 H), 4.11-2.61 (m, 12 H), 1.95-0.6 (m, 6 H).Preparation R3ah: 7-(4-chloro-3-fluorophenyl)-3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]piperidin-4-yl}methyl)-3H,4H,7H-pyrrolo[2,3-d] pyrimidin-4-one

[0293] Using General Procedure 5 starting from Preparation R2ah as reagent, Preparation R3ah was obtained as HCl salt. HRMS calculated for C 30 H 31 N 5 O 3 FCl: 563.2100; found 564.2181 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.08 / 8.66 (brm / brm, 2 H), 8.16 / 8.12 (s, 1 H), 7.98 / 7.97 (dd, 1 H), 7.82-7.72 (m, 1 H), 7.78 (m, 1 H), 7.65 / 7.63 (d, 1 H), 7.33-7.26 (m, 2 H), 7.26-7.2 (m, 2 H), 7.17 (brt, 1 H), 6.77 / 6.73 (d, 1 H), 4.86 (vbrs, 1 H), 4.12-0.58 (, 16 H), 4.05 / 3.94 / 3.67 (d / s, 2 H). 13< C-NMR (125 MHz, MSM-d6) δ ppm 158.3, 157.7, 148.7 / 148.6, 146.7 / 146.6, 131.6, 129 / 128.9, 128.3 / 128.1, 127.7, 124.1, 121, 112.7, 109.3 / 109.2, 104.5, 69.4, 53.6 / 53.3.Preparation R3ai: 7-(4-chloro-3-methoxyphenyl)-3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]piperidin-4-yl}methyl)-3H,4H,7H-pyrrolo[2,3-d] pyrimidin-4-one

[0294] Using General Procedure 5 starting from Preparation R2ai as reagent, Preparation R3ai was obtained as HCl salt. HRMS calculated for C 31 H 34 ClN 5 O 4 : 575.2230; found 576.2382 [(M+H) +< form]. 1< H-NMR (400 MHz, MSM-d6) δ ppm 8.89 (brs, 2 H), 8.14 / 8.06 (s, 1 H), 7.62 / 7.6 (d, 1 H), 7.6 (d, 1 H), 7.51 / 7.5 (d, 1 H), 7.38 / 7.36 (dd, 1 H), 7.35-7.13 (m, 5 H), 6.75 / 6.71 (d, 1 H), 4.87 (s, 1 H), 4.11-2.6 (m, 12 H), 3.93 (s, 3 H), 1.95-0.6 (m, 6 H).Preparation R3aj: 7-(4-fluoro-3-methoxyphenyl)-3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]piperidin-4-yl}methyl)-3H,4H,7H-pyrrolo[2,3-d] pyrimidin-4-one

[0295] Using General Procedure 5 starting from Preparation R2aj as reagent, Preparation R3aj was obtained as HCl salt. HRMS calculated for C 31 H 34 FN 5 O 4 : 559.2595; found 560.2638 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.13 / 8.7 (brd+brq, 1+1 H), 8.12 / 8.07 (s / s, 1 H), 7.55 / 7.53 (d / d, 1 H), 7.49 (m, 2 H), 7.39 (m, 2 H), 7.35-7.14 (m, 5 H), 7.28 (m, 2 H), 6.73 / 6.69 (d / d, 1 H), 4.65-0.6 (m, 16 H), 3.91 (s, 3 H), 3.48 / 3.42 (m / m, 1 H), 3.22 (m, 1 H). 13< C-NMR (125 MHz, MSM-d6) δ ppm 148.4 / 148.3, 124.8 / 124.7, 116.8, 116.6, 110.8, 103.7, 56.8, 42.6 / 42.5, 41 / 40.6.Preparation R3ak: 7-(3,4-dimethoxyphenyl)-3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]piperidin-4-yl}methyl)-3H,4H,7H-pyrrolo[2,3-d] pyrimidin-4-one

[0296] Using General Procedure 5 starting from Preparation R2ak as reagent, Preparation R3ak was obtained as HCl salt. HRMS calculated for C 32 H 37 N 5 O 5 : 571.2795; found 572.2892 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.11 / 8.69 (brd+brq, 2 H), 8.09 / 8.04 (s, 1 H), 7.48 / 7.46 (d, 1 H), 7.35-7.06 (m, 8 H), 6.69 / 6.68 (d, 1 H), 4.86 (brs, 1 H), 4.11-2.6 (m, 12 H), 3.81 (s, 6 H), 1.96-0.62 (m, 6 H).Preparation R3am: 3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl] piperidin-4-yl}methyl)-7-(4-methylphenyl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0297] Using General Procedure 5 starting from Preparation R2am as reagent, Preparation R3am was obtained as HCl salt. HRMS calculated for C 31 H 35 N 5 O 3 : 525.2734; found 526.2816 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.31 / 8.82 (brd+brq, 2 H), 8.11 / 8.06 (s, 1 H), 7.6 / 7.58 (m, 2 H), 7.49 / 7.46 (d, 1 H), 7.35 / 7.34 (m, 2 H), 7.32-7.11 (m, 5 H), 6.71 / 6.67 (d, 1 H), 4.81 (brs, 1 H), 4.11-2.61 (m, 12 H), 2.37 (s, 3 H), 1.94-0.61 (m, 6 H).Preparation R3an: 4-[3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl] piperidin-4-yl}methyl)-4-oxo-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-7-yl]benzonitrile

[0298] Using General Procedure 5 starting from Preparation R2an as reagent, Preparation R3an was obtained as HCl salt. HRMS calculated for C 31 H 32 N 6 O 3 : 536.2536; found 537.2599 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.19 / 8.73 (brd+brq, 2 H), 8.18 / 8.14 (s / s, 1 H), 8.12-8 (m, 4 H), 7.71 / 7.69 (d / d, 1 H), 7.35-7.13 (m, 5 H), 6.8 / 6.76 (d / d, 1 H), 4.85 (vbrs, 1 H), 4.15-0.6 (m, 16 H), 3.48 / 3.42 (m / m, 1 H), 3.22 (m, 1 H).Preparation R3ao: 3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]piperidin-4-yl}methyl)-7-[4-(trifluoromethyl)phenyl]-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0299] Using General Procedure 5 starting from Preparation R2ao as reagent, Preparation R3ao was obtained as HCl salt. HRMS calculated for C 31 H 32 N 5 O 3 F 3 : 579.2457; found 580.2529 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.13 / 8.7 (brs+brs, 2 H), 8.17 / 8.12 (s / s, 1 H), 8.05 / 8.04 (d / d, 2 H), 7.94 / 7.93 (d / d, 2 H), 7.68 / 7.66 (d / d, 1 H), 7.35-7.12 (m, 5 H), 6.79 / 6.75 (d / d, 1 H), 4.88 (s, 1 H), 4.2-0.59 (m, 16 H), 3.48 / 3.42 (m / m, 1 H), 3.22 (m, 1 H).Preparation R3ap: 7-[4-(difluoromethyl)phenyl]-3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]piperidin-4-yl}methyl)-3H,4H,7H-pyrrolo[2,3-d] pyrimidin-4-one

[0300] Using General Procedure 5 starting from Preparation R2ap as reagent, Preparation R3ap was obtained as HCl salt. HRMS calculated for C 31 H 33 F 2 N 5 O 3 : 561.2551; found 562.2636 [(M+H) form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.11 / 8.68 (brd+brq, 2 H), 8.14 / 8.09 (s, 1 H), 7.93 / 7.91 (m, 2 H), 7.76 / 7.75 (m, 2 H), 7.62 / 7.6 (d, 1 H), 7.34-7.12 (m, 5 H), 7.13 (t, 1 H), 6.77 / 6.73 (d, 1 H), 4.87 (s, 1 H), 4.11-2.61 (m, 12 H), 1.93-0.64 (m, 6 H).Preparation R3aq: 3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl] piperidin-4-yl}methyl)-7-[4-(hydroxymethyl)phenyl]-3H,4H,7H-pyrrolo[2,3-d] pyrimidin-4-one

[0301] Using General Procedure 5 starting from Preparation R2aq as reagent, Preparation R3aq was obtained as HCl salt. HRMS calculated for C 31 H 35 N 5 O 4 : 541.2689; found 542.2787 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.2 / 8.74 (brd+brq, 1+1 H), 8.11 / 8.06 (s / s, 1 H), 7.67 / 7.65 (dm / dm, 2 H), 7.51 / 7.48 (d / d, 1 H), 7.47 (m, 2 H), 7.34-7.1 (m, 5 H), 6.72 / 6.68 (d / d, 1 H), 4.56 (s, 2 H), 4.08-0.61 (m, 16 H), 3.48 / 3.43 (m / m, 1 H), 3.21 (m, 1 H). 13< C-NMR (125 MHz, MSM-d6) δ ppm 148.3 / 148.2, 127.8, 124.4, 124.2, 103.8, 62.8, 42.6 / 42.5, 41 / 40.6.Preparation R3ar: 7-(4-chlorophenyl)-3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]piperidin-4-yl}methyl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0302] Using General Procedure 5 starting from Preparation R2ar as reagent, Preparation R3ar was obtained as HCl salt. HRMS calculated for C 30 H 32 ClN 5 O 3 : 545.2194; found 546.2288 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.38 / 8.87 (brs, 2 H), 8.24-6.62 (m, 12 H), 4.13-0.58 (m, 18 H).Preparation R3as: 7-(4-fluorophenyl)-3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]piperidin-4-yl}methyl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0303] Using General Procedure 5 starting from Preparation R2as as reagent, Preparation R3as was obtained as HCl salt. HRMS calculated for C 30 H 32 N 5 O 3 F: 529.2489; found 530.2563 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.05 / 8.64 (brd+brq, 2 H), 8.11 / 8.06 (s, 1 H), 7.76 / 7.75 (m, 2 H), 7.52 / 7.5 (d, 1 H), 7.41 / 7.4 (m, 2 H), 7.34-7.13 (m, 5 H), 6.73 / 6.69 (d, 1 H), 4.84 (brs, 1 H), 4.1-2.65 (m, 12 H), 1.95-0.63 (m, 6 H).Preparation R3at: 7-[4-(dimethylamino)phenyl]-3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]piperidin-4-yl}methyl)-3H,4H,7H-pyrrolo[2,3-d] pyrimidin-4-one

[0304] Using General Procedure 5 starting from Preparation R2at as reagent, Preparation R3at was obtained as HCl salt. HRMS calculated for C 32 H 38 N 6 O 3 : 554.3005; found 555.3076 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.15 / 8.71 (brd+brq, 2 H), 8.07 / 8.02 (s, 1 H), 7.52 (brm, 2 H), 7.41 / 7.38 (d, 1 H), 7.33-7.11 (m, 5 H), 6.99 (brs, 2 H), 6.68 / 6.64 (d, 1 H), 4.07-2.62 (m, 12 H), 2.99 (s, 6 H), 1.93-0.64 (m, 6 H).Preparation R3ax: 3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]piperidin-4-yl}methyl)-7-(4-methoxyphenyl)-3H,4H,7H-pyrrolo[2,3-d] pyrimidin-4-one

[0305] Using General Procedure 5 starting from Preparation R2ax as reagent, Preparation R3ax was obtained as HCl salt. HRMS calculated for C 31 H 35 N 5 O 4 : 541.2689; found 542.2782 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.2 / 8.74 (brd+brq, 2 H), 8.09 / 8.04 (s, 1 H), 7.63-7.55 (m, 2 H), 7.44 / 7.42 (d, 1 H), 7.33-7.12 (m, 5 H), 7.12-7.06 (m, 2 H), 6.69 / 6.65 (d, 1 H), 4.85 (brs, 1 H), 4.07-2.63 (m, 12 H), 3.82 / 3.75 (s, 3 H), 1.95-0.61 (m, 6 H).Preparation R3ay: 3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]piperidin-4-yl}methyl)-7-[4-(trifluoromethoxy)phenyl]-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0306] Using General Procedure 5 starting from Preparation R2ay as reagent, Preparation R3ay was obtained as HCl salt. HRMS calculated for C 31 H 32 N 5 O 4 F 3 : 595.2407; found 596.2494 [(M+H) +< form]. 1< H-NMR (400 MHz, MSM-d6) δ ppm 9.08 / 8.66 (brs, 2 H), 8.13 / 8.08 (s, 1 H), 7.93-7.53 (m, 4 H), 7.59 / 7.57 (d, 1 H), 7.36-7.12 (m, 5 H), 6.75 / 6.72 (d, 1 H), 4.86 (s, 1 H), 4.14-2.59 (m, 12 H), 1.95-0.63 (m, 6 H).Preparation R3az: 7-[4-(benzyloxy)phenyl]-3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]piperidin-4-yl}methyl)-3H,4H,7H-pyrrolo[2,3-d] pyrimidin-4-one

[0307] Using General Procedure 5 starting from Preparation R2az as reagent, Preparation R3az was obtained as HCl salt. HRMS calculated for C 37 H 39 N 5 O 4 : 617.3002; found 618.3083 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.12 / 8.68 (brs+brs, 2 H), 8.08 / 8.03 (s, 1 H), 7.6 / 7.58 (m, 2 H), 7.51-7.11 (m, 10 H), 7.45 / 7.42 (d, 1 H), 7.17 (m, 2 H), 6.69 / 6.65 (d, 1 H), 5.18 (s, 2 H), 4.85 (s, 1 H), 4.1-2.6 (m, 12 H), 1.95-0.61 (m, 6 H).Preparation R3ba: 3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]piperidin-4-yl}methyl)-7-(5-methylthiophen-2-yl)-3H,4H,7H-pyrrolo[2,3-d] pyrimidin-4-one

[0308] Using General Procedure 5 starting from Preparation R2ba as reagent, Preparation R3ba was obtained as HCl salt. HRMS calculated for C 29 H 33 N 5 O 3 S: 531.2304; found 532.2361 [(M+H) form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.05 / 8.68 (brs+brs, 2 H), 8.14 / 8.1 (s, 1 H), 7.53 / 7.51 (d, 1 H), 7.33-7.11 (m, 5 H), 7.16 / 7.15 (d, 1 H), 6.77 / 6.76 (m, 1 H), 6.71 / 6.67 (d, 1 H), 4.88 / 4.87 (s, 1 H), 4.09-2.62 (m, 12 H), 2.46 (d, 3 H), 1.92-0.62 (m, 6 H).Preparation R3bb: 7-(5-chlorothiophen-2-yl)-3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]piperidin-4-yl}methyl)-3H,4H,7H-pyrrolo[2,3-d] pyrimidin-4-one

[0309] Using General Procedure 5 starting from Preparation R2bb as reagent, Preparation R3bb was obtained as HCl salt. HRMS calculated for C 28 H 30 ClN 5 O 3 S: 551.1758; found 552.1844 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.06 / 8.76 (brs+brs, 2 H), 8.21 / 8.16 (s / s, 1 H), 7.71 / 7.68 (d / d, 1 H), 7.32 / 7.31 (d / d, 1 H), 7.32-7.12 (m, 5 H), 7.15 / 7.14 (d / d, 1 H), 6.76 / 6.73 (d / d, 1 H), 4.1-0.58 (m, 16 H), 3.47 / 3.41 (m / m, 1 H), 3.21 (m, 1 H). 13< C-NMR (125 MHz, MSM-d6) δ ppm 149.2 / 149.1, 125.6, 123.6, 117.6 / 117.5, 104.9, 42.6 / 42.5, 41 / 40.6.Preparation R3bc: 7-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]piperidin-4-yl}methyl)-3H,4H,7H-pyrrolo[2,3-d] pyrimidin-4-one

[0310] Using General Procedure 5 starting from Preparation R2bc as reagent, Preparation R3bc was obtained as HCl salt. HRMS calculated for C 32 H 35 N 5 O 5 : 569.2638; found 570.2709 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.42 / 8.89 (brd+brq, 2 H), 8.11 / 8.06 (s, 1 H), 7.44 / 7.41 (d, 1 H), 7.33-7.11 (m, 5 H), 7.23 / 7.22 (d, 1 H), 7.15 / 7.13 (dd, 1 H), 7 / 6.99 (d, 1 H), 6.67 / 6.63 (d, 1 H), 4.35-4.26 (m, 4 H), 4.09-2.62 (m, 12 H), 1.94-0.61 (m, 6 H).Preparation R3bd: 7-(2H-1,3-benzodioxol-5-yl)-3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]piperidin-4-yl}methyl)-3H,4H,7H-pyrrolo[2,3-d] pyrimidin-4-one

[0311] Using General Procedure 5 starting from Preparation R2bd as reagent, Preparation R3bd was obtained as HCl salt. HRMS calculated for C 31 H 33 N 5 O 5 : 555.2482; found 570.2709 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.21 / 8.78 (brs+brs, 2 H), 8.1 / 8.05 (s, 1 H), 7.44 / 7.42 (d, 1 H), 7.35-7.11 (m, 5 H), 7.3 / 7.28 (d, 1 H), 7.14 / 7.13 (dd, 1 H), 7.07 / 7.06 (d, 1 H), 6.68 / 6.64 (d, 1 H), 6.12 (s, 2 H), 4.87 (s, 1 H), 4.09-2.62 (m, 12 H), 1.95-0.62 (m, 6 H).Preparation R3be: 3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl] piperidin-4-yl}methyl)-7-(naphthalen-2-yl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0312] Using General Procedure 5 starting from Preparation R2be as reagent, Preparation R3be was obtained as HCl salt. HRMS calculated for C 34 H 35 N 5 O 3 : 561.2740; found 562.2831 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.16 / 8.72 (brd+brq, 2 H), 8.3-7.54 (m, 7 H), 8.16 / 8.11 (s, 1 H), 7.67 / 7.65 (d, 1 H), 7.35-7.13 (m, 5 H), 6.79 / 6.75 (d, 1 H), 4.89 (brs, 1 H), 4.12-2.65 (m, 12 H), 1.96-0.65 (m, 6 H).Preparation R3bf: 3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl] piperidin-4-yl}methyl)-7-(3-methylphenyl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0313] Using General Procedure 5 starting from Preparation R2bf as reagent, Preparation R3bf was obtained. HRMS calculated for C 31 H 35 N 5 O 3 : 525.2740; found 526.2825 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.13 / 8.69 (brq+brd, 2 H), 8.11 / 8.06 (s, 1 H), 7.57-7.11 (m, 10 H), 6.71 / 6.67 (d, 1 H), 4.2-2.62 (m, 12 H), 1.94-0.59 (m, 6 H).Preparation R3bg: 3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]piperidin-4-yl}methyl)-7-[3-(trifluoromethyl)phenyl]-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0314] Using General Procedure 5 starting from Preparation R2bg as reagent, Preparation R3bg was obtained as HCl salt. HRMS calculated for C 31 H 32 F 3 N 5 O 3 : 579.2457; found 580.2509 [(M+H) +< form]. 1< H-NMR (400 MHz, MSM-d6) δ ppm 9.2 / 8.74 (brd+brq, 2 H), 8.19 / 8.17 (m, 1 H), 8.17 / 8.13 (s, 1 H), 8.09 / 8.07 (dm, 1 H), 7.86-7.74 (m, 2 H), 7.7 / 7.67 (d, 1 H), 7.35-7.11 (m, 5 H), 6.78 / 6.74 (d, 1 H), 4.78 (brs, 1 H), 4.11-2.6 (m, 12 H), 1.94-0.62 (m, 6 H).Preparation R3bh: 3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]piperidin-4-yl}methyl)-7-{3-[(4-methylpiperazin-1-yl)methyl]phenyl}-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0315] Using General Procedure 5 starting from Preparation R2bh as reagent, Preparation R3bh was obtained as HCl salt. HRMS calculated for C 36 H 45 N 7 O 3 : 623.3584; found 624.3656 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 12.37 / 11.6 (brs, 2 H), 9.33 / 8.83 (brd+brq, 2 H), 8.18 / 8.12 (s, 1 H), 8.04-7.5 (m, 5 H), 7.35-7.13 (m, 5 H), 6.75 / 6.72 (d, 1 H), 4.6-2.6 (m, 22 H), 2.79 (s, 3 H), 1.98-0.66 (m, 6 H).Preparation R3bi: 3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl] piperidin-4-yl}methyl)-7-[3-(hydroxymethyl)phenyl]-3H,4H,7H-pyrrolo[2,3-d] pyrimidin-4-one

[0316] Using General Procedure 5 starting from Preparation R2bi as reagent, Preparation R3bi was obtained as HCl salt. HRMS calculated for C 31 H 35 N 5 O 4 : 541.2689; found 542.2769 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 8.98 / 8.72 (brs+brs, 2 H), 8.1 / 8.05 (s / s, 1 H), 7.69-7.33 (m, 4 H), 7.51 / 7.48 (d / d, 1 H), 7.33-7.11 (m, 5 H), 6.73 / 6.69 (d / d, 1 H), 5.36 (t, 1 H), 4.59 (d, 2 H), 4.15-0.61 (m, 16 H), 3.48 / 3.42 (m / m, 1 H), 3.22 (m, 1 H).Preparation R3bj: 7-(3-chlorophenyl)-3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]piperidin-4-yl}methyl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0317] Using General Procedure 5 starting from Preparation R2bj as reagent, Preparation R3bj was obtained as HCl salt. HRMS calculated for C 30 H 32 N 5 O 3 Cl: 545.2194; found 546.2277 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.17 / 8.72 (brd+brq, 2 H), 8.15 / 8.11 (s, 1 H), 7.94-7.45 (m, 4 H), 7.63 / 7.6 (d, 1 H), 7.34-7.12 (m, 5 H), 6.75 / 6.71 (d, 1 H), 4.88 (brs, 1 H), 4.13-2.62 (m, 12 H), 1.95-0.62 (m, 6 H).Preparation R3bk: 7-(3-fluorophenyl)-3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]piperidin-4-yl}methyl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0318] Using General Procedure 5 starting from Preparation R2bk as reagent, Preparation R3bk was obtained. HRMS calculated for C 30 H 32 FN 5 O 3 : 529.2489; found 530.2571 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9 / 8.61 (brd+brq, 1+1 H), 8.14 / 8.09 (s / s, 1 H), 7.76-7.23 (m, 4 H), 7.62 / 7.6 (d / d, 1 H), 7.34-7.13 (m, 5 H), 6.75 / 6.71 (d / d, 1 H), 4.14-0.6 (m, 16 H), 3.47 / 3.42 (m / m, 1 H), 3.2 (m, 1 H). 13< C-NMR (125 MHz, MSM-d6) δ ppm 148.6 / 148.5, 124.2, 104.3 / 104.2, 42.6 / 42.5, 41 / 40.6.Preparation R3bl: 7-[3-(dimethylamino)phenyl]-3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]piperidin-4-yl}methyl)-3H,4H,7H-pyrrolo[2,3-d] pyrimidin-4-one

[0319] Using General Procedure 5 starting from Preparation R2bl as reagent, Preparation R3bl was obtained as HCl salt. HRMS calculated for C 32 H 38 N 6 O 3 : 554.3005; found 555.3086 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.23 / 8.76 (brd+brq, 1+1 H), 8.1 / 8.05 (s / s, 1 H), 7.51 / 7.49 (d / d, 1 H), 7.37 (brt, 1 H), 7.33-7.13 (m, 5 H), 7.18-6.76 (brd, 3 H), 6.7 / 6.66 (d / d, 1 H), 4.09-0.61 (m, 16 H), 3.47 / 3.43 (m / m, 1 H), 3.22 (m, 1 H), 2.98 (s, 6 H). 13< C-NMR (125 MHz, MSM-d6) δ ppm 148.2 / 148.1, 130.2, 124.7, 103.6 / 103.5, 42.6 / 42.5, 41.1, 41 / 40.6.Preparation R3bm: 3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl] piperidin-4-yl}methyl)-7-[3-(morpholin-4-yl)phenyl]-3H,4H,7H-pyrrolo[2,3-d] pyrimidin-4-one

[0320] Using General Procedure 5 starting from Preparation R2bm as reagent, Preparation R3bm was obtained as HCl salt. HRMS calculated for C 34 H 40 N 6 O 4 : 596.3111; found 597.3187 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.22 / 8.75 (brd+brq, 1+1 H), 8.1 / 8.06 (s / s, 1 H), 7.52 / 7.49 (d / d, 1 H), 7.38 / 7.37 (t / t, 1 H), 7.33-7.13 (m, 5 H), 7.23 / 7.21 (brs / brs, 1 H), 7.14 / 7.12 (d / d, 1 H), 7 (brd., 1 H), 6.7 / 6.66 (d / d, 1 H), 4.09-0.62 (m, 16 H), 3.76 (m, 4 H), 3.47 / 3.42 (m / m, 1 H), 3.22 (m, 1 H), 3.19 (m, 4 H). 13< C-NMR (125 MHz, MSM-d6) δ ppm 148.2 / 148.1, 130.1, 124.7 / 124.6, 115.3, 114.2, 111.3 / 111.2, 103.6 / 103.5, 66.5, 48.7, 42.6, 41 / 40.5.Preparation R3bo: 3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]piperidin-4-yl}methyl)-7-(3-methoxyphenyl)-3H,4H,7H-pyrrolo[2,3-d] pyrimidin-4-one

[0321] Using General Procedure 5 starting from Preparation R2bo as reagent, Preparation R3bo was obtained as HCl salt. HRMS calculated for C 31 H 35 N 5 O 4 : 541.2689; found 542.2762 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.21 / 8.75 (brd+brq, 2 H), 8.12 / 8.01 (s, 1 H), 7.56 / 7.54 (d, 1 H), 7.49-6.96 (m, 9 H), 6.72 / 6.68 (d, 1 H), 4.84 (brs, 1 H), 4.16-2.62 (m, 12 H), 1.95-0.63 (m, 6 H).Preparation R3bp: 3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]piperidin-4-yl}methyl)-7-[3-(trifluoromethoxy)phenyl]-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0322] Using General Procedure 5 starting from Preparation R2bp as reagent, Preparation R3bp was obtained as HCl salt. HRMS calculated for C 31 H 32 N 5 O 4 F 3 : 595.2407; found 596.2491 [(M+H) +< form]. 1< H-NMR (400 MHz, MSM-d6) δ ppm 8.87 (brs, 2 H), 8.16 / 8.11 (s, 1 H), 7.9 / 7.88 (brs, 1 H), 7.85 / 7.84 (dm, 1 H), 7.7 / 7.69 (t, 1 H), 7.66 / 7.63 (d, 1 H), 7.43 (dm, 1 H), 7.34-7.11 (m, 5 H), 6.77 / 6.73 (d, 1 H), 4.87 / 4.86 (s, 1 H), 4.12-2.62 (m, 12 H), 1.97-0.61 (m, 6 H).Preparation R3bcq: 7-[3-(benzyloxy)phenyl]-3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]piperidin-4-yl}methyl)-3H,4H,7H-pyrrolo[2,3-d] pyrimidin-4-one

[0323] Using General Procedure 5 starting from Preparation R2bq as reagent, Preparation R3bq was obtained as HCl salt. HRMS calculated for C 37 H 39 N 5 O 4 : 617.3002; found 618.3051 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.24 / 8.77 (brd+brq, 2 H), 8.12 / 8.08 (s, 1 H), 7.56 / 7.53 (d, 1 H), 7.51-7.03 (m, 14 H), 6.72 / 6.68 (d, 1 H), 5.18 (s, 2 H), 4.09-2.63 (m, 12 H), 1.94-0.62 (m, 6 H).Preparation R3br: 3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]piperidin-4-yl}methyl)-7-(6-methylpyridin-2-yl)-3H,4H,7H-pyrrolo[2,3-d] pyrimidin-4-one

[0324] Using General Procedure 5 starting from Preparation R2br as reagent, Preparation R3br was obtained as HCl salt. HRMS calculated for C 30 H 34 N 6 O 3 : 526.2692; found 527.2764 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.43 / 8.91 (brq+brd, 2 H), 8.26 / 8.25 (dm, 1 H), 8.25 / 8.2 (s, 1 H), 7.92 / 7.9 (d, 1 H), 7.92 (m, 1 H), 7.34-7.11 (m, 5 H), 7.26 (m, 1 H), 6.73 / 6.69 (d, 1 H), 4.12-2.63 (m, 12 H), 2.53 / 2.52 (s, 3 H), 1.95-0.64 (m, 6 H).Preparation R3bs: 3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]piperidin-4-yl}methyl)-7-(6-methoxypyridin-2-yl)-3H,4H,7H-pyrrolo[2,3-d] pyrimidin-4-one

[0325] Using General Procedure 5 starting from Preparation R2bs as reagent, Preparation R3bs was obtained as HCl salt. HRMS calculated for C 30 H 34 N 6 O 4 : 542.2642; found 543.2698 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 8.95 (brs, 2 H), 8.8 / 6.81 (dd, 1 H), 8.23 / 8.18 (s, 1 H), 8.08 / 8.07 (dd, 1 H), 8 / 7.98 (d, 1 H), 7.93 / 7.92 (t, 1 H), 7.35-7.1 (m, 5 H), 6.75 / 6.72 (d, 1 H), 4.14-2.62 (m, 12 H), 3.95 / 3.94 (s, 3 H), 1.96-0.62 (m, 6 H).Preparation R3bt: 3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl] piperidin-4-yl}methyl)-7-(naphthalen-1-yl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0326] Using General Procedure 5 starting from Preparation R2bt as reagent, Preparation R3bt was obtained as HCl salt. HRMS calculated for C 34 H 35 N 5 O 3 : 561.2740; found 562.2827 [(M+H) form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.28 / 8.8 (brq+brd, 2 H), 8.17-6.74 (m, 15 H), 4.82 (brs, 1 H), 4.26-0.57 (m, 18 H).Preparation R3bu: 3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]piperidin-4-yl}methyl)-7-phenyl-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0327] Using General Procedure 5 starting from Preparation R2bu as reagent, Preparation R3bu was obtained as HCl salt. HRMS calculated for C 30 H 33 N 5 O 3 : 511.2583; found 512.2675 [(M+H) form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.1 / 8.67 (brd+brd, 2 H), 8.11 / 8.06 (s / s, 1 H), 7.75-7.38 (m, 5 H), 7.54 / 7.52 (d / d, 1 H), 7.34-7.12 (m, 5 H), 6.73 / 6.69 (d / d, 1 H), 4.86 (s, 1 H), 4.13-0.62 (m, 16 H), 3.47 / 3.42 (m / m, 1 H), 3.22 (m, 1 H). 13< C-NMR (125 MHz, MSM-d6) δ ppm 148.3 / 148.2, 124.5 / 124.4, 103.9 / 103.8, 42.6 / 42.5, 41 / 40.6.Preparation R3ca: 3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl] piperidin-4-yl}methyl)-7-(pyridin-2-yl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0328] Using General Procedure 5 starting from Preparation R2ca as reagent, Preparation R3ca was obtained as HCl salt. HRMS calculated for C 29 H 32 N 6 O 3 : 512.2536; found 513.2612 [(M+H) form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.07 / 8.65 (brd+brq, 2 H), 8.56 / 8.55 (dm, 1 H), 8.48 / 8.46 (dm, 1 H), 8.22 / 8.17 (s, 1 H), 8.05 (m, 1 H), 7.94 / 7.92 (d, 1 H), 7.41 (m, 1 H), 7.33-7.12 (m, 5 H), 6.75 / 6.71 (d, 1 H), 4.9 (s, 1 H), 4.15-2.63 (m, 12 H), 1.92-0.65 (m, 6 H).Preparation R3cb: 3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl] piperidin-4-yl}methyl)-7-(pyridin-3-yl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0329] Using General Procedure 5 starting from Preparation R2cb as reagent, Preparation R3cb was obtained. HRMS calculated for C 29 H 32 N 6 O 3 : 512.2536; found 513.261 [(M+H) form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.35 / 8.85 (brd+brq, 1+1 H), 9.1 / 9.09 (d / d, 1 H), 8.68 (dd, 1 H), 8.39 (m, 1 H), 8.2 / 8.15 (s / s, 1 H), 7.75 (dd, 1 H), 7.69 / 7.67 (d / d, 1 H), 7.34-7.16 (m, 5 H), 6.81 / 6.77 (d / d, 1 H), 4.1-0.6 (m, 16 H), 3.49 / 3.43 (m / m, 1 H), 3.23 (m, 1 H) 13< C-NMR (500 MHz, MSM-d6) δ ppm 148.9 / 148.8, 146.5, 143.4, 133.6 / 133.5, 125.4, 124, 104.8 / 104.7, 42.6 / 42.4, 41 / 40.6Preparation R3cc: 3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl] piperidin-4-yl}methyl)-7-(thiophen-2-yl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0330] Using General Procedure 5 starting from Preparation R2cc as reagent, Preparation R3cc was obtained as HCl salt. HRMS calculated for C 28 H 31 N 5 O 3 S: 517.2148; found 518.2231 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.15 / 8.7 (brd+brq, 1+1 H), 8.18 / 8.13 (s / s, 1 H), 7.62 / 7.59 (d / d, 1 H), 7.45 / 7.44 (dd, 1 H), 7.4 / 7.39 (d / d, 1 H), 7.32-7.11 (m, 5 H), 7.09 / 7.08 (dd, 1 H), 6.74 / 6.7 (d / d, 1 H), 4.89 (brs, 1 H), 4.1-0.6 (m, 16 H), 3.47 / 3.42 (m / m, 1 H), 3.21 (m, 1 H). 13< C-NMR (125 MHz, MSM-d6) δ ppm 148.9 / 148.8, 126.1, 124.6, 122.9, 119.3 / 119.2, 104.5 / 104.4, 42.6 / 42.5, 41 / 40.6.Preparation R3cd: 3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl] piperidin-4-yl}methyl)-7-(pyridin-4-yl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0331] Using General Procedure 5 starting from Preparation R2cd as reagent, Preparation R3cd was obtained. HRMS calculated for C 29 H 32 N 6 O 3 : 512.2536; found 513.2609 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.46 / 8.94 (brs+brq, 1+1 H), 9 (dm, 2 H), 8.74 (m, 2 H), 8.4 / 8.36 (s / s, 1 H), 8.05 / 8.03 (d / d, 1 H), 7.38-7.17 (m, 5 H), 6.95 / 6.92 (d / d, 1 H), 4.16-0.56 (m, 16 H), 3.5 / 3.44 (m / m, 1 H), 3.24 (m, 1 H) 13< C-NMR (500 MHz, MSM-d6) δ ppm 149.8, 144.4, 123.2 / 123.1, 117.8, 107.4 / 107.3, 42.6 / 42.4, 41.1 / 40.6Preparation R3cf: 3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl] piperidin-4-yl}methyl)-7-(thiophen-3-yl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0332] Using General Procedure 5 starting from Preparation R2cf as reagent, Preparation R3cf was obtained as HCl salt. HRMS calculated for C 28 H 31 N 5 O 3 S: 517.2148; found 518.2233 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.29 / 8.8 (brd+brq, 2 H), 8.17 / 8.12 (s, 1 H), 7.97-7.66 (m, 3 H), 7.62 / 7.6 (d, 1 H), 7.33-7.11 (m, 5 H), 6.71 / 6.67 (d, 1 H), 4.91 (brs, 1 H), 4.12-2.63 (m, 12 H), 1.94-0.63 (m, 6 H).Preparation R3cg: 3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]piperidin-4-yl}methyl)-7-(1-methyl-1H-imidazol-4-yl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0333] Using General Procedure 5 starting from Preparation R2cg as reagent, Preparation R3cg was obtained as HCl salt. HRMS calculated for C 28 H 33 N 7 O 3 : 515.2645; found 516.2728 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.3 / 8.81 (brq+brd), 8.19 / 8.14 (s, 1 H), 7.85 (brs, 1 H), 7.68 (brs, 1 H), 7.6 / 7.57 (d, 1 H), 7.33-7.11 (m, 5 H), 6.68 / 6.64 (brs, 1 H), 4.14-2.63 (brs, 12 H), 3.77 (s, 3 H), 1.95-0.63 (m, 6 H).Preparation R3ch: 3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl] piperidin-4-yl}methyl)-7-(1-methyl-1H-pyrazol-4-yl)-3H,4H,7H-pyrrolo[2,3-d] pyrimidin-4-one

[0334] Using General Procedure 5 starting from Preparation R2ch as reagent, Preparation R3ch was obtained as HCl salt. HRMS calculated for C 28 H 33 N 7 O 3 : 515.2645; found 516.2716 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.25 / 8.78 (brd+brq., 2 H), 8.3 / 8.29 (s / s, 1 H), 8.15 / 8.1 (s / s, 1 H), 7.94 / 7.92 (d / d, 1 H), 7.47 / 7.44 (d / d, 1 H), 7.33-7.11 (m, 5 H), 6.68 / 6.64 (d / d, 1 H), 4.15-0.6 (m, 16 H), 3.9 (s, 3 H), 3.48 / 3.42 (m / m, 1 H), 3.22 (m, 1 H).Preparation R3ci: 7-[1-(difluoromethyl)-1H-pyrazol-4-yl]-3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]piperidin-4-yl}methyl)-3H,4H,7H-pyrrolo[2,3-d] pyrimidin-4-one

[0335] Using General Procedure 5 starting from Preparation R2ci as reagent, Preparation R3ci was obtained. HRMS calculated for C 28 H 31 F 2 N 7 O 3 : 551.2457; found 552.254 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.2 / 8.78 (brs+brs, 2 H), 8.87 / 8.85 (d, 1 H), 8.43 / 8.41 (d, 1 H), 8.2 / 8.15 (s, 1 H), 7.92 (t, 1 H), 7.61 / 7.59 (d, 1 H), 7.34-7.13 (m, 5 H), 6.74 / 6.7 (d, 1 H), 4.91 (s, 1 H), 4.1-2.63 (m, 12 H), 1.92-0.63 (m, 6 H).Preparation R3cj: 3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl] piperidin-4-yl}methyl)-7-(pyrimidin-2-yl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0336] Using General Procedure 5 starting from Preparation R2cj as reagent, Preparation R3cj was obtained as HCl salt. HRMS calculated for C 28 H 31 N 7 O 3 : 513.2488; found 257.6326 [(M+2H) 2+< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.24 / 8.77 (brd+brq, 2 H), 8.96 / 8.95 (brd, 1 H), 8.18 / 8.13 (brs, 1 H), 7.87 / 7.79 (d, 1 H), 7.55 (t, 1 H), 7.34-7.13 (m, 5 H), 6.76 / 6.72 (d, 1 H), 4.87 (brs, 1 H), 4.13-2.61 (m, 12 H), 1.93-0.63 (m, 6 H).Preparation R3ck: 3-({4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl] piperidin-4-yl}methyl)-7-(1,3-thiazol-2-yl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one

[0337] Using General Procedure 5 starting from Preparation R2ck as reagent, Preparation R3ck was obtained as HCl salt. HRMS calculated for C 27 H 30 N 6 O 3 S: 518.2100; found 519.2181 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.3 / 8.81 (brd / brq, 2 H), 8.35 / 8.31 (s, 1 H), 7.91 / 7.89 (d, 1 H), 7.7 / 7.69 (d, 1 H), 7.65 / 7.64 (d, 1 H), 7.33-7.12 (m, 5 H), 6.81 / 6.77 (d, 1 H), 4.14-2.61 (m, 12 H), 1.95-0.6 (m, 6 H).Preparation R3cn: 3-[[4-hydroxy-1-[(3S,4S)-3-phenylpiperidine-4-carbonyl]-4-piperidyl]methyl]pyrido[3,2-d]pyrimidin-4-one

[0338] Using General Procedure 5 starting from 3H-pyrido[3,2-d]pyrimidin-4-one and tert-butyl (3S,4S)-4-(1-oxa-6-azaspiro[2.5]oct-6-ylcarbonyl)-3-phenylpiperidine-1-carboxylate (instead of Preparation R1f) as reagents, Preparation R3cn was obtained as HCl salt. HRMS calculated for C 25 H 29 N 5 O 3 : 447.227; found 448.2365 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.34 / 8.83 (brs / brd, 2 H), 8.83 (brm, 1H), 8.34 / 8.30 (s / s, 1H), 8.14 / 8.12 (d / d, 1H), 7.40-7.09 (m, 5H), aliphatic protons: 4.13-0.52 (8xCH 2 ), 3.49 / 3.42 (m, 1H), 3.21 (m, 1H). 13< C-NMR (500 MHz, MSM-d6) δ ppm 150.3 / 150.2, 149.8, 136.1, 129.3, 42.6 / 42.4, 41.0 / 40.5.Preparation R3co: 3-[[4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]-4-piperidyl]methyl]pyrido[3,2-d]pyrimidin-4-one

[0339] Using General Procedure 5 starting from 3H-pyrido[3,2-d]pyrimidin-4-one as reagent, Preparation R3co was obtained as HCl salt. HRMS calculated for C 25 H 29 N 5 O 3 : 447.227; found 448.2365 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.34, 8.83 (brs+brs, 2 H), 8.83 (brs, 1H), 8.34 / 8.30 (s / s, 1H), 8.14 / 8.12 (d / d, 1H), 7.40-7.09 (m, 5H), aliphatic protons: 4.13-0.52 (8xCH 2 ), 3.49 / 3.42 (m, 1H), 3.21 (m, 1H). 13< C-NMR (500 MHz, MSM-d6) δ ppm 150.3 / 150.2, 149.8, 136.1, 129.3, 42.6 / 42.4, 41.0 / 40.5.Preparation R3cp: 3-[[4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]-4-piperidyl]methyl]thieno[2,3-d]pyrimidin-4-one

[0340] Using General Procedure 5 starting from 3H-thieno[2,3-d]pyrimidin-4-one as reagent, Preparation R3cp was obtained as HCl salt. HRMS calculated for C 24 H 28 N 4 O 3 S: 452.1882; found 453.1933 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.23 / 8.76 (brs / brm, 2 H), 8.83 (brs, 1H), 8.26 / 8.21 (s / s, 1H), 7.61 / 7.59 (d / d, 1H), 7.43 / 7.39 (d / d, 1H) 7.34-7.15 (m, 5H) 4.93 / 4.92 (s / s, 1H) 4.04, 3.93 / 3.75 (d+d / s, 2H) 4.00-2.60 (m, 4H) 3.48 / 3.42 (m / m, 1H) 3.41-2.98 (m, 2H) 3.33-3.00 (m, 2H) 3.21 (m, 1H) 1.94-1.80 (m, 2H) 1.51-0.57 (m, 4H). 13< C-NMR (500 MHz, MSM-d6) δ ppm 124.8, 122.5 / 122.4, 47.7 / 47.2, 42.7, 42.6 / 42.5, 41.1 / 40.4, 26.6 / 26.4.Preparation R3cg: 6-chloro-3-[[4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]-4-piperidyl]methyl]pyrido[3,2-d]pyrimidin-4-one

[0341] Using General Procedure 5 starting from 6-chloro-3H-pyrido[3,2-d]pyrimidin-4-one as reagent, Preparation R3cq was obtained as HCl salt. HRMS calculated for C 25 H 28 ClN 5 O 3 : 481.1881; found 482.1949 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.13, 8.69 (brs+brm, 2H), 8.33 / 8.28 (s / s, 1H), 8.18 / 8.17 (d / d, 1H), 7.93 / 7.91 (d / d, 1H), 7.38-7.19 (m, 5H), 4.09 (brm, 1H), 4.05, 3.97 / 3.75 (d+d / s, 2H), 4.00-2.61 (m, 4H), 3.40-2.99 (brm, 4H), 3.48 / 3.40 (m / m, 1H), 3.22 (m, 1H) 1.95-1.80 (m, 2H), 1.52-0.52 (m, 4H). 13< C-NMR (125 MHz, MSM-d6) δ ppm 150.8 / 150.7, 139.9, 130.4, 42.6 / 42.5, 41.1 / 40.5.Preparation R3cr: 3-[[4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]-4-piperidyl]methyl]-6-methoxy-pyrido[3,2-d]pyrimidin-4-one andPreparation R3cs: 3-[[4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]-4-piperidyl]methyl]-5H-pyrido[3,2-d]pyrimidine-4,6-dione

[0342] Using General Procedure 5 starting from 6-methoxy-3H-pyrido[3,2-d]pyrimidin-4-one as reagent, Preparation R3cr and Preparation R3cs (byproduct) were obtained as HCl salt and separated by chromatography.

[0343] Preparation R3cr: HRMS calculated for C 26 H 31 N 5 O 4 : 477.2376; found 478.2458 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.17, 8.72 (brs+brm, 2H) 8.22 / 8.17 (s / s, 1H) 8.02 / 8.00 (d / d, 1H), 7.35-7.15 (m, 5H), 7.31 / 7.29 (d / d, 1H), 4.06, 3.93 / 3.77, 3.74 (d+d / d+d, 2H), 4.00-2.60 (m, 4H), 3.99 / 3.96 (s / s, 3H), 3.48 / 3.42 (m, 1H), 3.34-2.98 (m, 4H), 3.21 (m, 1H), 1.94-1.80 (m, 2H), 1.52-0.57 (m, 4H). 13< C-NMR (125 MHz, MSM-d6) δ ppm 148.2 / 148.1, 139.5, 119.1, 54.2, 42.6 / 42.4, 41.1 / 40.5.

[0344] Preparation R3cs: HRMS calculated for C 25 H 29 N 5 O 4 : 463.222; found 464.2312 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 11.67 (vbrs, 1H), 9.11, 8.68 (brs+brs, 2H), 8.08 / 8.04 (s / s, 1H), 7.75 / 7.73 (d / d, 1H), 6.83 / 6.81 (d / d, 1H), 7.36-7.18 (m, 5H), 4.89 (vbrs, 1H), 4.00-2-60 (m, 4H), 3.99, 3.93 / 3.74, 3.70 (d+d / d+d, 2H), 3.48 / 3.41 (m, 1H), 3.34-3.01 (m, 4H), 3.20 (m, 1H), 1.92-1.80 (m, 2H), 1.51-0.48 (m, 4H). 13< C-NMR (125 MHz, MSM-d6) δ ppm 146.2 / 146.1, 140.3, 129.4, 42.6 / 42.5, 41.0 / 40.6.Preparation R3ct: 6-(benzylamino)-3-[[4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]-4-piperidyl]methyl]pyrido[3,2-d]pyrimidin-4-one

[0345] Using General Procedure 5 starting from 6-chloro-3H-pyrido[3,2-d]pyrimidin-4-one as reagent without the deprotection step, the resulted crude Boc-protected compound (0.76 mmol) and K 2 CO 3 (1.51 mmol) were stirred in benzylamine (5 ml) at 120 °C for 17 hours. The reaction mixture was purified by preparative LC (on C-18 Gemini-NX 5µm column, 5 mM aqueous NH 4 HCO 3 -MeCN, gradient).

[0346] The resulted crude product (187 mg, 0.283 mmol) was stirred in aqueous HC1 solution (1 N, 3 ml, 3 mmol) and PDO (3 ml) at 70 °C for 2 hours. The reaction mixture was purified by preparative LC (on C-18 Gemini-NX 5µm column, 5 mM aqueous NH 4 HCO 3 -MeCN, gradient) to give Preparation R3ct as HC1 salt. HRMS calculated for C 32 H 36 N 6 O 3 : 552.2849; found 277.1497 [(M+2H) 2+< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.37 / 8.86 (m / m, 2 H), 8.31-7.12 (m, aromatic protons, 13 H), 4.78-0,49 (m, aliphatic protons, 20 H).Preparation R3cu: 3-[[4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]-4-piperidyl]methyl]-6-[(4-methoxyphenyl)methylamino]pyrido[3,2-d]pyrimidin-4-one

[0347] Using General Procedure 5 starting from 6-chloro-3H-pyrido[3,2-d]pyrimidin-4-one as reagent without the deprotection step, the resulted crude Boc-protected compound (0.76 mmol) and K 2 CO 3 (1.51 mmol) were stirred in benzylamine (5 ml) at 120 °C for 17 hours. The reaction mixture was purified by preparative LC (on C-18 Gemini-NX 5µm column, 5 mM aqueous NH 4 HCO 3 -MeCN, gradient).

[0348] The resulted crude product (187 mg, 0.283 mmol) was stirred in aqueous HCl solution (1 N, 3 ml, 3 mmol) and PDO (3 ml) at 70 °C for 2 hours. The reaction mixture was purified by preparative LC (on C-18 Gemini-NX 5µm column, 5 mM aqueous NH 4 HCO 3 -MeCN, gradient) to give Preparation R3cu as HCl salt. HRMS calculated for C 33 H 38 N 6 O 4 : 582.2955; found 292.1552 [(M+2H) 2+< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.33 / 8.83 (brt / brd, 2 H), 8.23 / 8.18 (s / s, 1 H), 7.91 (vbrs, 1 H), 7.35-7.15 (m, 5 H), 7.34 (d / d, 2 H), 7.27 (brm, 1 H), 6.92 / 6.91 (d / d, 2 H), 4.62 / 4.59 (s / s, 2 H), 4.08-0.54 (m, aliphatic protons, 8 H), 3.73 (s, 3 H), 3.48 / 3.42 (m / m, 1 H), 3.21 (m, 1 H).Preparation R3cv: 6-[[4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]-4-piperidyl]methyl]-3-phenyl-triazolo[4,5-d]pyrimidin-7-one

[0349] Using General Procedure 5 starting from 3-phenyl-6H-triazolo[4,5-d]pyrimidin-7-one as reagent, Preparation R3cv was obtained as HCl salt. HRMS calculated for C 28 H 31 N 7 O 3 : 513.2488; found 514.2576 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.28 / 8.79 (brd+brq, 2 H), 8.5 / 8.47 (s, 1 H), 8.06-7.54 (m, 5 H), 7.4-7.19 (m, 5 H), 4.98 / 4.96 (brs, 1 H), 4.17-2.6 (m, 12 H), 1.96-0.53 (m, 6 H).Preparation R3cw: 1-[[4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]-4-piperidyl]methyl]-9-phenyl-purin-6-one

[0350] Using General Procedure 5 starting from 9-phenyl-1H-purin-6-one as reagent, Preparation R3cw was obtained as HCl salt. HRMS calculated for C 29 H 32 N 6 O 3 : 512.2536; found 513.2616 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.25 / 8.77 (brd+brq, 2 H), 8.52 / 8.5 (s, 1 H), 8.28 / 8.23 (s, 1 H), 7.82-7.46 (m, 5 H), 7.37-7.18 (s, 5 H), 4.91 (brs, 1 H), 4.14-2.63 (m, 12 H), 1.96-0.58 (m, 6 H).Preparation R3cx: 5-[[4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]-4-piperidyl]methyl]-1-phenyl-pyrazolo[3,4-d]pyrimidin-4-one

[0351] Using General Procedure 5 starting from 1-phenyl-5H-pyrazolo[3,4-d]pyrimidin-4-one as reagent, Preparation R3cx was obtained as HCl salt. HRMS calculated for C 29 H 32 N 6 O 3 : 512.2536; found 513.2627 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.22 / 8.76 (brs+brs, 2 H), 8.39 / 8.36 (s, 1 H), 8.34 / 8.3 (s, 1 H), 8.09-7.38 (m, 5 H), 7.36-7.16 (m, 5 H), 4.94 / 4.93 (s, 1 H), 4.12-2.59 (m, 12 H), 1.95-0.58 (m, 6 H).Preparation R3cy: 7-bromo-3-[[4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]-4-piperidyl]methyl]pyrrolo[2,1-f][1,2,4]triazin-4-one

[0352] Using General Procedure 5 starting from 7-bromo-3H-pyrrolo[2,1-f[1,2,4]triazin-4-one as reagent, Preparation R3cy was obtained as HCl salt. HRMS calculated for C 24 H 28 BrN 5 O 3 : 513.1376; found 514.1462 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.25 / 8.77 (brs+brs, 2 H), 8.03 / 8 (s, 1 H), 7.33-7.1 (m, 5 H), 7.03 / 6.99 / 6.77 / 6.75 (d, 2 H), 4.93 / 4.91 (s, 1 H), 4.02-2.61 (m, 12 H), 1.94-0.5 (m, 6 H). 13< C-NMR (125 MHz, MSM-d6) δ ppm 154, 120.9, 102.9.Preparation R3cz: 6-[[4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]-4-piperidyl]methyl]-3-phenyl-isothiazolo[4,5-d]pyrimidin-7-one

[0353] Using General Procedure 5 starting from 3-phenyl-6H-isothiazolo[4,5-d]pyrimidin-7-one as reagent, Preparation R3cz was obtained as HCl salt. HRMS calculated for C 29 H 31 N 5 O 3 S: 529.2148; found 530.2223 [(M+H) +< form]. 1< H-NMR (400 MHz, MSM-d6) δ ppm 9.37 / 8.86 (brs+brs, 2 H), 8.49 / 8.46 (s, 1 H), 8.43 (m, 2 H), 7.62-7.5 (m, 3 H), 7.39-7.13 (m, 5 H), 5.06 / 5.03 (s, 1 H), 4.2-2.6 (m, 12 H), 1.98-0.52 (m, 6 H).Preparation R3da: 3-[[4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]-4-piperidyl]methyl]-7-phenyl-thieno[3,4-d]pyrimidin-4-one

[0354] Using General Procedure 5 starting from 7-chloro-3H-thieno[3,4-d]pyrimidin-4-one as reagent, without the deprotection step, the resulted Boc-protected compound reacted with phenylboronic acid using General Procedure 9. The resulted phenylated crude product was deprotected according to Step 2 of General Procedure 5 to give Preparation R3da as HCl salt. HRMS calculated for C 30 H 32 N 4 O 3 S: 528.2195; found 529.2265 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.14 / 8.7 (brq+brd, 2 H), 8.51 / 8.47 (s, 1 H), 8.05 / 8.04 (m, 2 H), 8.03 / 7.98 (s, 1 H), 7.52-7.33 (m, 3 H), 7.32-7.1 (m, 5 H), 4.9 / 4.88 (s, 1 H), 4.02-2.61 (m, 12 H), 1.93-0.58 (m, 6 H). 13< C-NMR (125 MHz, MSM-d6) δ ppm 158, 143.5, 134, 127.4.Preparation R3db: 3-[[4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]-4-piperidyl]methyl]-7-phenyl-5H-pyrrolo[3,2-d]pyrimidin-4-one

[0355] sing General Procedure 5 starting from 7-phenyl-3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one as reagent, Preparation R3db was obtained as HCl salt. HRMS calculated for C 30 H 33 N 5 O 3 : 511.2583; found 512.2647 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 12.35 / 12.3 (d, 1 H), 9.26 / 8.79 (brs+brs, 2 H), 8.1 / 8.05 (s, 1 H), 8.1 / 8.08 (m, 2 H), 7.92 / 7.9 (d, 1 H), 7.43-7.08 (m, 8 H), 4.92 / 4.91 (s, 1 H), 4.07-2.62 (m, 12 H), 1.97-0.63 (m, 6 H).Preparation R3dc: 7-chloro-3-[[4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]-4-piperidyl]methyl]thieno[3,4-d]pyrimidin-4-one

[0356] Using General Procedure 5 starting from 7-chloro-3H-thieno[3,4-d]pyrimidin-4-one as reagent, Preparation R3dc was obtained as HCl salt. HRMS calculated for C 24 H 27 C1N 4 O 3 S: 486.1492; found 487.1544 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.16 / 8.71 (brd+brq, 2 H), 8.44 / 8.4 (s, 1 H), 8.01 / 7.96 (s, 1 H), 7.34-7.15 (m, 5 H), 4.87 / 4.85 (s, 1 H), 4-2.59 (m, 12 H), 1.93-0.52 (m, 6 H).Preparation R3dd: 6-[[4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]-4-piperidyl]methyl]-3-phenyl-isoxazolo[4,5-d]pyrimidin-7-one

[0357] Using General Procedure 5 starting from 3-phenyl-6H-isoxazolo[4,5-d]pyrimidin-7-one as reagent, Preparation R3dd was obtained as HCl salt. HRMS calculated for C 29 H 31 N s O 4 : 513.2376; found 514.2451 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.13 / 8.76 (brs+brs, 2 H), 8.44 / 8.4 (s, 1 H), 8.33-8.26 (m, 2 H), 7.67-7.59 (m, 3 H), 7.39-7.18 (m, 5 H), 4.99 / 4.97 (s, 1 H), 4.19-2.62 (m, 12 H), 1.95-0.52 (m, 6 H).Preparation R3de: 5-[[4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]-4-piperidyl]methyl]-1-(4-methoxyphenyl)pyrazolo[3,4-d]pyrimidin-4-one

[0358] Using General Procedure 5 starting from 1-(4-methoxyphenyl)-5H-pyrazolo[3,4-d] pyrimidin-4-one as reagent, Preparation R3de was obtained as HCl salt. HRMS calculated for C 30 H 34 N 6 O 4 : 542.2642; found 543.2711 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ ppm 9.11 / 8.69 (brs+brm, 2 H), 8.34 / 8.3 (s / s, 1 H), 8.29 / 8.25 (s / s, 1 H), 7.9 / 7.86 (dm / dm, 2 H), 7.37-7.16 (m, 5 H), 7.13 / 7.12 (m / m, 2 H), 4.91 (brs, 1 H), 4.13-0.53 (m, 16 H), 3.81 (s, 3 H), 3.48 / 3.42 (m / m, 1 H), 3.22 (m, 1 H). 13< C-NMR (125 MHz, MSM-d6) δ ppm 152.6 / 152.5, 136.3 / 136.2, 123.8, 114.9 / 114.8, 55.9, 42.6 / 42.5, 41.1 / 40.5.Preparation R3df: 1-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-[[4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]-4-piperidyl]methyl]pyrazolo[3,4-d]pyrimidin-4-one

[0359] Using General Procedure 5 starting from 1-(2,3-dihydro-1,4-benzodioxin-6-yl)-5H-pyrazolo[3,4-d]pyrimidin-4-one as reagent, Preparation R3df was obtained as HCl salt. HRMS calculated for C 31 H 34 N 6 O 5 : 570.2591; found 571.2663 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ ppm 9.16 / 8.74 (brs+brs, 2 H), 8.3 / 8.26 (s, 1 H), 8.29 / 8.23 (s, 1 H), 7.53 / 7.52 (d, 1 H), 7.48 / 7.47 (dd, 1 H), 7.36-7.15 (m, 5 H), 7.04 (d, 1 H), 4.92 / 4.9 (s, 1 H), 4.35-4.26 (m, 4 H), 4.1-2.6 (m, 12 H), 1.94-0.58 (m, 6 H).Preparation R3dg: 6-chloro-7-(4-chloro-3-fluoro-phenyl)-3-[[4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]-4-piperidyl]methyl]pyrrolo[2,3-d]pyrimidin-4-one

[0360] Using General Procedure 5 starting from Preparation R2ah as reagent, Preparation R3dg was obtained as HCl salt. HRMS calculated for C 30 H 30 N 5 O 3 FCl 2 : 597.171; found 598.1772 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ ppm 8.07 / 8.03 (s, 1 H), 7.85 (t, 1 H), 7.75 (dd, 1 H), 7.41 (dd, 1 H), 7.3-7.09 (m, 5 H), 6.87 / 6.84 (s, 1 H), 4.81 / 4.79 (s, 1 H), 4.06-2.51 (m, 12 H), 1.68-0.74 (m, 6 H).Preparation R3dh: 3-[[4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]-4-piperidyl]methyl]-6-methyl-7-phenyl-pyrrolo[2,3-d]pyrimidin-4-one

[0361] Using General Procedure 5 starting from Preparation R2de as reagent, Preparation R3dh was obtained as HCl salt. HRMS calculated for C 31 H 35 N 5 O 3 : 525.274; found 526.2827 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ ppm 9.14 / 8.69 (brs+brs, 2 H), 7.95 / 7.9 (s, 1 H), 7.61-7.37 (m, 5 H), 7.36-7.15 (m, 5 H), 6.45 / 6.42 (q, 1 H), 4.84 / 4.83 (s, 1 H), 4.06-2.61 (m, 12 H), 2.19 / 2.17 (d, 3 H), 1.95-0.6 (m, 6 H).Preparation R3di: 3-[[4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]-4-piperidyl]methyl]-9-methyl-pyrimido[4,5-b]indol-4-one

[0362] Using General Procedure 5 starting from Preparation R2df as reagent, Preparation R3di was obtained as HCl salt. HRMS calculated for C 29 H 33 N 5 O 3 : 499.2583; found 500.2677 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ ppm 9.19 / 8.74 (brq+brd, 2 H), 8.38 / 8.33 (s, 1 H), 8.07 / 8.02 (dm, 1 H), 7.66 / 7.65 (dm, 1 H), 7.43 / 7.42 (m, 1 H), 7.37-7.12 (m, 5 H), 7.32 (m, 1 H), 4.9 (brs, 1 H), 4.21-2.62 (m, 12 H), 3.87 / 3.86 (s, 3 H), 1.95-0.64 (m, 6 H). 13< C-NMR (125 MHz, MSM-d6) δ ppm 158, 152.7, 137.2, 122, 99.Preparation R3dj: 3-[(4-hydroxy-1-{[(3R,4R)-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-6,8-dimethylpyrimido[5,4-b]indolizin-4(3H)-one

[0363] Using General Procedure 5 starting from Preparation R2dg as reagent, Preparation R3dj was obtained as HCl salt. HRMS calculated for C 29 H 34 N 6 O 3 : 514.2692; found 515.2757 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6): δ ppm 9.25 / 8.77 (brq+brd, 2 H), 8.18 / 8.13 (s, 1 H), 7.34-7.1 (m, 5 H), 6.94 / 6.9 (s, 1 H), 6.71 / 6.7 (q, 1 H), 4.9 (brs, 1 H), 4.13-2.6 (m, 12 H), 2.47 / 2.45 (d, 3 H), 2.45 / 2.44 (s, 3 H), 1.95-0.62 (m, 6 H). 13< C-NMR (125 MHz, MSM-d6) δ ppm 159.3, 152.6, 140.4, 139, 127.9, 115.4, 108.8, 91.4.Preparation R3dk: 6-chloro-3-[[4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]-4-piperidyl]methyl]-7-phenyl-pyrrolo[2,3-d]pyrimidin-4-one

[0364] Using General Procedure 5 starting from Preparation R2dh as reagent, Preparation R3dk was obtained as HCl salt. HRMS calculated for C 30 H 32 ClN 5 O 3 : 545.2194; found 546.2277 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 9.15 / 8.71 (brd+brq, 2 H), 8.05 / 8 (s, 1 H), 7.64-7.41 (m, 5 H), 7.37-7.18 (m, 5 H), 6.83 / 6.8 (s, 1 H), 4.85 (s, 1 H), 4.07-2.61 (m, 12 H), 1.94-0.61 (m, 6 H).Preparation R3dl: 3-[[4-hydroxy-1-[(3R,4R)-3-phenylpiperidine-4-carbonyl]-4-piperidyl]methyl]-6-iodo-7-methyl-pyrrolo[2,3-d]pyrimidin-4-one

[0365] Using General Procedure 5 starting from Preparation R2di as reagent, Preparation R3dl was obtained as HCl salt. HRMS calculated for C 25 H 30 IN 5 O 3 : 575.1393; found 576.1455 [(M+H) +< form]. 1< H-NMR (500 MHz, MSM-d6) δ ppm 8.02 / 7.97 (s / s, 1 H), 7.28-7.02 (m, 5 H), 6.84 / 6.83 (s / s, 1 H), 4.16-0.65 (m, 16 H), 3.65 / 3.64 (s / s, 3 H), 3.21 / 3.16 (m / m, 1 H), 2.88 (m, 1 H) 13< C-NMR (125 MHz, MSM-d6) δ ppm 147.9 / 147.8, 111.7 / 111.6, 80.7 / 80.6, 46.2, 43.2 / 42.8, 33.1Preparation R3dm: 3-[[3,3-difluoro-4-hydroxy-1-[trans-3-phenylpiperidine-4-carbonyl]-4-piperidyl]methyl]-7-phenyl-pyrrolo[2,3-d]pyrimidin-4-one

[0366] Trimethyl-sulfoxonium iodide (1.11 g, 5 mmol) was dissolved in abs. MSM (10 ml) then sodium-hydride dispersion (60 % in mineral oil, 200 mg, 5 mmol) was added sequentially and stirred for 20 minutes at r.t. tert-butyl 3,3-difluoro-4-oxo-piperidine-1-carboxylate (783 mg, 3.33 mmol) solution in MSM (5 ml, abs.) was added to the mixture and stirred for 15 hours at r.t. The reaction mixture was poured into ice-water mixture (40 ml) and extracted with DEE (4 x 15 ml). The combined organic layer was washed with water, brine, then dried over MgSO 4 and evaporated.

[0367] The raw epoxide product was reacted with Preparation R2bu according to General Procedure 5.

[0368] The resulted raw HCl salt was reacted with trans-1-tert-butoxycarbonyl-3-phenylpiperidine-4-carboxylic acid using General Procedure 7.

[0369] The raw product was deprotected according to Step 2 of General Procedure 5 to give Preparation R3dm. HRMS calculated for C 30 H 31 F 2 N 5 O 3 : 547.2394; found 548.2454 and 548.2490 (two diastereomers) [(M+H) +< form]. 1< H NMR (500 MHz, MSM-d 6 ): δ ppm 9.24 / 8.82 (m+m, 2 H), 8.19-8.09 (4*s, 1 H), 7.71 (m, 2 H), 7.6-7.5 (4*d, 1 H), 7.56 (m, 2 H), 7.42 (m, 1 H), 7.34-7.16 (m, 5 H), 6.79-6.67 (4*d, 1 H), 6.08 (brs, 1 H), 4.74-2.35 (m, 12 H), 2.06-1.1 (m, 4 H)Preparation R3dn: 3-[[3,3-difluoro-4-hydroxy-1 -[trans-3-phenylpiperidine-4-carbonyl]-4-piperidyl]methyl]-7-(4-methoxyphenyl)pyrrolo[2,3-d]pyrimidin-4-one

[0370] Trimethyl-sulfoxonium iodide (1.11 g, 5 mmol) was dissolved in abs. MSM (10 ml) then sodium-hydride dispersion (60 % in mineral oil, 200 mg, 5 mmol) was added sequentially and stirred for 20 minutes at r.t. tert-butyl 3,3-difluoro-4-oxo-piperidine-1-carboxylate (783 mg, 3.33 mmol) solution in MSM (5 ml, abs.) was added to the mixture and stirred for 15 hours at r.t. The reaction mixture was poured into ice-water mixture (40 ml) and extracted with DEE (4 x 15 ml). The combined organic layer was washed with water, brine, then dried over MgSO 4 and evaporated.

[0371] The raw epoxide product was reacted with Preparation R2ax according to General Procedure 5.

[0372] The resulted raw HCl salt was reacted with trans-1-tert-butoxycarbonyl-3-phenylpiperidine-4-carboxylic acid according to General Procedure 7.

[0373] The raw product was deprotected according to Step 2 of General Procedure 5 to give Preparation R3dn. HRMS calculated for C 31 H 33 F 2 N 5 O 4 : 577.2501; found 578.2547 and 578.2572 (two diastereomers) [(M+H) +< form]. 1< H NMR (500 MHz, MSM-d 6 ): δ ppm 9.13 / 8.74 (m+m, 2 H), 8.16-8.05 (4*s, 1 H), 7.63-7.54 (m, 2 H), 7.48-7.41 (4*d, 1 H), 7.36-7.16 (m, 5 H), 7.14-7.06 (m, 2 H), 6.74-6.63 (4*d, 1 H), 6.17-5.95 (brs, 1 H), 4.69-2.77 (m, 12 H), 3.82 / 3.81 (s, 3 H), 2.05-1.15 (m, 4 H)EXAMPLES

[0374] The following Examples illustrate the invention but do not limit it in any way.▪ 3-[(1-{[(3S,4S)-1-benzyl-3-phenylpiperidin-4-yl]carbonyl}-4-hydroxypiperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 1)

[0375] Using General Procedure 6 starting from 3-[(4-hydroxy-1-{[(3S,4S)-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (which was obtained according to General Procedure 5 with tert-butyl (3S,4S)-4-(2-oxa-6-azaspiro[2.5]octane-6-carbonyl)-3-phenyl-piperidine-1-carboxylate and 3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one) and benzyl bromide as reagents, EXAMPLE 1 was obtained. HRMS calculated for C 31 H 35 N 5 O 3 : 525.2739; found 526.2815 [(M+H) +< form].▪ 7-(2-chlorobenzyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 2)

[0376] Using General Procedure 6 starting from Preparation R3aa and Preparation R1c as reagents, EXAMPLE 2 was obtained. HRMS calculated for C 41 H 42 ClN 7 O 3 S: 747.2758; found 374.6457 [(M+2H) 2+< form].▪ 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(3,4,5-trimethoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 3)

[0377] Using General Procedure 6 starting from Preparation R3ac and Preparation R1c as reagents, EXAMPLE 3 was obtained. HRMS calculated for C 43 H 47 N 7 O 6 S: 789.3309; found 395.6734 [(M+2H) 2+< form].▪ 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methy1}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(3,4,5-trimethoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 4)

[0378] Using General Procedure 6 starting from Preparation R3ac and 5-(chloromethyl)-2-(6-methoxy-3-pyridyl)thiazole as reagents, EXAMPLE 4 was obtained. HRMS calculated for C 43 H 47 N 7 O 7 S: 805.3257; found 403.6694 [(M+2H) 2+< form].▪ 7-(3,5-dichlorophenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 5)

[0379] Using General Procedure 6 starting from Preparation R3ad and Preparation R1c as reagents, EXAMPLE 5 was obtained. HRMS calculated for C 40 H 39 N 7 O 3 SCl 2 : 767.2212; found 768.2251 [(M+H) +< form].▪ 7-(3,5-dichlorophenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 6)

[0380] Using General Procedure 6 starting from Preparation R3ad and 5-(chloromethyl)-2-(6-methoxy-3-pyridyl)thiazole as reagents, EXAMPLE 6 was obtained. HRMS calculated for C 40 H 39 N 7 O 4 SCl 2 : 783.2161; found 784.2235 [(M+H) +< form].▪ 7-(3-chloro-5-methoxyphenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 7)

[0381] Using General Procedure 6 starting from Preparation R3ae and Preparation R1c as reagents, EXAMPLE 7 was obtained. HRMS calculated for C 41 H 42 ClN 7 O 4 S: 763.2708; found 764.2766 [(M+H) +< form].▪ 7-(3-chloro-5-methoxyphenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 8)

[0382] Using General Procedure 6 starting from Preparation R3ae and 5-(chloromethyl)-2-(6-methoxy-3-pyridyl)thiazole as reagents, EXAMPLE 8 was obtained. HRMS calculated for C 41 H 42 ClN 7 O 5 S: 779.2657; found 780.2734 [(M+H) +< form].▪ 7-(3,5-dimethoxyphenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 9)

[0383] Using General Procedure 6 starting from Preparation R3af and Preparation R1c as reagents, EXAMPLE 9 was obtained. HRMS calculated for C 42 H 45 N 7 O 5 S: 759.3203; found 760.3244 [(M+H) +< form].▪ 7-(3,5-dimethoxyphenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 10)

[0384] Using General Procedure 6 starting from Preparation R3af and 5-(chloromethyl)-2-(6-methoxy-3-pyridyl)thiazole as reagents, EXAMPLE 10 was obtained. HRMS calculated for C 42 H 45 N 7 O 6 S: 775.3152; found 776.32 [(M+H) +< form].▪ 7-(4-chloro-3-fluorophenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 11)

[0385] Using General Procedure 6 starting from Preparation R3ah and Preparation R1c as reagents, EXAMPLE 11 was obtained. HRMS calculated for C 40 H 39 ClFN 7 O 3 S: 751.2508; found 752.2564 [(M+H) +< form].▪ 7-(4-chloro-3-fluorophenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 12)

[0386] Using General Procedure 6 starting from Preparation R3ah and 5-(chloromethyl)-2-(6-methoxy-3-pyridyl)thiazole as reagents, EXAMPLE 12 was obtained. HRMS calculated for C 40 H 39 ClFN 7 O 4 S: 767.2457; found 768.2552 [(M+H) +< form].▪ 7-(4-chloro-3-methoxyphenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 13)

[0387] Using General Procedure 6 starting from Preparation R3ai and Preparation R1c as reagents, EXAMPLE 13 was obtained. HRMS calculated for C 41 H 42 ClN 7 O 4 S: 763.2708; found 764.2792 [(M+H) +< form].▪ 7-(4-chloro-3-methoxyphenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 14)

[0388] Using General Procedure 6 starting from Preparation R3ai and 5-(chloromethyl)-2-(6-methoxy-3-pyridyl)thiazole as reagents, EXAMPLE 14 was obtained. HRMS calculated for C 41 H 42 ClN 7 O 5 S: 779.2657; found 780.2729 [(M+H) +< form].▪ 7-(4-fluoro-3-methoxyphenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 15)

[0389] Using General Procedure 6 starting from Preparation R3aj and Preparation R1c as reagents, EXAMPLE 15 was obtained. HRMS calculated for C 41 H 42 FN 7 O 4 S: 747.3003; found 748.3047 [(M+H) +< form].▪ 7-(4-fluoro-3-methoxyphenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 16)

[0390] Using General Procedure 6 starting from Preparation R3aj and 5-(chloromethyl)-2-(6-methoxy-3-pyridyl)thiazole as reagents, EXAMPLE 16 was obtained. HRMS calculated for C 41 H 42 FN 7 O 5 S: 763.2952; found 764.3029 [(M+H) +< form].▪ 7-(3,4-dimethoxyphenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 17)

[0391] Using General Procedure 6 starting from Preparation R3ak and Preparation R1c as reagents, EXAMPLE 17 was obtained. HRMS calculated for C 42 H 45 N 7 O 5 S: 759.3203; found 380.6691 [(M+2H) 2+< form].▪ 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(4-methylphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 18)

[0392] Using General Procedure 6 starting from Preparation R3am and 5-(chloromethyl)-2-(6-methoxy-3-pyridyl)thiazole as reagents, EXAMPLE 18 was obtained. HRMS calculated for C 41 H 43 N 7 O 4 S: 729.3096; found 730.3162 [(M+H) +< form].▪ 4-{3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl}benzonitrile (EXAMPLE 19)

[0393] Using General Procedure 6 starting from Preparation R3an and Preparation R1c as reagents, EXAMPLE 19 was obtained. HRMS calculated for C 41 H 40 N 8 O 3 S: 724.2944; found 725.3009 [(M+H) +< form].▪ 4-{3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl}benzonitrile (EXAMPLE 20)

[0394] Using General Procedure 6 starting from Preparation R3an and 5-(chloromethyl)-2-(6-methoxy-3-pyridyl)thiazole as reagents, EXAMPLE 20 was obtained. HRMS calculated for C 41 H 40 N 8 O 4 S: 740.2893; found 741.2984 [(M+H) +< form].▪ 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-[4-(trifluoromethyl)phenyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 21)

[0395] Using General Procedure 6 starting from Preparation R3ao and Preparation R1c as reagents, EXAMPLE 21 was obtained. HRMS calculated for C 41 H 40 N 7 O 3 F 3 S: 767.2866; found 768.2899 [(M+H) +< form].▪ 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-[4-(trifluoromethyl)phenyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 22)

[0396] Using General Procedure 6 starting from Preparation R3ao and 5-(chloromethyl)-2-(6-methoxy-3-pyridyl)thiazole as reagents, EXAMPLE 22 was obtained. HRMS calculated for C 41 H 40 F 3 N 7 O 4 S: 783.2814; found 784.2887 [(M+H) +< form].▪ 7-[4-(difluoromethyl)phenyl]-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 23)

[0397] Using General Procedure 6 starting from Preparation R3ap and Preparation R1c as reagents, EXAMPLE 23 was obtained. HRMS calculated for C 41 H 41 F 2 N 7 O 3 S: 749.2959; found 750.3017 [(M+H) +< form].▪ 7-[4-(difluoromethyl)phenyl]-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 24)

[0398] Using General Procedure 6 starting from Preparation R3ap and 5-(chloromethyl)-2-(6-methoxy-3-pyridyl)thiazole as reagents, EXAMPLE 24 was obtained. HRMS calculated for C 41 H 41 F 2 N 7 O 4 S: 765.2909; found 766.297 [(M+H) +< form].▪ 7-[4-(hydroxymethyl)phenyl]-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 25)

[0399] Using General Procedure 6 starting from Preparation R3aq and Preparation R1c as reagents, EXAMPLE 25 was obtained. HRMS calculated for C 41 H 43 N 7 O 4 S: 729.3097; found 730.3137 [(M+H) +< form].▪ 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-[4-(hydroxymethyl)phenyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 26)

[0400] Using General Procedure 6 starting from Preparation R3aq and 5-(chloromethyl)-2-(6-methoxy-3-pyridyl)thiazole as reagents, EXAMPLE 26 was obtained. HRMS calculated for C 41 H 43 N 7 O 5 S: 745.3046; found 746.3142 [(M+H) +< form].▪ 7-(4-chlorophenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 27)

[0401] Using General Procedure 6 starting from Preparation R3ar and 5-(chloromethyl)-2-(6-methoxy-3-pyridyl)thiazole as reagents, EXAMPLE 27 was obtained. HRMS calculated for C 40 H 40 ClN 7 O 4 S: 749.2551; found 750.2639 [(M+H) +< form].▪ 3-{[1-({(3R,4R)-1-[(2-bromo-1,3-thiazol-5-yl)methyl]-3-phenylpiperidin-4-yl}carbonyl)-4-hydroxypiperidin-4-yl]methyl}-7-(4-chlorophenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 28)

[0402] Using General Procedure 6 starting from Preparation R3ar and 2-bromo-5-(bromomethyl)thiazole as reagents, EXAMPLE 28 was obtained. HRMS calculated for C 34 H 34 BrClN 6 O 3 S: 720.1285; found 721.1355 [(M+H) +< form].▪ 7-(4-fluorophenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 29)

[0403] Using General Procedure 6 starting from Preparation R3as and Preparation R1c as reagents, EXAMPLE 29 was obtained. HRMS calculated for C 40 H 40 N 7 O 3 FS: 717.2897; found 718.2982 [(M+H) +< form].▪ 7-(4-fluorophenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 30)

[0404] Using General Procedure 6 starting from Preparation R3as and 5-(chloromethyl)-2-(6-methoxy-3-pyridyl)thiazole as reagents, EXAMPLE 30 was obtained. HRMS calculated for C 40 H 40 FN 7 O 4 S: 733.2847; found 734.2907 [(M+H) +< form].▪ 3-{[1-({(3R,4R)-1-[(2-bromo-1,3-thiazol-5-yl)methyl]-3-phenylpiperidin-4-yl}carbonyl)-4-hydroxypiperidin-4-yl]methyl}-7-(4-fluorophenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 31)

[0405] Using General Procedure 6 starting from Preparation R3as and 2-bromo-5-(bromomethyl)thiazole as reagents, EXAMPLE 31 was obtained. HRMS calculated for C 34 H 34 BrFN 6 O 3 S: 704.1580; found 705.1642 [(M+H) +< form].▪ 7-[4-(dimethylamino)phenyl]-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 32)

[0406] Using General Procedure 6 starting from Preparation R3at and Preparation R1c as reagents, EXAMPLE 32 was obtained. HRMS calculated for C 42 H 46 N 8 O 3 S: 742.3414; found 743.3467 [(M+H) +< form].▪ 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 33)

[0407] Using General Procedure 6 starting from Preparation R3ax and 5-(chloromethyl)-2-(6-methoxy-3-pyridyl)thiazole as reagents, EXAMPLE 33 was obtained. HRMS calculated for C 41 H 43 N 7 O 5 S: 745.3047; found 746.3124 [(M+H) +< form].▪ 3-{[1-({(3R,4R)-1-[(2-bromo-1,3-thiazol-5-yl)methyl]-3-phenylpiperidin-4-yl}carbonyl)-4-hydroxypiperidin-4-yl]methyl}-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 34)

[0408] Using General Procedure 6 starting from Preparation R3ax and 2-bromo-5-(bromomethyl)thiazole as reagents, EXAMPLE 34 was obtained. HRMS calculated for C 35 H 37 BrN 6 O 4 S: 716.1780396; found 717.1836 [(M+H) +< form].▪ 3-{[4-hydroxy-1-({(3R,4R)-1-[(1-methyl-1H-pyrazol-4-yl)methyl]-3-phenylpiperidin-4-yl}carbonyl)piperidin-4-yl]methyl}-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 35)

[0409] Using General Procedure 6 starting from Preparation R3ax and 4-(chloromethyl)-1-methyl-pyrazole as reagents, EXAMPLE 35 was obtained. HRMS calculated for C 36 H 41 N 7 O 4 : 635.3220; found 636.3291 [(M+H) +< form].▪ 3-[(4-hydroxy-1-{[(3R,4R)-3-phenyl-1-(pyrazin-2-ylmethyl)piperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 36)

[0410] Using General Procedure 6 starting from Preparation R3ax and 2-(chloromethyl)pyrazine hydrochloride as reagents, EXAMPLE 36 was obtained. HRMS calculated for C 36 H 39 N 7 O 4 : 633.3063; found 634.3114 [(M+H) +< form].▪ 3-{[4-hydroxy-1-({(3R,4R)-1-[(5-methyl-1,3-thiazol-2-yl)methyl]-3-phenylpiperidin-4-yl}carbonyl)piperidin-4-yl]methyl}-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 37)

[0411] Using General Procedure 6 starting from Preparation R3ax and 2-(chloromethyl)-5-methyl-thiazole as reagents, EXAMPLE 37 was obtained. HRMS calculated for C 36 H 40 N 6 O 4 S: 652.2832031; found 653.2891 [(M+H) +< form].▪ 3-{[1-({(3R,4R)-1-[(5-bromopyridin-3-yl)methyl]-3-phenylpiperidin-4-yl}carbonyl)-4-hydroxypiperidin-4-yl]methyl}-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 38)

[0412] Using General Procedure 6 starting from Preparation R3ax and 3-bromo-5-(chloromethyl)pyridine as reagents, EXAMPLE 38 was obtained. HRMS calculated for C 37 H 39 BrN 6 O 4 : 710.2216; found 711.2297 [(M+H) +< form].▪ 3-[(4-hydroxy-1-{[(3R,4R)-3-phenyl-1-(pyridin-3-ylmethyl)piperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 39)

[0413] Using General Procedure 6 starting from Preparation R3ax and 3-(chloromethyl)pyridine hydrochloride as reagents, EXAMPLE 39 was obtained. HRMS calculated for C 37 H 40 N 6 O 4 : 632.3111; found 633.3167 [(M+H) +< form].▪ 3-[(4-hydroxy-1-{[(3R,4R)-3-phenyl-1-(1,3-thiazol-5-ylmethyl)piperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 40)

[0414] Using General Procedure 6 starting from Preparation R3ax and 5-(chloromethyl)thiazole as reagents, EXAMPLE 40 was obtained. HRMS calculated for C 35 H 38 N 6 O 4 S: 638.2675; found 639.2738 [(M+H) +< form].▪ 3-[(4-hydroxy-1-{[(3R,4R)-3-phenyl-1-(1,3-thiazol-2-ylmethyl)piperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 41)

[0415] Using General Procedure 6 starting from Preparation R3ax and 2-(chloromethyl)thiazole as reagents, EXAMPLE 41 was obtained. HRMS calculated for C 35 H 38 N 6 O 4 S: 638.2675; found 639.2758 [(M+H) +< form].▪ 3-{[4-hydroxy-1-({(3R,4R)-1-[(4-methyl-1,3-thiazol-2-yl)methyl]-3-phenylpiperidin-4-yl}carbonyl)piperidin-4-yl]methyl}-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 42)

[0416] Using General Procedure 6 starting from Preparation R3ax and 2-(chloromethyl)-4-methyl-thiazole as reagents, EXAMPLE 42 was obtained. HRMS calculated for C 36 H 40 N 6 O 4 S: 652.2832; found 653.2885 [(M+H) +< form].▪ 3-{[1-({(3R,4R)-1-[(4,5-dimethyl-1,3-thiazol-2-yl)methyl]-3-phenylpiperidin-4-yl}carbonyl)-4-hydroxypiperidin-4-yl]methyl}-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 43)

[0417] Using General Procedure 6 starting from Preparation R3ax and 2-(chloromethyl)-4,5-dimethyl-thiazole as reagents, EXAMPLE 43 was obtained. HRMS calculated for C 37 H 42 N 6 O 4 S: 666.2988; found 667.3059 [(M+H) +< form].▪ 3-{[1-({(3R,4R)-1-[(2,4-dimethyl-1,3-thiazol-5-yl)methyl]-3-phenylpiperidin-4-yl}carbonyl)-4-hydroxypiperidin-4-yl]methyl}-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 44)

[0418] Using General Procedure 6 starting from Preparation R3ax and 5-(chloromethyl)-2,4-dimethyl-thiazole as reagents, EXAMPLE 44 was obtained. HRMS calculated for C 37 H 42 N 6 O 4 S: 666.2988; found 667.3047 [(M+H) +< form].▪ 3-{[4-hydroxy-1-({(3R,4R)-1-[(1-methyl-1H-pyrazol-5-yl)methyl]-3-phenylpiperidin-4-yl}carbonyl)piperidin-4-yl]methyl}-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 45)

[0419] Using General Procedure 6 starting from Preparation R3ax and 5-(chloromethyl)-1-methyl-pyrazole as reagents, EXAMPLE 45 was obtained. HRMS calculated for C 36 H 41 N 7 O 4 : 635.3220; found 636.3288 [(M+H) +< form].▪ 3-{[1-({(3R,4R)-1-[(1,3-dimethyl-1H-pyrazol-5-yl)methyl]-3-phenylpiperidin-4-yl}carbonyl)-4-hydroxypiperidin-4-yl]methyl}-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 46)

[0420] Using General Procedure 6 starting from Preparation R3ax and 5-(chloromethyl)-1,3-dimethyl-pyrazole as reagents, EXAMPLE 46 was obtained. HRMS calculated for C 37 H 43 N 7 O 4 : 649.3376; found 650.3455 [(M+H) +< form].▪ 4-({(3R,4R)-4-[(4-hydroxy-4-{[7-(4-methoxyphenyl)-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-3-yl]methyl}piperidin-1-yl)carbonyl]-3-phenylpiperidin-1-yl}methyl)pyridine-2-carbonitrile (EXAMPLE 47)

[0421] Using General Procedure 6 starting from Preparation R3ax and 4-(chloromethyl)pyridine-2-carbonitrile as reagents, EXAMPLE 47 was obtained. HRMS calculated for C 38 H 39 N 7 O 4 : 657.3063; found 658.3133 [(M+H) +< form].▪ 3-{[4-hydroxy-1-({(3R,4R)-1-[(6-methylpyridin-3-yl)methyl]-3-phenylpiperidin-4-yl}carbonyl)piperidin-4-yl]methyl}-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 48)

[0422] Using General Procedure 6 starting from Preparation R3ax and 5-(bromomethyl)-2-methyl-pyridine hydrobromide as reagents, EXAMPLE 48 was obtained. HRMS calculated for C 38 H 42 N 6 O 4 : 646.3267; found 647.3343 [(M+H) +< form].▪ 5-({(3R,4R)-4-[(4-hydroxy-4-{[7-(4-methoxyphenyl)-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-3-yl]methyl}piperidin-1-yl)carbonyl]-3-phenylpiperidin-1-yl}methyl)pyridine-2-carbonitrile (EXAMPLE 49)

[0423] Using General Procedure 6 starting from Preparation R3ax and 5-(bromomethyl)pyridine-2-carbonitrile as reagents, EXAMPLE 49 was obtained. HRMS calculated for C 38 H 39 N 7 O 4 : 657.3063; found 658.3138 [(M+H) +< form].▪ 3-[(4-hydroxy-1-{[(3R,4R)-1-(1,3-oxazol-4-ylmethyl)-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 50)

[0424] Using General Procedure 6 starting from Preparation R3ax and 4-(chloromethyl)oxazole as reagents, EXAMPLE 50 was obtained. HRMS calculated for C 35 H 38 N 6 O 5 : 622.2903; found 623.2975 [(M+H) +< form].▪ 3-{[1-({(3R,4R)-1-[(1,5-dimethyl-1H-pyrazol-3-yl)methyl]-3-phenylpiperidin-4-yl}carbonyl)-4-hydroxypiperidin-4-yl]methyl}-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 51)

[0425] Using General Procedure 6 starting from Preparation R3ax and 3-(chloromethyl)-1,5-dimethyl-pyrazole as reagents, EXAMPLE 51 was obtained. HRMS calculated for C 37 H 43 N 7 O 4 : 649.3376; found 650.3431 [(M+H) +< form].▪ 3-{[4-hydroxy-1-({(3R,4R)-1-[(5-methyl-1,3-oxazol-2-yl)methyl]-3-phenylpiperidin-4-yl}carbonyl)piperidin-4-yl]methyl}-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 52)

[0426] Using General Procedure 6 starting from Preparation R3ax and 2-(chloromethyl)-5-methyl-oxazole as reagents, EXAMPLE 52 was obtained. HRMS calculated for C 36 H 40 N 6 O 5 : 636.3060; found 637.3141 [(M+H) +< form].▪ 3-{[4-hydroxy-1-({(3R,4R)-1-[(2-methyl-1,3-thiazol-4-yl)methyl]-3-phenylpiperidin-4-yl}carbonyl)piperidin-4-yl]methyl}-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 53)

[0427] Using General Procedure 6 starting from Preparation R3ax and 4-(chloromethyl)-2-methyl-thiazole as reagents, EXAMPLE 53 was obtained. HRMS calculated for C 36 H 40 N 6 O 4 S: 652.2832; found 653.2896 [(M+H) +< form].▪ 3-{[4-hydroxy-1-({(3R,4R)-1-[(5-methyl-1,2-oxazol-3-yl)methyl]-3-phenylpiperidin-4-yl}carbonyl)piperidin-4-yl]methyl}-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 54)

[0428] Using General Procedure 6 starting from Preparation R3ax and 3-(chloromethyl)-5-methyl-isoxazole as reagents, EXAMPLE 54 was obtained. HRMS calculated for C 36 H 40 N 6 O 5 : 636.3060; found 637.3118 [(M+H) +< form].▪ 3-[(4-hydroxy-1-{[(3R,4R)-1-(1,2-oxazol-3-ylmethyl)-3-phenylpiperidin-4-yl]carbonyllpiperidin-4-yl)methyl]-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 55)

[0429] Using General Procedure 6 starting from Preparation R3ax and 3-(chloromethyl)isoxazole as reagents, EXAMPLE 55 was obtained. HRMS calculated for C 35 H 38 N 6 O 5 : 622.2903; found 623.2961 [(M+H) +< form].▪ 3-{[4-hydroxy-1-({(3R,4R)-1-[(3-methyl-1,2-oxazol-5-yl)methyl]-3-phenylpiperidin-4-yl}carbonyl)piperidin-4-yl]methyl}-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 56)

[0430] Using General Procedure 6 starting from Preparation R3ax and 5-(chloromethyl)-3-methyl-isoxazole as reagents, EXAMPLE 56 was obtained. HRMS calculated for C 36 H 40 N 6 O 5 : 636.3060; found 637.3119 [(M+H) +< form].▪ 3-{[4-hydroxy-1-({(3R,4R)-1-[(5-methyl-1,2-oxazol-4-yl)methyl]-3-phenylpiperidin-4-yl}carbonyl)piperidin-4-yl]methyl}-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 57)

[0431] Using General Procedure 6 starting from Preparation R3ax and 4-(chloromethyl)-5-methyl-isoxazole as reagents, EXAMPLE 57 was obtained. HRMS calculated for C 36 H 40 N 6 O 5 : 636.3060; found 637.3139 [(M+H) +< form].▪ 3-[(4-hydroxy-1-{[(3R,4R)-3-phenyl-1-{[6-(trifluoromethyl)pyridin-3-yl]methyl}piperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 58)

[0432] Using General Procedure 6 starting from Preparation R3ax and 5-(bromomethyl)-2-(trifluoromethyl)pyridine as reagents, EXAMPLE 58 was obtained. HRMS calculated for C 38 H 39 F 3 N 6 O 4 : 700.2985; found 701.3082 [(M+H) +< form].▪ 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-[4-(trifluoromethoxy)phenyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 59)

[0433] Using General Procedure 6 starting from Preparation R3ay and 5-(chloromethyl)-2-(6-methoxy-3-pyridyl)thiazole as reagents, EXAMPLE 59 was obtained. HRMS calculated for C 41 H 40 F 3 N 7 O 5 S: 799.2764; found 800.2855 [(M+H) +< form].▪ 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-[4-(trifluoromethoxy)phenyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 60)

[0434] Using General Procedure 6 starting from Preparation R3ay and Preparation R1c as reagents, EXAMPLE 60 was obtained. HRMS calculated for C 41 H 40 F 3 N 7 O 4 S: 783.2814; found 784.2904 [(M+H) +< form].▪ 7-[4-(benzyloxy)phenyl]-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 61)

[0435] Using General Procedure 6 starting from Preparation R3az and Preparation R1c as reagents, EXAMPLE 61 was obtained. HRMS calculated for C 47 H 47 N 7 O 4 S: 805.3410; found 403.6767 [(M+2H) 2+< form].▪ 7-[4-(benzyloxy)phenyl]-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 62)

[0436] Using General Procedure 5 starting from Preparation R3az and 5-(chloromethyl)-2-(6-methoxy-3-pyridyl)thiazole as reagents, EXAMPLE 62 was obtained. HRMS calculated for C 47 H 47 N 7 O 5 S: 821.3359; found 822.3433 [(M+H) +< form].▪ 3-[(1-{[(3S,4S)-1-benzyl-3-phenylpiperidin-4-yl]carbonyl}-4-hydroxypiperidin-4-yl)methyl]-7-methyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 63)

[0437] Using General Procedure 6 starting from 3-({4-hydroxy-1-[(3S,4S)-3-phenylpiperidine-4-carbonyl]piperidin-4-yl}methyl)-7-methyl-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one (which was obtained according to General Procedure 5 with tert-butyl (3S,4S)-4-(2-oxa-6-azaspiro[2.5]octane-6-carbonyl)-3-phenyl-piperidine-1-carboxylate and Preparation R2b) and benzyl bromide as reagents, EXAMPLE 63 was obtained. HRMS calculated for C 32 H 37 N 5 O 3 : 539.2896; found 540.2984 [(M+H) +< form].▪ 3-[(1-{[(3R,4R)-1-benzyl-3-phenylpiperidin-4-yl]carbonyl}-4-hydroxypiperidin-4-yl)methyl]-7-methyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 64)

[0438] Using General Procedure 6 starting from Preparation R3b and benzyl bromide as reagents, EXAMPLE 64 was obtained. HRMS calculated for C 32 H 37 N 5 O 3 : 539.2896; found 540.2977 [(M+H) +< form].▪ 3-[(1-{[(3R,4R)-1-(2-fluorobenzyl)-3-phenylpiperidin-4-yl]carbonyl}-4-hydroxypiperidin-4-yl)methyl]-7-methyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 65)

[0439] Using General Procedure 6 starting from Preparation R3b and 1-(bromomethyl)-2-fluoro-benzene as reagents, EXAMPLE 65 was obtained. HRMS calculated for C 32 H 36 FN 5 O 3 : 557.2802; found 558.2879 [(M+H) +< form].▪ 3-[(1-{[(3R,4R)-1-(3-fluorobenzyl)-3-phenylpiperidin-4-yl]carbonyl}-4-hydroxypiperidin-4-yl)methyl]-7-methyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 66)

[0440] Using General Procedure 6 starting from Preparation R3b and 1-(bromomethyl)-3-fluoro-benzene as reagents, EXAMPLE 66 was obtained. HRMS calculated for C 32 H 36 FN 5 O 3 : 557.2802; found 558.2902 [(M+H) +< form].▪ 3-[(4-hydroxy-1-{[(3R,4R)-1-(2-methylbenzyl)-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-methyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 67)

[0441] Using General Procedure 6 starting from Preparation R3b and 1-(bromomethyl)-2-methyl-benzene as reagents, EXAMPLE 67 was obtained. HRMS calculated for C 33 H 39 N 5 O 3 : 553.3053; found 554.3138 [(M+H) +< form].▪ 3-[(4-hydroxy-1-{[(3R,4R)-1-(3-methylbenzyl)-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-methyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 68)

[0442] Using General Procedure 6 starting from Preparation R3b and 1-(bromomethyl)-3-methyl-benzene as reagents, EXAMPLE 68 was obtained. HRMS calculated for C 33 H 39 N 5 O 3 : 553.3052; found 554.3090 [(M+H) +< form].▪ 3-[(1-{[(3R,4R)-1-(3-bromobenzyl)-3-phenylpiperidin-4-yl]carbonyl}-4-hydroxypiperidin-4-yl)methyl]-7-methyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 69)

[0443] Using General Procedure 6 starting from Preparation R3b and 1-bromo-3-(bromomethyl)benzene as reagents, EXAMPLE 69 was obtained. HRMS calculated for C 32 H 36 BrN 5 O 3 : 617.2001; found 618.2094 [(M+H) +< form].▪ 6-{[(3R,4R)-4-({4-hydroxy-4-[(7-methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-3-yl)methyl]piperidin-1-yl}carbonyl)-3-phenylpiperidin-1-yl]methyl}-1-methyl-3,4-dihydroquinolin-2(1H)-one (EXAMPLE 70)

[0444] Using General Procedure 6 starting from Preparation R3b and 6-(chloromethyl)-1-methyl-3,4-dihydroquinolin-2-one as reagents, EXAMPLE 70 was obtained. HRMS calculated for C 36 H 42 N 6 O 4 : 622.3268; found 623.3354 [(M+H) +< form].▪ 3-[(1-{[(3R,4R)-1-(3-acetylbenzyl)-3-phenylpiperidin-4-yl]carbonyl}-4-hydroxypiperidin-4-yl)methyl]-7-methyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 71)

[0445] Using General Procedure 6 starting from Preparation R3b and 1-[3-(chloromethyl)phenyl]ethanone as reagents, EXAMPLE 71 was obtained. HRMS calculated for C 34 H 39 N 5 O 4 : 581.3002; found 582.3054 [(M+H) +< form].▪ 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(5-methylthiophen-2-yl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 72)

[0446] Using General Procedure 6 starting from Preparation R3ba and Preparation R1c as reagents, EXAMPLE 72 was obtained. HRMS calculated for C 39 H 41 N 7 O 3 S 2 : 719.2712; found 720.2762 [(M+H) +< form].▪ 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(5-methylthiophen-2-yl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 73)

[0447] Using General Procedure 6 starting from Preparation R3ba and 5-(chloromethyl)-2-(6-methoxy-3-pyridyl)thiazole as reagents, EXAMPLE 73 was obtained. HRMS calculated for C 39 H 41 N 7 O 4 S 2 : 735.2661; found 736.2727 [(M+H) +< form].▪ 7-(5-chlorothiophen-2-yl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 74)

[0448] Using General Procedure 6 starting from Preparation R3bb and 5-(chloromethyl)-2-(6-methoxy-3-pyridyl)thiazole as reagents, EXAMPLE 74 was obtained. HRMS calculated for C 38 H 38 ClN 7 O 4 S 2 : 755.2115; found 756.219 [(M+H) +< form].▪ 7-(5-chlorothiophen-2-yl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 75)

[0449] Using General Procedure 6 starting from Preparation R3bb and Preparation R1c as reagents, EXAMPLE 75 was obtained. HRMS calculated for C 38 H 38 N 7 O 3 S 2 Cl:739.2166; found 740.2222 [(M+H) +< form].▪ 7-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 76)

[0450] Using General Procedure 6 starting from Preparation R3bc and Preparation R1c as reagents, EXAMPLE 76 was obtained. HRMS calculated for C 42 H 43 N 7 O 5 S: 757.3046; found 758.3125 [(M+H) +< form].▪ 7-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 77)

[0451] Using General Procedure 6 starting from Preparation R3bc and 5-(chloromethyl)-2-(6-methoxy-3-pyridyl)thiazole as reagents, EXAMPLE 77 was obtained. HRMS calculated for C 42 H 43 N 7 O 6 S: 773.2996; found 774.3038 [(M+H) +< form].▪ 7-(1,3-benzodioxol-5-yl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 78)

[0452] Using General Procedure 6 starting from Preparation R3bd and Preparation R1c as reagents, EXAMPLE 78 was obtained. HRMS calculated for C 41 H 41 N 7 O 5 S: 743.2890; found 372.6517 [(M+2H) 2+< form].▪ 7-(1,3-benzodioxol-5-yl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 79)

[0453] Using General Procedure 6 starting from Preparation R3bd and 5-(chloromethyl)-2-(6-methoxy-3-pyridyl)thiazole as reagents, EXAMPLE 79 was obtained. HRMS calculated for C 41 H 41 N 7 O 6 S: 759.2838; found 380.6487 [(M+2H) 2+< form].▪ 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(3-methylphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 80)

[0454] Using General Procedure 6 starting from Preparation R3bf and 5-(chloromethyl)-2-(6-methoxy-3-pyridyl)thiazole as reagents, EXAMPLE 80 was obtained. HRMS calculated for C 41 H 43 N 7 O 4 S: 729.3097; found 730.3189 [(M+H) +< form].▪ 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-[3-(trifluoromethyl)phenyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 81)

[0455] Using General Procedure 6 starting from Preparation R3bg and Preparation R1c as reagents, EXAMPLE 81 was obtained. HRMS calculated for C 41 H 40 F 3 N 7 O 3 S: 767.2865; found 768.2943 [(M+H) +< form].▪ 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-[3-(trifluoromethyl)phenyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 82)

[0456] Using General Procedure 6 starting from Preparation R3bg and 5-(chloromethyl)-2-(6-methoxy-3-pyridyl)thiazole as reagents, EXAMPLE 82 was obtained. HRMS calculated for C 41 H 40 F 3 N 7 O 4 S: 783.2814; found 784.2897 [(M+H) +< form].▪ 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-{3-[(4-methylpiperazin-1-yl)methyl]phenyl}-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 83)

[0457] Using General Procedure 6 starting from Preparation R3bh and Preparation R1c as reagents, EXAMPLE 83 was obtained. HRMS calculated for C 46 H 53 N 9 O 3 S:811.3992; found 406.7081 [(M+2H) 2+< form].▪ 7-[3-(hydroxymethyl)phenyl]-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 84)

[0458] Using General Procedure 6 starting from Preparation R3bi and Preparation R1c as reagents, EXAMPLE 84 was obtained. HRMS calculated for C 41 H 43 N 7 O 4 S: 729.3098; found 730.3153 [(M+H) +< form].▪ 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-[3-(hydroxymethyl)phenyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 85)

[0459] Using General Procedure 6 starting from Preparation R3bi and 5-(chloromethyl)-2-(6-methoxy-3-pyridyl)thiazole as reagents, EXAMPLE 85 was obtained. HRMS calculated for C 41 H 43 N 7 O s S:745.3046; found 746.313 [(M+H) +< form].▪ 7-(3-chlorophenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 86)

[0460] Using General Procedure 6 starting from Preparation R3bj and 5-(chloromethyl)-2-(6-methoxy-3-pyridyl)thiazole as reagents, EXAMPLE 86 was obtained. HRMS calculated for C 40 H 40 N 7 O 4 SCl: 749.2551; found 750.2624 [(M+H) +< form].▪ 3-{[1-({(3R,4R)-1-[(2-bromo-1,3-thiazol-5-yl)methyl]-3-phenylpiperidin-4-yl}carbonyl)-4-hydroxypiperidin-4-yl]methyl}-7-(3-chlorophenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 87)

[0461] Using General Procedure 6 starting from Preparation R3bj and 2-bromo-5-(bromomethyl)thiazole as reagents, EXAMPLE 87 was obtained. HRMS calculated for C 34 H 34 BrClN 6 O 3 S: 720.1284; found 721.1336 [(M+H) +< form].▪ 7-(3-fluorophenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 88)

[0462] Using General Procedure 6 starting from Preparation R3bk and Preparation R1c as reagents, EXAMPLE 88 was obtained. HRMS calculated for C 40 H 40 FN 7 O 3 S: 717.2897; found 359.6513 [(M+2H) 2+< form].▪ 7-(3-fluorophenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 89)

[0463] Using General Procedure 6 starting from Preparation R3bk and 5-(chloromethyl)-2-(6-methoxy-3-pyridyl)thiazole as reagents, EXAMPLE 89 was obtained. HRMS calculated for C 40 H 40 FN 7 O 4 S: 733.2847; found 734.2893 [(M+H) +< form].▪ 7-[3-(dimethylamino)phenyl]-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 90)

[0464] Using General Procedure 6 starting from Preparation R3bl and Preparation R1c as reagents, EXAMPLE 90 was obtained. HRMS calculated for C 42 H 46 N 8 O 3 S: 742.3413; found 372.1784 [(M+2H) 2+< form].▪ 7-[3-(dimethylamino)phenyl]-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 91)

[0465] Using General Procedure 6 starting from Preparation R3bl and 5-(chloromethyl)-2-(6-methoxy-3-pyridyl)thiazole as reagents, EXAMPLE 91 was obtained. HRMS calculated for C 42 H 46 N 8 O 4 S: 758.3362; found 380.1752 [(M+2H) 2+< form].▪ 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-[3-(morpholin-4-yl)phenyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 92)

[0466] Using General Procedure 6 starting from Preparation R3bm and Preparation R1c as reagents, EXAMPLE 92 was obtained. HRMS calculated for C 44 H 48 N 8 O 4 S: 784.3519; found 785.3594 [(M+H) +< form].▪ 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-[3-(morpholin-4-yl)phenyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 93)

[0467] Using General Procedure 6 starting from Preparation R3bm and 5-(chloromethyl)-2-(6-methoxy-3-pyridyl)thiazole as reagents, EXAMPLE 93 was obtained. HRMS calculated for C 44 H 4s N s O s S: 800.3468; found 801.3546 [(M+H) +< form].▪ 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(3-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 94)

[0468] Using General Procedure 6 starting from Preparation R3bo and 5-(chloromethyl)-2-(6-methoxy-3-pyridyl)thiazole as reagents, EXAMPLE 94 was obtained. HRMS calculated for C 41 H 43 N 7 O 5 S: 745.3046; found 746.3117 [(M+H) +< form].▪ 3-{[1-({(3R,4R)-1-[(2-bromo-1,3-thiazol-5-yl)methyl]-3-phenylpiperidin-4-yl}carbonyl)-4-hydroxypiperidin-4-yl]methyl}-7-(3-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 95)

[0469] Using General Procedure 6 starting from Preparation R3bo and 2-bromo-5-(bromomethyl)thiazole as reagents, EXAMPLE 95 was obtained. HRMS calculated for C 35 H 37 BrN 6 O 4 S: 716.1780; found 717.1825 [(M+H) +< form].▪ 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-[3-(trifluoromethoxy)phenyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 96)

[0470] Using General Procedure 6 starting from Preparation R3bp and Preparation R1c as reagents, EXAMPLE 96 was obtained. HRMS calculated for C 41 H 40 F 3 N 7 O 4 S: 783.2814; found 784.2878 [(M+H) +< form].▪ 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-[3-(trifluoromethoxy)phenyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 97)

[0471] Using General Procedure 6 starting from Preparation R3bp and 5-(chloromethyl)-2-(6-methoxy-3-pyridyl)thiazole as reagents, EXAMPLE 97 was obtained. HRMS calculated for C 41 H 40 F 3 N 7 O 5 S: 799.2764; found 800.2856 [(M+H) +< form].▪ 7-[3-(benzyloxy)phenyl]-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 98)

[0472] Using General Procedure 6 starting from Preparation R3bq and 5-(chloromethyl)-2-(6-methoxy-3-pyridyl)thiazole as reagents, EXAMPLE 98 was obtained. HRMS calculated for C 47 H 47 N 7 O 5 S: 821.3359; found 822.343 [(M+H) +< form].▪ 7-[3-(benzyloxy)phenyl]-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 99)

[0473] Using General Procedure 6 starting from Preparation R3bq and Preparation R1c as reagents, EXAMPLE 99 was obtained. HRMS calculated for C 47 H 47 N 7 O 4 S: 805.3410; found 806.3484 (M+H) +< form].▪ 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(6-methoxypyridin-2-yl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 100)

[0474] Using General Procedure 6 starting from Preparation R3bs and Preparation R1c as reagents, EXAMPLE 100 was obtained. HRMS calculated for C 40 H 42 N 8 O 4 S:730.3049; found 731.3128 [(M+H) +< form].▪ 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(6-methoxypyridin-2-yl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 101)

[0475] Using General Procedure 6 starting from Preparation R3bs and 5-(chloromethyl)-2-(6-methoxy-3-pyridyl)thiazole as reagents, EXAMPLE 101 was obtained. HRMS calculated for C 40 H 42 N 8 O 5 S: 746.2998; found 747.308 [(M+H) +< form].▪ 3-[(1-{[(3R,4R)-1-benzyl-3-phenylpiperidin-4-yl]carbonyl}-4-hydroxypiperidin-4-yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 102)

[0476] Using General Procedure 6 starting from Preparation R3bu and benzyl bromide as reagents, EXAMPLE 102 was obtained. HRMS calculated for C 37 H 39 N 5 O 3 : 601.3053; found 602.3155 [(M+H) +< form].▪ 3-{[1-({(3R,4R)-1-[(2-bromo-1,3-thiazol-5-yl)methyl]-3-phenylpiperidin-4-yl}carbonyl)-4-hydroxypiperidin-4-yl]methyl}-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 103)

[0477] Using General Procedure 6 starting from Preparation R3bu and 2-bromo-5-(bromomethyl)thiazole as reagents, EXAMPLE 103 was obtained. HRMS calculated for C 34 H 35 N 6 O 3 SBr: 686.1675; found 687.1743 [(M+H) +< form].▪ 3-{[1-({(3R,4R)-1-[(5-bromopyridin-3-yl)methyl]-3-phenylpiperidin-4-yl}carbonyl)-4-hydroxypiperidin-4-yl]methyl}-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 104)

[0478] Using General Procedure 6 starting from Preparation R3bu and 3-bromo-5-(chloromethyl)pyridine as reagents, EXAMPLE 104 was obtained. HRMS calculated for C 36 H 37 BrN 6 O 3 : 680.2111; found 681.2179 [(M+H) +< form].▪ 3-[(4-hydroxy-1-{[(3R,4R)-3-phenyl-1-(pyridin-4-ylmethyl)piperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 105)

[0479] Using General Procedure 6 starting from Preparation R3bu and 4-(chloromethyl)pyridine as reagents, EXAMPLE 105 was obtained. HRMS calculated for C 36 H 38 N 6 O 3 : 602.3005; found 603.3085 [(M+H) +< form].▪ 3-[(4-hydroxy-1-{[(3R,4R)-3-phenyl-1-(pyridin-3-ylmethyl)piperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 106)

[0480] Using General Procedure 6 starting from Preparation R3bu and 3-(bromomethyl)pyridine hydrobromide as reagents, EXAMPLE 106 was obtained. HRMS calculated for C 36 H 38 N 6 O 3 : 602.3005; found 603.3062 [(M+H) +< form].▪ 3-{[4-hydroxy-1-({(3R,4R)-1-[(1-methyl-1H-pyrazol-4-yl)methyl]-3-phenylpiperidin-4-yl}carbonyl)piperidin-4-yl]methyl}-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 107)

[0481] Using General Procedure 6 starting from Preparation R3bu and 4-(chloromethyl)-1-methyl-pyrazo...

Claims

1. Compound of formula (I): wherein: ◆ R1 represents an aryl group or a heteroaryl group, ◆ R2 represents a hydrogen atom or a halogen atom, ◆ n is an integer equal to 0, 1 or 2, ◆ J represents a -C(O)- group, a -CH(R3)- group, or a -SO2- group, ◆ R3 represents a hydrogen atom or a linear or branched (C1-C6)alkyl group, ◆ K represents a bond or a -Cy1- group, ◆ L represents a -Cy2 group or a -CH2-Cy2 group, ◆ W represents the group wherein: ▪ A represents a heteroaryl ring, ▪ X represents a carbon atom or a nitrogen atom, ▪ R4 represents a hydrogen atom, a halogen atom, a linear or branched (C1-C6)alkyl group, a linear or branched (C2-C6)alkenyl group, a linear or branched (C2-C6)alkynyl group, a -Y1-NR5R7 group, a -Y1-OR6 group, a linear or branched halo(C1-C6)alkyl group, an oxo group, a -Y1-CY3 group, a -Cy3-R7 group, a -Cy3-OR7 group, or a -Y1-NR6-C(O)-R7 group, ▪ R5 represents a hydrogen atom, a halogen atom, or a linear or branched (C1-C6)alkyl group, ▪ R6 represents a hydrogen atom or a linear or branched (C1-C6)alkyl group, ▪ R7 represents a hydrogen atom, a linear or branched (C1-C6)alkyl group, or a -Y2-Cy4 group, ▪ Y1 and Y2 independently of one another represent a bond or a linear or branched (C1-C4)alkylene group, ◆ Cy1 represents a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group, which is linked to the group J and to the group L, ◆ Cy2, Cy3 and Cy4 independently of one another, represent a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group, it being understood that: - "aryl" means a phenyl, naphthyl, or indanyl group, - "heteroaryl" means any mono- or fused bi-cyclic group composed of from 5 to 10 ring members, having at least one aromatic moiety and containing from 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen, - "cycloalkyl" means any mono- or fused bi-cyclic non-aromatic carbocyclic group containing from 3 to 7 ring members, - "heterocycloalkyl" means any non-aromatic mono- or fused bi-cyclic group containing from 3 to 10 ring members, and containing from 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen, it being possible for the aryl, heteroaryl, cycloalkyl and heterocycloalkyl groups so defined to be substituted by from 1 to 4 groups selected from linear or branched (C1-C6)alkyl, linear or branched (C2-C6)alkenyl, linear or branched (C2-C6)alkynyl, linear or branched halo(C1-C6)alkyl, -Y1-OR', -Y1-NR'R", -Y1-S(O)m-R', oxo (or N-oxide where appropriate), nitro, cyano, -C(O)-R', -C(O)-OR', -O-C(O)-R', -C(O)-NR'R", -Y1-NR'-C(O)-R", -Y1-NR'-C(O)-OR", halogen, cyclopropyl, and pyridinyl which can be substituted by a linear or branched (C1-C6)alkyl group, it being understood that R' and R" independently of one another, represent a hydrogen atom, a linear or branched (C1-C6)alkyl group, a linear or branched (C2-C6)alkenyl group, a linear or branched (C1-C6)alkoxy group, a linear or branched halo(C1-C6)alkyl, a linear or branched hydroxy(C1-C6)alkyl group, a linear or branched (C1-C6)alkoxy(C1-C6)alkyl group, a phenyl group, a cyclopropylmethyl group, a tetrahydropyranyl group, or the substituents of the pair (R', R") form together with the nitrogen atom carrying them a non-aromatic ring composed of from 5 to 7 ring members, which may contain in addition to the nitrogen a second heteroatom selected from oxygen and nitrogen, it being understood that the second nitrogen in question may be substituted by from 1 to 2 groups representing a hydrogen atom, or a linear or branched (C1-C6)alkyl group, and it being understood that m is an integer equal to 0, 1 or 2, their enantiomers, diastereoisomers and addition salts thereof with a pharmaceutically acceptable acid or base.

2. Compounds according to claim 1, wherein W represents the group wherein R4, R5 and A are as defined in claim 1.

3. Compounds according to claim 1, wherein W represents the group wherein R4, R5 and A are as defined in claim 1.

4. Compounds according to claim 1, wherein R1 represents a phenyl group or a thienyl group.

5. Compounds according to claim 1, wherein R2 represents a hydrogen atom and a fluorine atom.

6. Compounds according to claim 1, wherein R3 represents a hydrogen atom or a methyl group.

7. Compounds according to claim 1, wherein J represents a -C(O)- group or a -CH2- group.

8. Compounds according to claim 1, wherein K represents a bond or a -Cy1- group selected from a phenyl group, a pyrrolyl group, a thienyl group, a thiazolyl group, a pyridinyl group, a tetrahydrobenzothienyl group, a dihydrothienodioxinyl group, a cyclopropyl group, a cyclobutyl group, or a pyrrolidinyl group.

9. Compound according to claim 1, wherein L represents a -Cy2 group.

10. Compound according to claim 1, wherein Cy2 represents a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group which are substituted by 1 or 2 groups selected from linear or branched (C1-C6)alkyl, linear or branched halo(C1-C6)alkyl, -Y1-OR', -Y1-NR'R", N-oxide, cyano, -C(O)-OR', -C(O)-NR'R", halogen, in which R' and R" independently of one another represent a hydrogen atom, a linear or branched (C1-C6)alkyl group, a linear or branched (C1-C6)alkoxy group, or a tetrahydropyranyl group, or the substituents of the pair (R', R") form together with the nitrogen atom carrying them a non-aromatic ring composed of from 5 to 7 ring members, which may contain in addition to the nitrogen a second heteroatom selected from oxygen and nitrogen, it being understood that the second nitrogen in question may be substituted by a linear or branched (C1-C6)alkyl group.

11. Compound according to claim 1, wherein K represents a thienyl group, a thiazolyl group or a pyridinyl group and L represents a pyrrolyl group, a furyl group, a thienyl group, a pyrazolyl group, a pyridinyl group, a pyrimidinyl group, or an imidazopyridinyl group, each said heteroaryl group may be substituted by 1 or 2 groups selected from linear or branched (C1-C6)alkyl, linear or branched halo(C1-C6)alkyl, -Y1-OR', -Y1-NR'R", N-oxide, cyano, -C(O)-NR'R", halogen, in which R' and R" independently of one another represent a hydrogen atom, a linear or branched (C1-C6)alkyl group, a linear or branched (C1-C6)alkoxy group, a linear or branched (C1-C6)alkoxy(C1-C6)alkyl group, or a tetrahydropyranyl group, or the substituents of the pair (R', R") form together with the nitrogen atom carrying them a non-aromatic ring composed of from 5 to 7 ring members, which may contain in addition to the nitrogen a second heteroatom selected from oxygen and nitrogen.

12. Compounds according to claim 1, wherein K represents a bond and L represents a phenyl group, thiazolyl group, an oxazolyl group, an isoxazolyl group, a pyrazolyl group, a pyridinyl group, a pyrazinyl group, a pyridazinyl group or a pyrimidinyl group, each said heteroaryl group may be substituted by 1 or 2 groups selected from linear or branched (C1-C6)alkyl, -Y1-OR', -Y1-NR'R", cyano, -C(O)-OR', halogen, it being understood that R' and R" independently of one another represent a hydrogen atom, a linear or branched (C1-C6)alkyl group, or the substituents of the pair (R', R") form together with the nitrogen atom carrying them a non-aromatic ring composed of from 5 to 7 ring members, which may contain in addition to the nitrogen a second heteroatom selected from oxygen and nitrogen, it being understood that the second nitrogen in question may be substituted by from 1 to 2 groups representing a hydrogen atom, or a linear or branched (C1-C6)alkyl group.

13. Compounds according to claim 1, wherein R4 represents a halogen atom, a linear or branched (C1-C6)alkyl group, or a -Y1-Cy3 group.

14. Compounds according to claim 1, wherein Cy3 represents a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group which are substituted by from 1 to 3 groups selected from linear or branched (C1-C6)alkyl, linear or branched halo(C1-C6)alkyl, -Y1-OR', -Y1-NR'R", cyano, halogen, in which R' and R" independently of one another represent a hydrogen atom or a linear or branched (C1-C6)alkyl group, or the substituents of the pair (R', R") form together with the nitrogen atom carrying them a non-aromatic ring composed of from 5 to 7 ring members which may contain in addition to the nitrogen a second heteroatom selected from oxygen and nitrogen.

15. Compounds according to claim 1, wherein R5 represents a hydrogen atom or a methyl group.

16. Compounds according to claim 1, wherein R6 represents a hydrogen atom or a methyl group.

17. Compounds according to claim 1, wherein R7 represents a hydrogen atom, a methyl group, or a -CH2-Cy4 group.

18. Compounds according to claim 1, which are: - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[3-methyl-5-(pyridin-4-yl)thiophen-2-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-methyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(1-{[(3R,4R)-1-{[5-(6-aminopyridin-3-yl)-3-fluorothiophen-2-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}-4-hydroxypiperidin-4-yl)methyl]-7-methyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 7-cyclopropyl-3-[(1-{[(3R,4R)-1-{[3-fluoro-5-(pyridin-4-yl)thiophen-2-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}-4-hydroxypiperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(1-{[(3R,4R)-1-{[3-fluoro-5-(6-methylpyridin-3-yl)thiophen-2-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}-4-hydroxypiperidin-4-yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(pyridin-3-yl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(thiophen-3-yl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(naphthalen-2-yl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 7-(4-chlorophenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(3-methylphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(4-methylphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 7-(3-chlorophenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 7-(furan-3-yl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperiin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 7-(2-fluorophenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 7-(2-chlorophenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 7-[4-(dimethylamino)phenyl]-3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-[4-(4-methylpiperazin-1-yl)phenyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 7-[3-(dimethylamino)phenyl]-3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(1H-pyrrol-1-yl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-{[1-({(3R,4R)-1-[(2-bromo-4-methyl-1,3-thiazol-5-yl)carbonyl]-3-phenylpiperidin-4-yl}carbonyl)-4-hydroxypiperidin-4-yl]methyl}-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 5-(5-{[(3R,4R)-4-({4-hydroxy-4-[(4-oxo-7-phenyl-4,7-dihydro-3H-pyrrolo[2,3-d] pyrimidin-3-yl)methyl]piperidin-1-yl}carbonyl)-3-phenylpiperidin-1-yl]carbonyl}-4-methyl-1,3-thiazol-2-yl)pyridine-2-carbonitrile; - 3-[(1-{[(3R,4R)-1-({2-[6-(dimethylamino)pyridin-3-yl]-4-methyl-1,3-thiazol-5-yl}carbonyl)-3-phenylpiperidin-4-yl]carbonyl}-4-hydroxypiperidin-4-yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-({4-methy|-2-[6-(trifluoromethyl)pyridin-3-yl]-1,3-thiazol-5-yl}carbonyl)-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-4-methyl-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(3-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 7-(3-fluorophenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(1-{[(3R,4R)-1-({2-[6-(dimethylamino)pyridin-3-yl]-1,3-thiazol-5-yl}methyl)-3-phenylpiperidin-4-yl]carbonyl}-4-hydroxypiperidin-4-yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 7-(4-fluorophenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(thiophen-3-yl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-({2-[6-(morpholin-4-yl)pyridin-3-yl]-1,3-thiazol-5-yl}methyl)-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(3-methylphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(4-methylphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(1-{[(3R,4R)-1-({2-[6-(dimethylamino)pyridin-3-yl]-1,3-thiazol-5-yl}methyl)-3-phenylpiperidin-4-yl]carbonyl}-4-hydroxypiperidin-4-yl)methyl]-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 7-(4-chlorophenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 7-(4-chlorophenyl)-3-[(1-{[(3R,4R)-1-({2-[6-(dimethylamino)pyridin-3-yl]-1,3-thiazol-5-yl}methyl)-3-phenylpiperidin-4-yl]carbonyl}-4-hydroxypiperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-6,8-dimethylpyrimido[5',4':4,5]pyrrolo[1,2-b]pyridazin-4(3H)-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-[3-(morpholin-4-yl)phenyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-[4-(morpholin-4-yl)phenyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 7-(3-chlorophenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[-oxidopyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-3-phenyl-1-({2-[6-(piperazin-1-yl)pyridin-3-yl]-1,3-thiazol-5-yl}methyl)piperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-3-phenyl-1-({2-[6-(trifluoromethyl)pyridin-3-yl]-1,3-thiazol-5-yl}methyl)piperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 7-(3,4-dichlorophenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 5-(5-{[(3R,4R)-4-({4-hydroxy-4-[(4-oxo-7-phenyl-4,7-dihydro-3H-pyrrolo[2,3-d] pyrimidin-3-yl)methyl]piperidin-1-yl}carbonyl)-3-phenylpiperidin-1-yl]methyl}-1,3-thiazol-2-yl)pyridine-2-carbonitrile; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(3-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(pyridin-2-yl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-[4-(hydroxymethyl)phenyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(thiophen-2-yl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 7-(3,4-dimethoxyphenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 7-(3,4-dimethoxyphenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(pyridin-3-yl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 5-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-1-phenyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one; - 7-(3,5-dimethoxyphenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 7-(3,5-dimethoxyphenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 7-(4-fluorophenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 4-{3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl}benzonitrile; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(1-methyl-1H-pyrazol-4-yl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(1-methyl-1H-pyrazol-4-yl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-[3-(hydroxymethyl)phenyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 7-[3-(hydroxymethyl)phenyl]-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 7-(4-chloro-3-fluorophenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 5-[(4-hydroxy-1-{[(3R,4R)-1-{[-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-1-phenyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(1-methyl-1H-pyrazol-4-yl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-[3-(hydroxymethyl)phenyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 7-(4-fluorophenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 7-(4-chloro-3-fluorophenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 7-(3-chloro-5-methoxyphenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 7-(3-chloro-5-methoxyphenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 7-(4-fluoro-3-methoxyphenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 7-(4-fluoro-3-methoxyphenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 7-(4-fluoro-3-methoxyphenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 7-(4-chloro-3-methoxyphenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 7-(4-chloro-3-methoxyphenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 7-(4-chlorophenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 7-(5-chlorothiophen-2-yl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 7-(5-chlorothiophen-2-yl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 7-bromo-3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]pyrrolo[2,1-f][1,2,4]triazin-4(3H)-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(5-methylthiophen-2-yl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(5-methylthiophen-2-yl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(5-methylthiophen-2-yl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 7-[4-(hydroxymethyl)phenyl]-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-[4-(hydroxymethyl)phenyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl} piperidin-4-yl)methyl]-7-phenylpyrrolo[2,1-f] [1,2,4]triazin-4(3H)-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-phenylpyrrolo[2,1-f][1,2,4]triazin-4(3H)-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(thiophen-2-yl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(thiophen-2-yl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-phenylthieno[3,4-d]pyrimidin-4(3H)-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-phenylthieno[3,4-d] pyrimidin-4(3H)-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-phenyl-3,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-phenyl-3,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-phenyl-3,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(3-methylphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(4-methylphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(thiophen-3-yl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-[3-(morpholin-4-yl)phenyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-[3-(morpholin-4-yl)phenyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-{[1-({(3R,4R)-1-[(2-bromo-1,3-thiazol-5-yl)methyl]-3-phenylpiperidin-4-yl}carbonyl)-4-hydroxypiperidin-4-yl]methyl}-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(4-hydroxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(4-hydroxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-hydroxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(4-hydroxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-hydroxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-({2-[6-(hydroxymethyl)pyridin-3-yl]-1,3-thiazol-5-yl}methyl)-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-[3-(trifluoromethyl)phenyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-[3-(trifluoromethyl)phenyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 7-[4-(difluoromethyl)phenyl]-3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 7-[4-(difluoromethyl)phenyl]-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 7-[4-(difluoromethyl)phenyl]-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 7-[1-(difluoromethyl)-1H-pyrazol-4-yl]-3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 7-[1-(difluoromethyl)-1H-pyrazol-4-yl]-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(3-methyl-3H-imidazo[4,5-b]pyridin-6-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(3-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 7-[3-(dimethylamino)phenyl]-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 7-(3-fluorophenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(1-{[(3R,4R)-1-{[2-(5-fluoro-6-hydroxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}-4-hydroxypiperidin-4-yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 5-(5-{[(3R,4R)-4-({4-hydroxy-4-[(4-oxo-7-phenyl-4,7-dihydro-3H-pyrrolo[2,3-d] pyrimidin-3-yl)methyl]piperidin-1-yl}carbonyl)-3-phenylpiperidin-1-yl]methyl}-1,3-thiazol-2-yl)pyridine-3-carboxamide; - 3-[(4-hydroxy-1-{[(3R,4R)-1-({2-[5-(hydroxymethyl)pyridin-3-yl]-1,3-thiazol-5-yl}methyl)-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-3-phenyl-1-({2-[6-(tetrahydro-2H-pyran-4-yloxy)pyridin-3-yl]-1,3-thiazo1-5-yl}methyl)piperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(1-{[(3R,4R)-1-{[2-(5-amino-6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}-4-hydroxypiperidin-4-yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-{[1-({(3R,4R)-1-[(2-bromo-1,3-thiazol-5-yl)methyl]-3-phenylpiperidin-4-yl}carbonyl)-4-hydroxypiperidin-4-yl]methyl}-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-3-phenyl-1-{[2-(thiophen-2-yl)-1,3-thiazol-5-yl]methyl}piperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-3-phenyl-1-{[2-(pyrimidin-5-yl)-1,3-thiazol-5-yl]methyl}piperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(1-methyl-1H-pyrazol-5-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(1-methyl-1H-pyrazol-4-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(1-methyl-1H-pyrrol-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-3-phenyl-1-{[2-(thiophen-3-yl)-1,3-thiazol-5-yl]methyl}piperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 7-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 7-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(3-hydroxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-{[1-({(3R,4R)-1-[(2-bromopyridin-4-yl)carbonyl]-3-phenylpiperidin-4-yl}carbonyl)-4-hydroxypiperidin-4-yl]methyl}-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-{[1-({(3R,4R)-1-[(5-bromopyridin-3-yl)carbonyl]-3-phenylpiperidin-4-yl}carbonyl)-4-hydroxypiperidin-4-yl]methyl}-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 7-(3-chlorophenyl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-hydroxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(1-{[(3R,4R)-1-{[2-(furan-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}-4-hydroxypiperidin-4-yl)methyl]-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(1-{[(3R,4R)-1-{[2-(furan-2-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}-4-hydroxypiperidin-4-yl)methyl]-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-3-phenyl-1-{[2-(thiophen-2-yl)-1,3-thiazol-5-yl]methyl}piperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(3-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-3-phenyl-1-{[2-(pyrimidin-5-yl)-1,3-thiazol-5-yl]methyl}piperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(3-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(1-methyl-1H-pyrazol-5-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(3-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(1-methyl-1H-pyrazol-4-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(3-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(1-methyl-1H-pyrrol-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(3-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-3-phenyl-1-{[2-(thiophen-3-yl)-1,3-thiazol-5-yl]methyl}piperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(3-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(1-{[(3R,4R)-1-{[2-(furan-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}-4-hydroxypiperidin-4-yl)methyl]-7-(3-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(1-{[(3R,4R)-1-{[2-(furan-2-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}-4-hydroxypiperidin-4-yl)methyl]-7-(3-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 7-(2,3-dihydro-1 ,4-benzodioxin-6-yl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(3,4,5-trimethoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(3,4,5-trimethoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 7-(1,3-benzodioxol-5-yl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 7-(1,3-benzodioxol-5-yl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 7-(1,3-benzodioxol-5-yl)-3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-{[1-({(3R,4R)-1-[(5-bromopyridin-3-yl)methyl]-3-phenylpiperidin-4-yl}carbonyl)-4-hydroxypiperidin-4-yl]methyl}-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(3,4,5-trimethoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-3-phenyl-1-(pyridin-3-ylmethyl)piperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d] pyrimidin-4-one; - 3-{[4-hydroxy-1-({(3R,4R)-1-[(6'-methyl-3,3'-bipyridin-5-yl)carbonyl]-3-phenylpiperidin-4-yl}carbonyl)piperidin-4-yl]methyl}-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(3-hydroxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-[(3R,4R)-3-phenyl-1-(pyridin-4-ylmethyl)piperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d] pyrimidin-4-one; - 5-[5-({(3R,4R)-4-[(4-hydroxy-4-{[7-(3-methoxyphenyl)-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-3-yl]methyl}piperidin-1-yl)carbonyl]-3-phenylpiperidin-1-yl}methyl)-1,3-thiazol-2-yl]pyridine-2-carbonitrile; - 5-[5-({(3R,4R)-4-[(4-{[7-(4-chlorophenyl)-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d] pyrimidin-3-yl]methyl}-4-hydroxypiperidin-1-yl)carbonyl]-3-phenylpiperidin-1-yl}methyl)-1,3-thiazol-2-yl]pyridine-2-carbonitrile; - 5-[5-({(3R,4R)-4-[(4-hydroxy-4-{[7-(4-methoxyphenyl)-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-3-yl]methyl}piperidin-1-yl)carbonyl]-3-phenylpiperidin-1-yl}methyl)-1,3-thiazol-2-yl]pyridine-2-carbonitrile; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(morpholin-4-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-({2-[6-(2-methoxyethoxy)pyridin-3-yl]-1,3-thiazol-5-yl}methyl)-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(4-methylpiperazin-1-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-hydroxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(3-hydroxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-{[4-hydroxy-1-({(3R,4R)-1-[(4-methyl-1,3-thiazol-5-yl)carbonyl]-3-phenylpiperidin-4-yl}carbonyl)piperidin-4-yl]methyl}-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-{[4-hydroxy-1-({(3R,4R)-1-[(2-methyl-1,3-thiazol-5-yl)carbonyl]-3-phenylpiperidin-4-yl}carbonyl)piperidin-4-yl]methyl}-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-{[1-({(3R,4R)-1-[(2-chloro-1,3-thiazol-5-yl)carbonyl]-3-phenylpiperidin-4-yl}carbonyl)-4-hydroxypiperidin-4-yl]methy}-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-3-phenyl-1-(pyrazin-2-ylmethyl)piperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d] pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-3-phenyl-1-(1,3-thiazol-5-ylmethyl)piperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d] pyrimidin-4-one; - 5-[5-({(3R,4R)-4-[(4-{[7-(4-fluorophenyl)-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d] pyrimidin-3-yl]methyl}-4-hydroxypiperidin-1-yl)carbonyl]-3-phenylpiperidin-1-yl}methyl)-1,3-thiazol-2-yl]pyridine-2-carbonitrile; - methyl 3-{[(3R,4R)-4-({4-hydroxy-4-[(4-oxo-7-phenyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-3-yl)methyl]piperidin-1-yl}carbonyl)-3-phenylpiperidin-1-yl]carbonyl}benzoate; - 5-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-1-(4-methoxyphenyl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one; - 5-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methoxypyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-1-(4-methoxyphenyl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one; - 5-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-1-(4-methoxyphenyl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one; - 3-{[4-hydroxy-1-((3R,4R)-1-[(2-{6-[(2-methoxyethyl)amino]pyridin-3-yl}-1,3-thiazol-5-yl)methyl]-3-phenylpiperidin-4-yl}carbonyl)piperidin-4-yl]methyl}-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-{[4-hydroxy-1-({(3R,4R)-1-[(1-methyl-1H-pyrazol-4-yl)methyl]-3-phenylpiperidin-4-yl}carbonyl)piperidin-4-yl]methyl}-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-3-phenyl-1-(pyrazin-2-ylmethyl)piperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-{[4-hydroxy-1-({(3R,4R)-1-[(5-methyl-1,3-thiazol-2-yl)methyl]-3-phenylpiperidin-4-yl}carbonyl)piperidin-4-yl]methyl}-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-{[1-({(3R,4R)-1-[(5-bromopyridin-3-yl)methyl]-3-phenylpiperidin-4-yl}carbonyl)-4-hydroxypiperidin-4-yl]methyl}-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - methyl 5-{[(3R,4R)-4-({4-hydroxy-4-[(4-oxo-7-phenyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-3-yl)methyl]piperidin-1-yl}carbonyl)-3-phenylpiperidin-1-yl]carbonyl}pyridine-3-carboxylate; - 1-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-[(4-hydroxy-1-{[(3R,4R)-1-{[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]carbonyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one; - 1-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-[(4-hydroxy-1-{[(3R,4R)-1-{[2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]methyl}-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one; - 3-{[4-hydroxy-1-({(3R,4R)-1-[(5-methyl-1,3-thiazol-2-yl)methyl]-3-phenylpiperidin-4-yl}carbonyl)piperidin-4-yl]methyl}-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-{[4-hydroxy-1-({(3R,4R)-1-[(3-methyl-1,2-oxazol-5-yl)methyl]-3-phenylpiperidin-4-yl}carbonyl)piperidin-4-yl]methyl}-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-{[1-({(3R,4R)-1-[(2,4-dimethyl-1,3-thiazol-5-yl)methyl]-3-phenylpiperidin-4-yl}carbonyl)-4-hydroxypiperidin-4-yl]methyl}-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[(4-hydroxy-1-{[(3R,4R)-1-(1,3-oxazol-4-ylmethyl)-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 3-{[4-hydroxy-1-({(3R,4R)-1-[(5-methyl-1,3-oxazol-2-yl)methyl]-3-phenylpiperidin-4-yl}carbonyl)piperidin-4-yl]methyl}-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; - 5-{[(3R,4R)-4-({4-hydroxy-4-[(4-oxo-7-phenyl-4,7-dihydro-3H-pyrrolo[2,3-d] pyrimidin-3-yl)methyl]piperidin-1-yl}carbonyl)-3-phenylpiperidin-1-yl]methyl}pyridine-2-carbonitrile; - 3-[[4-hydroxy-1-[(3R,4R)-1-[4-methyl-2-(6-methyl-3-pyridyl)thiazole-5-carbonyl]-3-phenyl-piperidine-4-carbonyl]-4-piperidyl]methyl]-7-[4-(hydroxymethyl)phenyl]pyrrolo[2,1-f][1,2,4]triazin-4-one; - 3-[[4-hydroxy-1-[(3R,4R)-1-[4-methyl-2-(6-methyl-3-pyridyl)thiazole-5-carbonyl]-3-phenyl-piperidine-4-carbonyl]-4-piperidyl]methyl]-7-[4-(hydroxymethyl)phenyl]thieno[3,4-d]pyrimidin-4-one; - 3-[[4-hydroxy-1-[(3R,4R)-1-[2-(6-methyl-3-pyridyl)thiazole-5-carbonyl]-3-phenylpiperidine-4-carbonyl]-4-piperidyl]methyl]-7-(3-methoxyphenyl)pyrrolo[2,3-d] pyrimidin-4-one; - 3-[[3,3-difluoro-4-hydroxy-1-[(3R,4R)-1-[4-methyl-2-(6-methyl-3-pyridyl)thiazole-5-carbonyl]-3-phenyl-piperidine-4-carbonyl]-4-piperidyl]methyl]-7-phenyl-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[[3,3-difluoro-4-hydroxy-1-[(3R,4R)-1-[4-methyl-2-(6-methyl-3-pyridyl)thiazole-5-carbonyl]-3-phenyl-piperidine-4-carbonyl]-4-piperidyl]methyl]-7-(4-methoxyphenyl)pyrrolo[2,3-d]pyrimidin-4-one; - 3-[[4-hydroxy-1-[(3R,4R)-1-[(2-methoxypyrimidin-4-yl)methyl]-3-phenylpiperidine-4-carbonyl]-4-piperidyl]methyl]-7-phenyl-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[[4-hydroxy-1-[(3R,4R)-1-[(2-methoxypyrimidin-4-yl)methyl]-3-phenylpiperidine-4-carbonyl]-4-piperidyl]methyl]-7-(4-methoxyphenyl)pyrrolo[2,3-d] pyrimidin-4-one; - 3-[[4-hydroxy-1-[(3R,4R)-1-[(5-methylpyrazin-2-yl)methyl]-3-phenyl-piperidine-4-carbonyl]-4-piperidyl]methyl]-7-phenyl-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[[4-hydroxy-1-[(3R,4R)-1-[(5-methylpyrazin-2-yl)methyl]-3-phenyl-piperidine-4-carbonyl]-4-piperidyl]methyl]-7-(4-methoxyphenyl)pyrrolo[2,3-d]pyrimidin-4-one; - 3-[[4-hydroxy-1-[(3R,4R)-3-phenyl-1-(pyrimidin-2-ylmethyl)piperidine-4-carbonyl]-4-piperidyl]methyl]-7-phenyl-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[[4-hydroxy-1-[(3R,4R)-3-phenyl-1-(pyrimidin-2-ylmethyl)piperidine-4-carbonyl]-4-piperidyl]methyl]-7-(4-methoxyphenyl)pyrrolo[2,3-d]pyrimidin-4-one; - 3-[[4-hydroxy-1-[(3R,4R)-1-[(2-methylpyrimidin-4-yl)methyl]-3-phenylpiperidine-4-carbonyl]-4-piperidyl]methyl]-7-phenyl-pyrrolo[2,3-d]pyrimidin-4-one; - 3-[[4-hydroxy-1-[(3R,4R)-1-[(2-methylpyrimidin-4-yl)methyl]-3-phenylpiperidine-4-carbonyl]-4-piperidyl]methyl]-7-(4-methoxyphenyl)pyrrolo[2,3-d] pyrimidin-4-one; - 3-[[4-hydroxy-1-[(3R,4R)-1-[(6-methoxypyridazin-3-yl)methyl]-3-phenylpiperidine-4-carbonyl]-4-piperidyl]methyl]-7-(4-methoxyphenyl)pyrrolo[2,3-d] pyrimidin-4-one; - 3-[[4-hydroxy-1-[(3R,4R)-1-[(5-methylpyrazin-2-yl)methyl]-3-phenyl-piperidine-4-carbonyl]-4-piperidyl]methyl]-7-phenyl-thieno[3,4-d]pyrimidin-4-one; - 3-[[4-hydroxy-1-[(3R,4R)-1-[(2-methylpyrimidin-4-yl)methyl]-3-phenylpiperidine-4-carbonyl]-4-piperidyl]methyl]-7-phenyl-thieno[3,4-d]pyrimidin-4-one.

19. Process for the preparation of a compound of formula (I) according to claim 1, characterized in that there is used as starting material the compound of formula (II): wherein R2 and n are as defined for formula (I), which is subjected to coupling with a compound of formula (III): wherein R1 is as defined for formula (I), and PG represents a protecting group of the amine function, to yield the compound of formula (IV): wherein R1, R2, n and PG are as defined hereinbefore, compound of formula (IV) which is further converted to an epoxide compound of formula (V): wherein R1, R2, n and PG are as defined hereinbefore, compound of formula (V) which is further subjected to coupling with compound of formula (VI): wherein W is as defined for formula (I), to yield the compound of formula (VII): wherein R1, R2, n, W and PG are as defined hereinbefore, compound of formula (VII) which, after a reaction removing the protecting group PG, is further subjected to: ▪ either coupling with compound of formula (VIII): wherein J is as defined in formula (I), K' represents a -Cy1- group, Y represents a hydroxy group or a halogen atom, and Z represents a halogen atom, to yield the compound of formula (IX): wherein R1, R2, J, K', n, W and Z are as defined hereinbefore, compound of formula (IX) which is further subjected to coupling with compound of formula (X): wherein L is as defined for formula (I), and RB1 and RB2 represent a hydrogen atom, a linear or branched (C1-C6) alkyl group, or RB1 and RB2 are linked together by a linear or branched (C2-C6)alkylene group, to yield the compound of formula (I-a), a particular case of the compounds of formula (I): wherein R1, R2, J, K', L, n and W are as defined hereinbefore, ▪ or coupling with compound of formula (XI): wherein J, K and L are as defined in formula (I), and Y represents a hydroxy group or a halogen atom, to yield the compound of formula (I), compound of formula (I) or compound of formula (I-a), which is a particular case of compound of formula (I), may then be purified according to a conventional separation technique, which is converted, if desired, into its addition salts with a pharmaceutically acceptable acid or base and which is optionally separated into its isomers according to a conventional separation technique, it being understood that at any moment considered appropriate during the course of the process described above, some groups (hydroxy, amino...) of the starting reagents or of the synthesis intermediates can be protected, subsequently deprotected and functionalized, as required by the synthesis.

20. Process for the preparation of a compound of formula (I) according to claim 1, characterized in that there is used as starting material the compound of formula (XII): wherein R1 is as defined for formula (I), and PG represents a protecting group of the carboxylic acid function, which is subjected to: ▪ either coupling with compound of formula (VIII): wherein J is as defined in formula (I), K' represents a -Cy1- group, Y represents a hydroxy group or a halogen atom, and Z represents a halogen atom, to yield the compound of formula (XIII): wherein R1, J, K', Z and PG are as defined hereinbefore, compound of formula (XIII) which is further subjected to coupling with compound of formula (X): wherein L is as defined for formula (I), and RB1 and RB2 represent a hydrogen atom, a linear or branched (C1-C6) alkyl group, or RB1 and RB2 are linked together by a linear or branched (C2-C6)alkylene group, to yield the compound of formula (XIV): wherein R1, J, K', L and PG are as defined hereinbefore, ▪ or coupling with compound of formula (XI): wherein J, K and L are as defined in formula (I), and Y represents a hydroxy group or a halogen atom, to yield the compound of formula (XV), wherein R1, J, K, L and PG are as defined hereinbefore, compounds of formula (XIV) and (XV) which, after a reaction removing the protecting group PG, are further subjected to coupling with a compound of formula (II), to yield the compound of formula (XVI): wherein R1, R2, J, L and n are as defined hereinbefore, and K" is either K' or K as defined hereinbefore, compound of formula (XVI) which is further converted to an epoxide compound of formula (XVII): wherein R1, R2, J, K", L and n are as defined hereinbefore, compound of formula (XVII) which is further subjected to coupling with compound of formula (VI): wherein W is as defined for formula (I), to yield the compound of formula (I), which may be purified according to a conventional separation technique, which is converted, if desired, into its addition salts with a pharmaceutically acceptable acid or base and which is optionally separated into its isomers according to a conventional separation technique, it being understood that at any moment considered appropriate during the course of the process described above, some groups (hydroxy, amino...) of the starting reagents or of the synthesis intermediates can be protected, subsequently deprotected and functionalized, as required by the synthesis.

21. Pharmaceutical composition comprising a compound of formula (I) according to any one of claims 1 to 18 or an addition salt thereof with a pharmaceutically acceptable acid or base in combination with one or more pharmaceutically acceptable excipients.

22. Pharmaceutical composition according to claim 21 for use as pro-apoptotic and / or anti-proliferative agents.

23. Pharmaceutical composition according to claim 22 for use in the treatment of cancers and of auto-immune and immune system diseases.

24. Pharmaceutical composition according to claim 23 for use in the treatment of cancers of the bladder, brain, breast and uterus, chronic lymphoid leukemia, cancer of the colon, esophagus and liver, lymphoblastic leukemia, acute myeloid leukemia, lymphomas, melanomas, malignant haemopathies, myelomas, ovarian cancer, non-small-cell lung cancer, prostate cancer, pancreatic cancer and small-cell lung cancer.

25. Use of a pharmaceutical composition according to claim 21 in the manufacture of medicaments for use as pro-apoptotic and / or anti-proliferative agents.

26. Use of a pharmaceutical composition according to claim 21 in the manufacture of medicaments for use in the treatment of cancers and of auto-immune and immune system diseases.

27. Use of a pharmaceutical composition according to claim 21 in the manufacture of medicaments for use in the treatment of cancers of the bladder, brain, breast and uterus, chronic lymphoid leukemia, cancer of the colon, esophagus and liver, lymphoblastic leukemia, acute myeloid leukemia, lymphomas, melanomas, malignant haemopathies, myelomas, ovarian cancer, non-small-cell lung cancer, prostate cancer, pancreatic cancer and small-cell lung cancer.

28. Compound of formula (I) according to any one of claims 1 to 18 , or an addition salt thereof with a pharmaceutically acceptable acid or base, for use in the treatment of cancers of the bladder, brain, breast and uterus, chronic lymphoid leukemia, cancer of the colon, esophagus and liver, lymphoblastic leukemia, acute myeloid leukemia, lymphomas, melanomas, malignant haemopathies, myelomas, ovarian cancer, non-small-cell lung cancer, prostate cancer, pancreatic cancer and small-cell lung cancer.

29. Use of a compound of formula (I) according to any one of claims 1 to 18 or an addition salt thereof with a pharmaceutically acceptable acid or base, in the manufacture of medicaments for use in the treatment of cancers of the bladder, brain, breast and uterus, chronic lymphoid leukemia, cancer of the colon, esophagus and liver, lymphoblastic leukemia, acute myeloid leukemia, lymphomas, melanomas, malignant haemopathies, myelomas, ovarian cancer, non-small-cell lung cancer, prostate cancer, pancreatic cancer and small-cell lung cancer.

30. Combination of a compound of formula (I) according to any one of claims 1 to 18 with anti-cancer agents selected from genotoxic agents, mitotic poisons, anti-metabolites, proteasome inhibitors, kinase inhibitors, protein-protein interaction inhibitors, immunomodulators, E3 ligase inhibitors, chimeric antigen receptor T-cell therapy and antibodies.

31. Pharmaceutical composition comprising a combination according to claim 30 in combination with one or more pharmaceutically acceptable excipients.

32. Combination according to claim 30 for use in the treatment of cancers.

33. Use of a combination according to claim 30 in the manufacture of medicaments for use in the treatment of cancers.

34. Compound of formula (I) according to any one of claims 1 to 18 for use in the treatment of cancers requiring radiotherapy.